# EDGAR Filing Document

**Accession Number:** 0001865759
**File Stem:** 0001477932-26-000746
**Filing Date:** 2026-2
**Character Count:** 383782
**Document Hash:** 6f25f37083901272fba33c1554de0b08
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-26-000746.hdr.sgml**: 20260211

**ACCESSION NUMBER**: 0001477932-26-000746

**CONFORMED SUBMISSION TYPE**: S-1

**PUBLIC DOCUMENT COUNT**: 65

**FILED AS OF DATE**: 20260211

**DATE AS OF CHANGE**: 20260211

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pharmaceutical Resource Technology, Inc.
- **CENTRAL INDEX KEY:** 0001865759
- **STANDARD INDUSTRIAL CLASSIFICATION:** MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS [2090]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 000000000
- **STATE OF INCORPORATION:** WY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293366
- **FILM NUMBER:** 26618271

**BUSINESS ADDRESS:**
- **STREET 1:** 1 KAKI BUKIT AVE 3, #09-11, KB-1
- **CITY:** SINGAPORE
- **STATE:** U0
- **ZIP:** 416087
- **BUSINESS PHONE:** 65 6841 0120

**MAIL ADDRESS:**
- **STREET 1:** 1 KAKI BUKIT AVE 3, #09-11, KB-1
- **CITY:** SINGAPORE
- **STATE:** U0
- **ZIP:** 416087

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Jaison Phytochem, Inc.
- **DATE OF NAME CHANGE:** 20210603

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-1**

REGISTRATION STATEMENT

UNDER THE SECURITIES ACT OF 1933

![](pharmaceutical_s1img1.jpg)

---

| |
|:---|
| **PHARMACEUTICAL RESOURCE TECHNOLOGY, INC.**  |
| (Exact name of Registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **State or Other Jurisdiction** <br> **of Incorporation** | **Primary Standard Industrial** <br> **Classification Code Number** | **I.R.S. Employer** <br> **Identification Number** |
| Wyoming | 1540 | 35-2894750 |

---

**No.1 Kaki Bukit Avenue 3, #09-11, KB-1** 

**Singapore 416087** 

**Telephone: +65 6841 0120** 

**Email: jacksaa@pharmaceuticalresource.com**

(Address and Telephone Number of Registrant's Principal

Executive Offices and Principal Place of Business)

Please send copies of all correspondence to:

**PHARMACEUTICAL RESOURCE TECHNOLOGY, INC.**

**No.1 Kaki Bukit Avenue 3, #09-11, KB-1** 

**Singapore 416087** 

**Telephone: +65 6841 0132** 

**Email: jacksaa@pharmaceuticalresource.com**

(Name, address, including zip code, and telephone number,

including area code, of agent for service)

Approximate date of proposed sale to the public:

As soon as practicable and from time to time after the effective date of this Registration Statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Non-accelerated filer ☐ <br> Accelerated filer ☐ Smaller reporting company ☒ <br> Emerging Growth Company ☒ (Do not check if a smaller reporting company)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

(1) The registration fee payable to the Securities and Exchange Commission has been calculated and is set forth in Part II of this registration statement.

(2) The offering price has been arbitrarily determined by the Company and bears no relationship to assets, earnings, or any other valuation criteria. No assurance can be given that the shares offered hereby will have a market value or that they may be sold at this, or at any price.

(3) Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(o) of the Securities Act of 1933.

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY OUR EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A), MAY DETERMINE.

SUBJECT TO COMPLETION, DATED FEBRUARY 11, 2026

THE INFORMATION IN THIS PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. WE MAY NOT SELL THESE SECURITIES UNTIL THE REGISTRATION STATEMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER TO SELL THESE SECURITIES AND IT IS NOT SOLICITING AN OFFER TO BUY THESE SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED. THERE IS NO MINIMUM PURCHASE REQUIREMENT FOR THE OFFERING TO PROCEED.

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **[PART I — PROSPECTUS](#P1)** |  |
| ***[1. PROSPECTUS SUMMARY](#PROSPECTUSSUMMARY)*** | 3 |
| ***[2. RISK FACTORS](#RISKFACTORS)*** | 7 |
| ***[3. USE OF PROCEEDS](#USEOFPROCEEDS)*** | 13 |
| ***[4. DILUTION](#DILUTION)*** | 17 |
| ***[5. CAPITALIZATION](#CAPITALIZATION)*** | 21 |
| ***[6. PLAN OF DISTRIBUTION](#PLANOFDISTRIBUTION)*** | 25 |
| ***[7. DETERMINATION OF OFFERING PRICE](#DETERMINATIONOFOFFERINGPRICE)*** | 27 |
| ***[8. DESCRIPTION OF SECURITIES](#DESCRIPTIONOFSECURITIES)*** | 28 |
| ***[9. INTERESTS OF NAMED EXPERTS AND COUNSEL](#INTERESTSOFNAMEDEXPERTSANDCOUNSEL)*** | 30 |
| ***[10. INFORMATION WITH RESPECT TO THE REGISTRANT](#INFORMATIONWITHRESPECTTOTHEREGISTRANT)*** | 30 |
| ***[11. SELLING STOCKHOLDERS](#SELLINGSTOCKHOLDERS)*** | 34 |
| ***[12. BUSINESS](#BUSINESS)*** | 39 |
| ***[13. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#MDA13)*** | 47 |
| ***[14. MANAGEMENT, EXECUTIVE COMPENSATION, AND SECURITY OWNERSHIP](#MANAGEMENTEXECUTIVECOMPENSATION)*** | 54 |
| ***[15. CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS](#CERTAINRELATIONSHIPSANDRELATEDPARTY)*** | 59 |
| ***[16. LEGAL PROCEEDINGS](#LEGALPROCEEDINGS)*** | 64 |
| **[PART II — INFORMATION NOT REQUIRED IN PROSPECTUS](#P2)** |  |
| ***[17. CALCULATION OF REGISTRATION FEE](#CALCULATIONOFREGISTRATIONFEE)*** | 67 |
| ***[18. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION](#OTHEREXPENSESOFISSUANCEANDDISTRIBUTION)*** | 67 |
| ***[19. INDEMNIFICATION OF DIRECTORS AND OFFICERS](#INDEMNIFICATIONOFDIRECTORSANDOFFICERS)*** | 68 |
| ***[20. RECENT SALES OF UNREGISTERED SECURITIES](#RECENTSALESOFUNREGISTEREDSECURITIES)*** | 69 |
| ***[21. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES](#EXHIBITSANDFINANCIALSTATEMENTSCHEDULES)*** | 70 |
| ***[22. FINANCIAL STATEMENTS](#FINANCIALSTATEMENTS)*** | 71 |
| ***[23. UNDERTAKINGS](#UNDERTAKINGS)*** | 72 |
| ***[24. SIGNATURES](#SIGNATURES)*** | 74 |

---

---

| |
|:---|
| 2 |
| *[**Table of Contents**](#TOC)* |

---

**PART I — PROSPECTUS**

**1. PROSPECTUS SUMMARY**

In this prospectus, "Pharmaceutical Resource Technology, Inc.," the "Company," "we," "us," and "our" refer to Pharmaceutical Resource Technology, Inc., unless the context otherwise requires. Unless otherwise indicated, references to our fiscal year refer to the fiscal year ended December 31.

This prospectus contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements are based on management's current expectations, assumptions, and beliefs regarding future events and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Words such as "may," "will," "expect," "intend," "plan," "believe," "estimate," "anticipate," "project," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this prospectus.

This prospectus summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you should consider before making an investment decision. You should carefully read this entire prospectus, including the sections titled "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," and the financial statements and related notes, before deciding to invest in our common stock.

**1.1. The Company**

Pharmaceutical Resource Technology, Inc. is a Wyoming corporation originally incorporated on June 17, 2019 under the name Jaison Phytochem, Inc. We commenced material operations in January 2020. In March 2023, we completed a corporate reorganization and changed our name to Pharmaceutical Resource Technology, Inc. to reflect a strategic shift and expansion of our business focus.

We operate as a U.S. holding company with principal executive offices in Singapore. We do not legally own any subsidiaries. Our operations are conducted primarily through asset-based acquisitions and management arrangements in Singapore. Our business activities currently span three primary areas: (i) honey straw manufacturing, (ii) pharmaceutical and dietary supplements manufacturing, and (iii) building and construction services. Based on recent operations, our revenue mix is approximately 18% from honey straw manufacturing, 18% from pharmaceutical and dietary supplements manufacturing, and 64% from building and construction activities.

In 2023, we acquired, through asset purchases, a certified pharmaceutical manufacturing business and a building and construction business in Singapore. These acquisitions were structured as asset acquisitions rather than equity acquisitions, and the acquired operations are conducted through managing agencies rather than owned subsidiaries. We believe the pharmaceutical manufacturing capabilities enhance our food health and safety standards applicable to our honey straw and dietary supplements operations, while the construction business supports the development of manufacturing facilities in targeted regions.

Our manufacturing, operational staffing, and certain administrative functions are heavily dependent on a long-standing contractual relationship with Superbee Network Singapore Pte. Ltd., a Singapore company. Pursuant to management and consultancy arrangements, Superbee provides personnel, operational support, and other services necessary for our manufacturing, packaging, sales, and construction-related activities in Singapore and the surrounding region. From time to time, Superbee may also collect customer payments on our behalf and advance or prepay certain operating expenses. We currently have two permanent employees, both of whom are our executive officers and directors.

---

| |
|:---|
| 3 |
| *[**Table of Contents**](#TOC)* |

---

Our officers and directors, Jacksaa Tan and Hui Eng Ling, also serve as directors of Superbee Network Singapore Pte. Ltd. and collectively control a substantial majority of that entity. As a result, our relationship with Superbee constitutes a related-party relationship and represents a significant operational dependency. Any disruption, termination, or material modification of this relationship could require us to materially restructure our business operations and could have an adverse effect on our business, financial condition, and results of operations.

We currently market and sell our products and services primarily in Asia and have customers in approximately ten countries. We hold the material licenses, certifications, and regulatory approvals required for our existing operations in Singapore; however, additional licenses or approvals may be required as we expand into new territories.

We intend to use the proceeds from this offering to support the expansion of our honey straw and dietary supplements manufacturing operations into new geographic markets, increase production capacity, and fund general corporate and operating expenses. Even if we sell all of the shares offered in this offering, the proceeds may be insufficient to fully execute our business plan, and we may require additional financing in the future.

**1.2. Our Business / Operations**

We operate as an integrated manufacturing and services company focused on honey straw products, pharmaceutical and dietary supplements manufacturing, and building and construction services, with operations conducted primarily in Singapore and other parts of Asia. Our business model is designed to support scalable manufacturing capabilities, product quality and safety, and geographic expansion into additional markets.

Our honey straw business involves the manufacturing, packaging, and sale of single-serve honey products primarily for food and consumer markets. These operations rely on specialized packaging machinery and production processes designed to meet applicable food safety and quality standards. Our pharmaceutical and dietary supplements business involves the manufacturing of health-related products in compliance with applicable regulatory and certification requirements in Singapore. We believe that the operational standards applied in our pharmaceutical and dietary supplements manufacturing enhance quality control and safety practices across our honey straw operations.

In addition to manufacturing activities, we conduct building and construction services through acquired operations in Singapore. This business supports the development, construction, and expansion of manufacturing facilities and related infrastructure. The construction segment currently represents a significant portion of our revenues and provides in-house capabilities that we use to support expansion of production capacity in targeted regions.

Our operations are conducted without owned subsidiaries. Instead, we conduct business through asset-based acquisitions and management arrangements. We rely substantially on Superbee Network Singapore Pte. Ltd., a Singapore company, for operational staffing, manufacturing support, administrative services, and certain logistical and financial functions. Pursuant to management and consultancy arrangements, Superbee provides personnel and operational resources necessary to conduct our manufacturing, sales, and construction activities. From time to time, Superbee may also collect customer payments on our behalf and advance or prepay certain operating expenses, which are subsequently settled by us. These arrangements allow us to operate with a limited number of direct employees while maintaining operational capacity.

We currently have two permanent employees, both of whom are our executive officers and directors. All other personnel involved in manufacturing, sales, and construction activities are provided through third-party arrangements. Our reliance on third-party service providers, and in particular on Superbee, represents a significant operational dependency.

We sell our products and services primarily in Asia and currently have customers in approximately ten countries. Our ability to continue operating and expand our business depends on maintaining required licenses, certifications, and regulatory approvals in the jurisdictions in which we operate. While we hold the material approvals required for our existing operations in Singapore, expansion into new territories may require additional regulatory approvals, certifications, or licenses.

---

| |
|:---|
| 4 |
| *[**Table of Contents**](#TOC)* |

---

Our business strategy is to use the proceeds from this offering, together with existing resources, to expand honey straw and dietary supplements manufacturing capacity, establish additional production facilities in new markets, and support general corporate and operating activities. Our future performance will depend on our ability to manage growth, maintain quality and regulatory compliance, and sustain key operational relationships that support our business model.

**1.3. Recent Developments**

Since the completion of our corporate reorganization and name change to Pharmaceutical Resource Technology, Inc. in March 2023, our business operations have remained focused on the execution and integration of the asset-based acquisitions and operating arrangements previously disclosed in this prospectus. These include our pharmaceutical and dietary supplements manufacturing operations and our building and construction activities in Singapore, which continue to be conducted through managing agencies rather than owned subsidiaries.

In connection with this registration statement, we have completed audited financial statements for the periods presented and updated related disclosures to reflect the correct auditor engagements and applicable audit periods. Other than the foregoing, there have been no material changes to our business operations, organizational structure, or operating strategy that have not otherwise been described in this prospectus.

Except as disclosed elsewhere in this prospectus, we have not entered into any material definitive agreements, completed any additional material acquisitions or dispositions, or experienced any material changes in our financial condition or results of operations that would require additional disclosure under this heading.

**1.4. Our Offering**

The following summary describes the principal terms of this offering. This summary is qualified in its entirety by the more detailed information appearing elsewhere in this prospectus.

---

| | |
|:---|:---|
| **Issuer** | **Pharmaceutical Resource Technology, Inc.** |
| Securities Offered by the Company | 100,000,000 shares of common stock |
| Securities Offered by Selling Stockholders | 170,175,496 shares of common stock |
| Common Stock Outstanding Prior to this Offering | 2,854,462,696 shares |
| Common Stock Outstanding After this Offering (assuming sale of all shares offered by the Company) | 2,954,462,696 shares |
| Offering Price | $0.50 per share |
| Offering Type | Direct public offering by the Company and resale offering by selling stockholders |
| Underwriting | Self-underwritten, best efforts |
| Use of Proceeds | We will receive the proceeds from the sale of shares offered by us. We will not receive any proceeds from the sale of shares by the selling stockholders. |
| Minimum Offering Amount |  |
| Duration of Offering | The offering will terminate upon the earlier of (i) the date all shares offered are sold or (ii) 365 days from the effective date of this prospectus, unless extended by our Board of Directors for up to an additional 90 days. |
| Market for Common Stock | There is currently no public market for our common stock. We intend to seek quotation on the OTCQB; however, there is no assurance that a public market will develop. |
| Risk Factors | Investing in our common stock involves a high degree of risk. See "Risk Factors". |

---

The primary offering of shares by the Company is separate from the resale offering by the selling stockholders. Proceeds from the sale of shares by selling stockholders, if any, will be paid directly to the selling stockholders and will not be used by the Company. We will receive proceeds only from the sale of shares offered by us.

Our Chief Executive Officer will offer the shares on behalf of the Company on a best-efforts basis. There is no minimum number of shares that must be sold for the offering to proceed, and investors may lose their entire investment.

---

| |
|:---|
| 5 |
| *[**Table of Contents**](#TOC)* |

---

**1.5. Use of Proceeds**

We estimate that the net proceeds to us from the sale of the 100,000,000 shares of common stock offered by us in this offering, after deducting estimated offering expenses payable by us, will be approximately $50,000,000 if all of the shares offered by us are sold. If fewer shares are sold, our net proceeds will be reduced proportionately. We will not receive any proceeds from the sale of shares by the selling stockholders.

We intend to use the net proceeds from this offering primarily to support the expansion of our honey straw and pharmaceutical and dietary supplements manufacturing operations, including increasing production capacity, establishing or expanding manufacturing facilities in new geographic markets, and acquiring additional machinery and equipment. We also intend to use a portion of the proceeds for general corporate purposes, including working capital, operating expenses, and costs associated with maintaining our status as a public company.

Our management will have broad discretion in the application of the net proceeds from this offering, and the timing and amount of expenditures will depend on a number of factors, including the amount of proceeds actually raised, operational requirements, market conditions, regulatory considerations, and business opportunities that may arise. Pending their use, we intend to invest the net proceeds in short-term, interest-bearing, investment-grade securities or deposit them in bank accounts.

Even if we sell all of the shares offered by us in this offering, the net proceeds may be insufficient to fully fund our planned expansion and operations, and we may require additional financing in the future. There can be no assurance that the proceeds from this offering will be sufficient to achieve our business objectives or that we will be able to obtain additional financing on acceptable terms, or at all.

**1.6. Summary Risk Factors**

An investment in our common stock involves a high degree of risk. The following summary highlights certain material risks associated with an investment in our common stock. This summary does not describe all of the risks that we face. You should carefully consider these risks, together with the more detailed discussion under the heading "Risk Factors" and the other information contained in this prospectus, before deciding to invest in our common stock.

· **We are highly dependent on third-party operating arrangements, particularly with Superbee Network Singapore Pte. Ltd.** We rely extensively on Superbee for personnel, manufacturing support, administrative services, and certain financial and operational functions. Any disruption, termination, or adverse change in this relationship could materially harm our business, financial condition, and results of operations.

· **Our business operations are geographically concentrated outside the United States.** Substantially all of our operations are conducted in Singapore and other parts of Asia, subjecting us to economic, regulatory, political, and legal risks associated with operating in foreign jurisdictions.

· **Our officers and directors exercise significant control over the Company.** Our executive officers and directors hold a substantial number of our outstanding shares and, as a result, have significant influence over matters requiring stockholder approval. This concentration of control may limit the ability of other stockholders to influence corporate matters and could discourage potential investors.

· **Investors in this offering will experience immediate and substantial dilution.** The offering price of our common stock is substantially higher than the net tangible book value per share, and purchasers in this offering will incur immediate dilution in the net tangible book value of their investment.

· **There is no public market for our common stock, and a market may never develop.** There is currently no established public trading market for our common stock. Although we intend to seek quotation on the OTCQB, there can be no assurance that our common stock will be quoted or that an active trading market will develop or be sustained.

· **Even if this offering is completed, we may require additional capital.** The proceeds from this offering, even if fully subscribed, may be insufficient to fully implement our business plan. We may need to raise additional capital in the future, which may not be available on acceptable terms or at all and could result in further dilution to investors.

These risks could materially and adversely affect our business, financial condition, results of operations, and the value of our common stock.

---

| |
|:---|
| 6 |
| *[**Table of Contents**](#TOC)* |

---

**1.7. Control and Voting Power**

As of the date of this prospectus, our Chief Executive Officer, **Jacksaa Tan**, and our Chief Financial Officer, **Hui Eng Ling**, collectively own and control approximately **94.03% of the voting power** of our outstanding common stock. As a result, these individuals have the ability to control the outcome of all matters submitted to our stockholders for approval, including the election of directors, amendments to our certificate of incorporation and bylaws, and the approval of significant corporate transactions.

The following table sets forth the voting power of our executive officers and directors **before and after this offering**, assuming the sale of all 100,000,000 shares offered by the Company and no sale of shares by the selling stockholders.

**1.8. Beneficial Ownership and Voting Power of Officers and Directors**

---

| | | |
|:---|:---|:---|
|  | **Before Offering** | **After Offering** |
| Shares of common stock outstanding | 2854462696 | 2954462696 |
| Voting power held by officers and directors (collectively) | 94.03% | 90.85% |

---

Beneficial ownership is determined in accordance with Rule 13d-3 of the Securities Exchange Act of 1934 and includes shares over which a person has voting or dispositive power, whether directly or indirectly, including through immediate family members or controlled entities.

Even after completion of this offering, Mr. Tan and Ms. Ling will continue to control approximately **90.85% of the voting power** of our outstanding common stock, enabling them to substantially influence all matters requiring stockholder approval. This concentration of ownership may discourage a change of control, limit the ability of other stockholders to influence corporate governance, and result in decisions that may not be aligned with the interests of other investors.

**2. RISK FACTORS**

**2.1. Risks Relating to Our Business and Operations**

Our business and operations are subject to numerous risks and uncertainties, including those described below. Any of these risks could materially and adversely affect our business, financial condition, results of operations, and prospects.

**We are highly dependent on third-party service providers and management arrangements to conduct our operations.** 

We do not conduct our operations through owned subsidiaries and instead rely on asset-based acquisitions and third-party management and consultancy arrangements to carry out manufacturing, administrative, and operational functions. These arrangements expose us to risks that are outside of our direct control, including the risk that such third parties may fail to perform their obligations, experience financial or operational difficulties, or terminate or modify their relationship with us. Any disruption in these arrangements could materially impair our ability to operate our business.

---

| |
|:---|
| 7 |
| *[**Table of Contents**](#TOC)* |

---

**Our operations are heavily dependent on Superbee Network Singapore Pte. Ltd. for core operational functions.** 

A substantial portion of our manufacturing, staffing, administrative, and operational activities are performed through Superbee Network Singapore Pte. Ltd. Pursuant to management and consultancy arrangements, Superbee provides personnel, manufacturing support, and other essential services, and from time to time may collect customer payments on our behalf or advance operating expenses. Our reliance on a single third-party provider for these critical functions represents a significant operational risk. If our relationship with Superbee were terminated, disrupted, or materially altered, we could be required to rapidly restructure our operations, incur significant costs, or experience interruptions that could materially harm our business and results of operations.

**We have a very limited number of direct employees and rely extensively on outsourced staffing.**

We currently have only two permanent employees, both of whom are our executive officers and directors. All other personnel involved in our manufacturing, sales, and construction activities are provided through third-party arrangements. This limited internal staffing increases our dependence on third-party service providers and reduces our ability to independently manage and oversee day-to-day operations. Any loss of access to outsourced personnel or inability to attract or retain qualified service providers could adversely affect our operations.

**We may have difficulty managing growth and scaling our operations.**

Our business strategy contemplates expansion of manufacturing capacity and entry into new geographic markets. Managing growth will require us to coordinate multiple third-party service providers, comply with additional regulatory requirements, and increase operational complexity. Our limited internal resources and reliance on third-party arrangements may constrain our ability to effectively manage expansion, which could result in inefficiencies, increased costs, operational disruptions, or failure to achieve anticipated growth.

**A significant portion of our revenues is derived from specific business segments.** 

Our revenues are concentrated in a limited number of business activities, including building and construction services and manufacturing operations. Changes in demand, competitive conditions, regulatory requirements, or operating performance within any of these segments could have a disproportionate impact on our overall financial condition and results of operations.

**Our operations are geographically concentrated outside the United States, which exposes us to additional risks.**

Substantially all of our operations are conducted in Singapore and other parts of Asia. As a result, we are subject to risks associated with operating in foreign jurisdictions, including changes in economic conditions, regulatory frameworks, political instability, currency controls, and enforcement of contractual and property rights. These risks could adversely affect our ability to operate our business and repatriate funds, and could result in increased costs or reduced revenues.

**2.2. Risks Relating to Our Industry and Regulatory Environment**

**Our operations are subject to extensive regulatory requirements applicable to manufacturing and construction activities.**

Our manufacturing and construction operations are subject to numerous laws, regulations, standards, and regulatory oversight in the jurisdictions in which we operate, particularly in Singapore and other parts of Asia. These requirements relate to, among other things, product quality and safety, health and environmental standards, workplace safety, construction practices, and manufacturing processes. Compliance with these requirements involves ongoing costs, administrative burdens, and operational constraints. Failure to comply with applicable regulations could result in fines, penalties, suspension or revocation of licenses, delays in operations, or restrictions on our ability to conduct business, any of which could materially and adversely affect our business and results of operations.

---

| |
|:---|
| 8 |
| *[**Table of Contents**](#TOC)* |

---

**We must obtain and maintain various licenses, permits, and certifications to operate our business.**

Our ability to conduct manufacturing and construction activities depends on obtaining and maintaining required licenses, permits, certifications, and regulatory approvals. These approvals may be subject to renewal, modification, or revocation and may require compliance with evolving standards and conditions. There can be no assurance that we will be able to timely obtain or renew all required approvals, or that such approvals will remain in effect on commercially acceptable terms. Any failure to obtain, maintain, or renew necessary licenses or certifications could result in operational disruptions, increased costs, or limitations on our ability to expand into new markets.

**We are exposed to changes in laws and regulations in foreign jurisdictions.**

Substantially all of our operations are conducted outside the United States, and we are subject to the legal and regulatory frameworks of foreign jurisdictions, which may differ significantly from those in the United States. Changes in laws, regulations, regulatory interpretations, or enforcement practices could impose additional compliance obligations, restrict our operations, increase costs, or adversely affect our contractual arrangements. Regulatory changes may occur with limited notice and could have a material adverse effect on our business, financial condition, and results of operations.

**We operate in competitive industries that may experience pricing pressure and increased competition.**

The manufacturing and construction industries in which we operate are competitive and subject to pricing pressure from existing and new competitors. Competitors may have greater financial resources, operational capabilities, established customer relationships, or regulatory advantages. Increased competition or pricing pressure could reduce demand for our products and services, compress margins, or require increased expenditures to remain competitive. Our inability to effectively compete could materially and adversely affect our revenues and operating results.

**2.3. Risks Relating to Our Financial Condition and Capital Requirements**

**We have a history of operating losses and a limited operating history in our current business lines.** 

We have incurred operating losses in prior periods and have a limited operating history following our reorganization and expansion into our current business activities. Our historical financial results may not be indicative of future performance, and we may continue to incur losses as we expand our operations, invest in manufacturing capacity, and incur additional costs associated with being a public company. Our limited operating history in our current structure makes it difficult to evaluate our business prospects and increases the risk that we may not achieve or sustain profitability.

**We do not present a ratio of earnings to fixed charges, which may limit investors' ability to evaluate our ability to service fixed obligations.**

We have not presented a ratio of earnings to fixed charges for the periods included in this prospectus. This ratio is commonly used by investors to assess a company's ability to meet fixed obligations, such as interest payments, from its earnings. Because we do not present this ratio, investors may find it more difficult to evaluate our historical or prospective ability to cover fixed charges on a comparative basis with other companies that disclose this information. Although we currently do not have material interest-bearing debt, we may incur fixed charges in the future, including interest expense, lease obligations, or other contractual commitments. If our earnings are insufficient to cover such fixed charges in future periods, we may be required to obtain additional financing, refinance existing obligations, or reduce or delay planned expenditures, any of which could adversely affect our business, financial condition, results of operations, and liquidity.

---

| |
|:---|
| 9 |
| *[**Table of Contents**](#TOC)* |

---

**We may require additional capital even if this offering is completed.**

The proceeds from this offering, even if we sell all of the shares offered by us, may be insufficient to fully fund our business plans, including expansion of manufacturing capacity and entry into new markets. Our future capital requirements will depend on numerous factors, including operating results, regulatory requirements, capital expenditures, and market conditions. If we are unable to raise additional capital when needed, or if such capital is unavailable on acceptable terms, we may be required to delay, reduce, or eliminate planned operations or growth initiatives, which could materially and adversely affect our business.

**Our future revenues and profitability are uncertain.**

We have not established a consistent record of generating revenues or achieving profitability, and there can be no assurance that we will be able to generate sufficient revenues to become profitable. Our future revenues will depend on numerous factors, including demand for our products and services, competition, pricing, regulatory compliance, and our ability to manage growth and operational complexity. Failure to achieve anticipated revenue growth or control costs could prevent us from becoming profitable and adversely affect our financial condition.

**We may experience liquidity and cash flow constraints.**

Our operations require ongoing expenditures for manufacturing, construction activities, regulatory compliance, and general corporate purposes. If our operating cash flows are insufficient to meet our obligations, we may need to rely on external financing or third-party arrangements to fund operations. Any inability to manage cash flows effectively or access additional liquidity could result in delays in operations, increased costs, or adverse impacts on our financial condition and results of operations.

**2.4. Risks Relating to This Offering**

**There is no minimum offering amount, and the proceeds from this offering may be insufficient to meet our objectives.** 

This offering does not have a minimum subscription requirement, and we may raise significantly less than the maximum offering amount. As a result, the net proceeds available to us may be insufficient to fully implement our business plans or achieve our intended objectives. If we raise only a limited amount of proceeds, we may be required to delay, scale back, or eliminate planned operations or expansion initiatives, which could materially and adversely affect our business and financial condition.

**This is a best-efforts, self-underwritten offering, and there is no assurance that we will be able to sell any shares.** 

This offering is being conducted on a self-underwritten, best-efforts basis, and our Chief Executive Officer will offer the shares on our behalf. There is no assurance that any of the shares offered will be sold or that the offering will be completed on favorable terms, or at all. The absence of a firm commitment underwriting arrangement increases the risk that the offering may not raise sufficient capital to support our operations and growth plans.

**Our management will have broad discretion in the use of the proceeds from this offering.** 

Our management will have significant discretion in applying the net proceeds from this offering, and investors will be relying on the judgment of our management regarding the allocation of these funds. The actual use of proceeds may differ from our current plans based on various factors, including business opportunities, regulatory requirements, and market conditions. Any failure by management to effectively allocate the proceeds could adversely affect our business and results of operations.

**The offering price of our common stock was arbitrarily determined and is not based on traditional valuation metrics.**

The offering price of our common stock was determined by our management and does not bear any relationship to our assets, earnings, book value, or other generally accepted valuation criteria. As a result, investors may experience immediate dilution in the value of their investment, and the market price of our common stock, if a trading market develops, may decline below the offering price.

---

| |
|:---|
| 10 |
| *[**Table of Contents**](#TOC)* |

---

**2.5. Risks Relating to Dilution**

**Investors in this offering will experience immediate and substantial dilution.**

The public offering price of $0.50 per share is substantially higher than our net tangible book value per share before this offering. As a result, investors who purchase shares in this offering will experience immediate dilution in the net tangible book value of their shares. Net tangible book value per share represents the amount of our total tangible assets less total liabilities, divided by the number of shares of common stock outstanding.

The following table illustrates the dilution that new investors will experience, assuming various levels of completion of this offering:

---

| | | | |
|:---|:---|:---|:---|
|  | **100% of** <br> **Offering Sold** | **75% of** <br> **Offering Sold** | **50% of** <br> **Offering Sold** |
| **Net tangible book value before offering** | $9775456 | $9775456 | $9775456 |
| **Net proceeds from offering** | $50000000 | $37500000 | $25000000 |
| **As adjusted net tangible book value after offering** | $59775456 | $47275456 | $34775456 |
| **Shares outstanding before offering** | 2854462696 | 2854462696 | 2854462696 |
| **Shares issued in this offering** | 100000000 | 75000000 | 50000000 |
| **Total shares outstanding after offering** | 2954462696 | 2929462696 | 2904462696 |
| **Net tangible book value per share after offering** | $0.0202 | $0.0161 | $0.0120 |
| **Dilution per share to new investors** | $0.4798 | $0.4839 | $0.4880 |

---

**Existing stockholders have acquired shares at prices substantially below the offering price.**

The majority of our outstanding shares were issued to existing stockholders at prices significantly lower than the public offering price. As a result, new investors will incur substantial dilution, while existing stockholders will experience an immediate increase in the net tangible book value of their shares attributable to the capital raised in this offering.

---

| |
|:---|
| 11 |
| *[**Table of Contents**](#TOC)* |

---

**Future issuances of equity securities may result in additional dilution.**

We may need to raise additional capital in the future through the issuance of equity or equity-linked securities to fund operations, expansion, or other corporate purposes. Any such issuances could further dilute the ownership interests of investors in this offering and could occur at prices lower than the offering price, resulting in additional dilution.

**2.6. Risks Relating to Ownership Structure and Control**

**Our officers and directors have significant ownership and voting power, which may limit the ability of other stockholders to influence corporate matters.**

As of the date of this prospectus, our executive officers and directors beneficially own a substantial majority of our outstanding common stock. Because each share of our common stock is entitled to one vote, this concentration of ownership provides our officers and directors with significant voting power over matters requiring stockholder approval, including the election of directors, amendments to our certificate of incorporation and bylaws, and the approval of significant corporate transactions.

**Investors in this offering will have limited ability to influence corporate decisions.**

Due to the concentration of voting power held by our officers and directors, investors purchasing shares in this offering will have limited ability to influence corporate actions or policies, even if such investors collectively hold a significant number of shares. This concentration of control may discourage or delay a change in control of the Company, including transactions that some investors may consider favorable, and may result in decisions that are not aligned with the interests of other stockholders.

**Our ownership structure and related-party relationships may give rise to conflicts of interest.**

Our officers and directors are involved in related-party relationships, including operational and service arrangements with entities under common control. These relationships may present conflicts of interest in connection with decisions regarding the allocation of resources, the negotiation or continuation of third-party arrangements, and other corporate matters. While such arrangements are intended to support our operations, the interests of our officers, directors, and related parties may differ from or conflict with the interests of other stockholders, which could adversely affect our business and the value of our common stock.

**2.7. Risks Relating to the Trading Market for Our Common Stock**

**There is currently no public market for our common stock.**

There is no established public trading market for our common stock, and investors may have difficulty selling their shares or obtaining accurate market quotations. The lack of a public market may adversely affect the liquidity and market value of our common stock, and investors may be required to hold their shares for an indefinite period of time.

**There is no assurance that our common stock will be quoted on the OTCQB or that a trading market will be sustained.**

We intend to seek quotation of our common stock on the OTCQB operated by OTC Markets Group Inc.; however, there can be no assurance that a market maker will agree to file an application for quotation or that our application will be approved. Even if our common stock is quoted, there can be no assurance that an active or liquid trading market will develop or be maintained. The failure to obtain or sustain a public trading market could materially limit investors' ability to resell their shares.

---

| |
|:---|
| 12 |
| *[**Table of Contents**](#TOC)* |

---

**The market price of our common stock may be volatile if a trading market develops.**

If a public trading market for our common stock develops, the market price of our shares may be subject to significant volatility. Factors such as our operating performance, financial condition, dilution from future equity issuances, limited trading volume, changes in investor perception, and broader market conditions could cause the trading price of our common stock to fluctuate substantially. As a result, investors may not be able to resell their shares at or above the offering price, or at all.

**2.8. Risks Relating to Our Status as an Emerging Growth Company and Smaller Reporting Company**

**We are an emerging growth company and a smaller reporting company and are subject to reduced disclosure requirements.**

We qualify as an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012, and as a "smaller reporting company" under the Securities Exchange Act of 1934. As a result, we are permitted to take advantage of certain reduced disclosure and reporting requirements, including exemptions from the requirement to provide auditor attestation of internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act and reduced executive compensation disclosure. While these reduced requirements lower our compliance costs, they may also make it more difficult for investors to compare us with other public companies that are not subject to such exemptions.

**The reduced disclosure requirements applicable to us may adversely affect investor perception of our common stock.**

Because we provide less comprehensive disclosure than companies that do not qualify as emerging growth companies or smaller reporting companies, some investors may find our common stock less attractive. This reduced level of disclosure may result in decreased analyst coverage, reduced market interest, or lower trading volumes, which could adversely affect the market price and liquidity of our common stock.

**We may be subject to increased reporting and compliance costs when we cease to qualify as an emerging growth company.**

We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year following the fifth anniversary of the completion of this offering, (ii) the date on which we have total annual gross revenues of $1.235 billion or more, (iii) the date on which we are deemed to be a large accelerated filer, or (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the preceding three-year period. When we no longer qualify as an emerging growth company, we will be required to comply with increased disclosure, reporting, and compliance obligations, which may increase our operating costs and divert management's attention from operating our business.

**3. USE OF PROCEEDS**

**3.1. Gross and Net Proceeds From This Offering**

We are offering up to 100,000,000 shares of our common stock at a public offering price of $0.50 per share. Assuming all of the shares offered by us are sold, we expect to receive gross proceeds of $50,000,000.

We estimate that our total offering expenses, payable by us, will be approximately $92,000. These expenses include legal, accounting, filing, printing, and other costs associated with this offering. We will not pay any underwriting commissions in connection with this offering.

---

| |
|:---|
| 13 |
| *[**Table of Contents**](#TOC)* |

---

After deducting the estimated offering expenses payable by us, we expect to receive net proceeds of approximately $49,908,000, assuming the sale of all 100,000,000 shares offered by us. If fewer shares are sold, our gross and net proceeds will be reduced proportionately.

The following table sets forth the estimated gross and net proceeds to us assuming various levels of completion of this offering:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Percentage of Shares Sold** | **Shares Sold by the Company** | **Gross Proceeds** | **Estimated Offering Expenses** | **Net Proceeds to the Company** |
| 100% | 100000000 | $50000000 | $92000 | $49908000 |
| 75% | 75000000 | $37500000 | $92000 | $37408000 |
| 50% | 50000000 | $25000000 | $92000 | $24908000 |
| 25% | 25000000 | $12500000 | $92000 | $12408000 |

---

We will not receive any proceeds from the sale of shares by the selling stockholders. All proceeds from the sale of shares offered by selling stockholders, if any, will be paid directly to the selling stockholders.

The foregoing amounts are estimates and may vary depending on the actual costs incurred in connection with this offering and the number of shares sold.

**3.2. Use of Net Proceeds by Category**

We intend to use the net proceeds from this offering for the purposes described below. The amounts and timing of our actual expenditures will depend on the amount of proceeds raised, operating results, regulatory requirements, market conditions, and other factors. Accordingly, management retains discretion over the allocation of the net proceeds.

The following table sets forth our current intended use of the net proceeds assuming the sale of all shares offered by us in this offering:

---

| | | |
|:---|:---|:---|
| **Use of Net Proceeds** | **Estimated** <br> **Amount** | **Percentage of** <br> **Net Proceeds** |
| **Expansion of honey straw manufacturing operations** | $15000000 | 30% |
| **Expansion of pharmaceutical and dietary supplements manufacturing operations** | $12500000 | 25% |
| **Capital expenditures (machinery, equipment, facilities)** | $10000000 | 20% |
| **Working capital and general corporate purposes** | $7408000 | 15% |
| **Public company and compliance-related expenses** | $5000000 | 10% |
| **Total Net Proceeds** | $**49908000** | **100%** |

---

---

| |
|:---|
| 14 |
| *[**Table of Contents**](#TOC)* |

---

The expansion of honey straw manufacturing operations is expected to include increased production capacity, packaging capabilities, and related infrastructure in existing and new geographic markets. The expansion of pharmaceutical and dietary supplements manufacturing operations is expected to support increased production volumes, product development, and compliance with applicable regulatory and quality standards.

Capital expenditures are expected to include the acquisition of manufacturing machinery, equipment, and improvements to facilities used in our operations. Working capital and general corporate purposes may include operating expenses, inventory purchases, administrative costs, and other general business expenses. Public company and compliance-related expenses are expected to include costs associated with legal, accounting, reporting, regulatory compliance, investor relations, and corporate governance requirements.

If we raise less than the maximum amount of net proceeds, we intend to prioritize expenditures supporting core manufacturing operations and essential working capital needs, and we may reduce or delay other planned uses. Pending their use, we intend to invest the net proceeds in short-term, interest-bearing, investment-grade securities or deposit them in bank accounts.

**3.3. Proceeds Under Alternative Subscription Scenarios**

Because this offering does not have a minimum subscription requirement, the amount of net proceeds available to us will depend on the number of shares sold. The following table illustrates our estimated net proceeds assuming various levels of completion of this offering, after deducting estimated offering expenses payable by us:

---

| | | |
|:---|:---|:---|
| **Percentage of Shares Sold** | **Shares Sold by the Company** | **Estimated Net Proceeds** |
| 100% | 100000000 | $49908000 |
| 75% | 75000000 | $37408000 |
| 50% | 50000000 | $24908000 |
| 25% | 25000000 | $12408000 |

---

---

| |
|:---|
| 15 |
| *[**Table of Contents**](#TOC)* |

---

If less than the maximum number of shares offered by us are sold, we intend to adjust the use of proceeds by prioritizing expenditures that are critical to maintaining and supporting our core operations. Specifically, in the event of partial completion of the offering, we expect to allocate proceeds in the following order of priority:

1. Working capital and operating expenses necessary to support ongoing manufacturing, construction, and administrative activities.

2. Essential capital expenditures required to maintain existing production capacity and regulatory compliance.

3. Expansion of honey straw manufacturing operations.

4. Expansion of pharmaceutical and dietary supplements manufacturing operations.

5. Public company and compliance-related expenses beyond baseline reporting and regulatory requirements.

If the proceeds raised are substantially less than anticipated, we may delay, reduce, or eliminate certain planned expansion activities and capital expenditures. The amounts and timing of expenditures under any alternative subscription scenario will depend on operational needs, regulatory requirements, and market conditions at the time proceeds are received.

We will not receive any proceeds from the sale of shares by the selling stockholders under any subscription scenario.

**3.4. Management Discretion and Timing of Use**

Our management will have broad discretion in the allocation and use of the net proceeds from this offering. Accordingly, investors will be relying on the judgment of our management with respect to the application of these proceeds. The amounts and timing of our actual expenditures may differ from those described in this prospectus and will depend on a number of factors, including the amount of proceeds actually raised, operating results, regulatory requirements, market conditions, and business opportunities that may arise.

The timing of the use of proceeds will be influenced by factors such as the pace of expansion of our manufacturing operations, the availability and cost of equipment and facilities, regulatory approval processes, and general economic and industry conditions. As a result, we may not be able to immediately apply the proceeds to their intended uses.

Our management may determine that it is in the best interests of the Company to reallocate proceeds among the uses described in this prospectus or to use proceeds for purposes other than those currently contemplated. Any such changes could occur without further stockholder approval. Actual use of proceeds may differ materially from our current plans, and there can be no assurance that the proceeds will be used in a manner that enhances stockholder value.

**3.5. Pending Use and Temporary Investment of Proceeds**

Pending the application of the net proceeds from this offering to the uses described in this prospectus, we intend to invest any unused proceeds in short-term, interest-bearing, investment-grade securities, deposit accounts, or other cash equivalents. Such investments are expected to be consistent with our liquidity needs and capital preservation objectives.

These temporary investments may not yield a significant return and may be subject to risks, including changes in interest rates, market conditions, and the financial condition of the institutions in which funds are deposited or invested. There can be no assurance that we will achieve any particular return on these investments, or that we will not incur losses on amounts temporarily invested.

---

| |
|:---|
| 16 |
| *[**Table of Contents**](#TOC)* |

---

**3.6. Relationship to Liquidity and Capital Resources**

The net proceeds from this offering are expected to improve our liquidity position and provide additional working capital to support our ongoing operations and planned expansion activities. The proceeds are intended to supplement our existing cash resources and are expected to enhance our ability to fund operating expenses, capital expenditures, and regulatory and compliance costs in the near term.

Even if we sell all of the shares offered by us in this offering, the net proceeds may not be sufficient to fully fund our operations, planned expansion initiatives, and capital requirements over the long term. Our future liquidity and capital resources will depend on numerous factors, including our operating performance, cash flows from operations, capital expenditure requirements, regulatory compliance costs, and market conditions.

If our cash flows from operations and the net proceeds from this offering are insufficient to meet our liquidity needs, we may be required to obtain additional financing through debt or equity offerings or other financing arrangements. There can be no assurance that such additional financing will be available on acceptable terms, or at all. Any additional equity financing could result in further dilution to stockholders, while debt financing could impose restrictive covenants or require significant interest payments.

For a more detailed discussion of our liquidity, capital resources, and cash flow requirements, see "Management's Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources."

**4. DILUTION**

**4.1. Net Tangible Book Value Before the Offering**

Net tangible book value represents the amount of our total tangible assets less total liabilities. Tangible assets consist of total assets excluding intangible assets.

As of **December 31, 2025**, the date of our most recent audited balance sheet included in this prospectus, our net tangible book value was **$9,775,456**. Based on **2,854,462,696 shares of common stock outstanding** as of that date, our net tangible book value per share was approximately **$0.0034**.

The following table sets forth our net tangible book value before this offering:

---

| | |
|:---|:---|
| **Amount** | **Before** <br> **the Offering** |
| Total assets | $29506190 |
| Less: Intangible assets | (19046731) |
| **Total tangible assets** | **10459459** |
| Total liabilities | (684003) |
| **Net tangible book value** | $**9775456** |
| Shares of common stock outstanding | 2854462696 |
| **Net tangible book value per share** | $**0.0034** |

---

The net tangible book value information set forth above is derived from our **audited financial statements** included elsewhere in this prospectus and should be read in conjunction with those financial statements and the related notes thereto.

---

| |
|:---|
| 17 |
| *[**Table of Contents**](#TOC)* |

---

**4.2. Effect of This Offering on Net Tangible Book Value**

After giving effect to the sale of 100,000,000 shares of our common stock offered by us at a public offering price of $0.50 per share, and after deducting estimated offering expenses payable by us of approximately $92,000, our net tangible book value as of the most recent balance sheet date would have been **$59,683,456**. This represents an increase in net tangible book value attributable to new investors of **$49,908,000**, which equals the estimated net proceeds from this offering.

Based on **2,954,462,696** shares of common stock outstanding after this offering, our as-adjusted net tangible book value per share would have been approximately **$0.0202**.

The following table illustrates the effect of this offering on our net tangible book value:

---

| | |
|:---|:---|
|  | **Amount** |
| **Net tangible book value before the offering** | $9775456 |
| **Net proceeds from the offering** | $49908000 |
| **As-adjusted net tangible book value after the offering** | $59683456 |
| **Shares outstanding before the offering** | 2854462696 |
| **Shares issued in this offering** | 100000000 |
| **Shares outstanding after the offering** | 2954462696 |
| **As-adjusted net tangible book value per share** | $0.0202 |

---

The as-adjusted net tangible book value information set forth above is based on the assumptions described above and should be read together with our financial statements and related notes, the "Capitalization" section, and the "Use of Proceeds" section included elsewhere in this prospectus.

---

| |
|:---|
| 18 |
| *[**Table of Contents**](#TOC)* |

---

**4.3. Dilution to New Investors**

Dilution per share to new investors represents the difference between the public offering price per share and the as-adjusted net tangible book value per share after giving effect to this offering.

As described above, our net tangible book value per share before this offering was approximately **$0.0034**. After giving effect to the sale of 100,000,000 shares of our common stock offered by us at a public offering price of **$0.50** per share, and after deducting estimated offering expenses payable by us, our as-adjusted net tangible book value per share would have been approximately **$0.0202**.

Accordingly, investors purchasing shares of common stock in this offering will experience immediate dilution of approximately **$0.4798** per share, which represents the difference between the offering price of **$0.50** per share and the as-adjusted net tangible book value per share of **$0.0202** after this offering.

This dilution is attributable to the fact that existing stockholders acquired their shares at prices substantially lower than the offering price and that the offering price significantly exceeds our net tangible book value per share prior to this offering.

**4.4. Dilution Under Alternative Offering Scenarios**

The following table illustrates the dilution to new investors assuming partial completion of this offering at various subscription levels. The calculations below are based on the assumptions described in this prospectus, including a public offering price of $0.50 per share, estimated offering expenses payable by us of approximately $92,000, and net tangible book value as of the most recent balance sheet date.

---

| | | | |
|:---|:---|:---|:---|
|  | **75% of** <br> **Offering Sold** | **50% of** <br> **Offering Sold** | **25% of** <br> **Offering Sold** |
| **Shares sold by the Company** | 75000000 | 50000000 | 25000000 |
| **Net tangible book value before offering** | $9775456 | $9775456 | $9775456 |
| **Net proceeds from offering** | $37408000 | $24908000 | $12408000 |
| **As-adjusted net tangible book value after offering** | $47183456 | $34683456 | $22183456 |
| **Shares outstanding after offering** | 2929462696 | 2904462696 | 2879462696 |
| **As-adjusted net tangible book value per share** | $0.0161 | $0.0120 | $0.0077 |
| **Dilution per share to new investors** | $0.4839 | $0.4880 | $0.4923 |

---

---

| |
|:---|
| 19 |
| *[**Table of Contents**](#TOC)* |

---

The information above assumes that only the shares offered by the Company are sold and that no shares are sold by the selling stockholders. The dilution to new investors increases as fewer shares are sold in this offering because the fixed offering expenses are spread over a smaller number of shares, resulting in a lower as-adjusted net tangible book value per share.

These alternative offering scenarios demonstrate the sensitivity of dilution to the level of proceeds raised in this offering.

**4.5. Comparative Ownership and Capital Contribution**

Existing stockholders acquired their shares of common stock at prices that were substantially lower than the public offering price of $0.50 per share. As a result, investors purchasing shares in this offering will make a significantly greater capital contribution on a per-share basis than existing stockholders for the same class of securities.

The following table summarizes the comparative ownership and capital contribution of existing stockholders and new investors based on information contained in this prospectus:

---

| | | |
|:---|:---|:---|
|  | **Existing Stockholders** | **New Investors** |
| **Class of security** | Common stock | Common stock |
| **Price per share** | Substantially below $0.50 | $0.50 |
| **Timing of issuance** | Prior periods | This offering |
| **Capital contribution per share** | Significantly lower | Significantly higher |
| **Immediate effect on net tangible book value** | Increase | Dilution |

---

Because the consideration paid by existing stockholders for their shares was significantly lower than the offering price, existing stockholders will experience an immediate increase in the net tangible book value of their shares as a result of the proceeds from this offering. In contrast, new investors will incur immediate dilution because the offering price exceeds the net tangible book value per share before and after this offering.

Accordingly, a substantial portion of the benefit of the capital raised in this offering will accrue to existing stockholders through an increase in the net tangible book value attributable to their previously acquired shares.

---

| |
|:---|
| 20 |
| *[**Table of Contents**](#TOC)* |

---

**4.6. Relationship to Capitalization**

The dilution information presented in this section is directly derived from, and should be read together with, the capitalization of the Company before and after this offering. The capitalization table included elsewhere in this prospectus reflects the same assumptions regarding the number of shares outstanding, the number of shares offered by the Company, and the estimated net proceeds from this offering.

The increase in net tangible book value and the dilution to new investors described above are attributable to the net proceeds received by the Company from the sale of shares offered by us, as reflected in the "Use of Proceeds" section of this prospectus. The capitalization table and the dilution calculations are based on the same offering price, estimated offering expenses, and share counts and are intended to present a consistent view of the financial impact of this offering on the Company and its stockholders.

Any changes in the assumptions used in the "Capitalization" or "Use of Proceeds" sections, including changes in the number of shares sold, offering expenses, or use of proceeds, would result in corresponding changes to the dilution information presented in this section. Investors are encouraged to review the "Capitalization" and "Use of Proceeds" sections in conjunction with this dilution disclosure to fully understand the effects of this offering on the Company's capitalization and stockholder equity.

**5. CAPITALIZATION**

**5.1. Capitalization as of the Most Recent Balance Sheet Date**

The following table sets forth our capitalization as of **December 31, 2025**, the date of our most recent audited balance sheet included in this prospectus. This information should be read in conjunction with our audited financial statements and the related notes included elsewhere in this prospectus.

---

| | |
|:---|:---|
| **Amount**  | **December 31,** <br> **2025** |
| Total assets | $29506190 |
| Total liabilities | $684003 |
| **Stockholders' equity** | $**28822187** |
| **Net tangible book value** | $**9775456** |

---

Net tangible book value represents total tangible assets less total liabilities. Tangible assets consist of total assets excluding intangible assets. As of December 31, 2025, the Company had $19,046,731 of intangible assets, resulting in total tangible assets of $10,459,459.

---

| |
|:---|
| 21 |
| *[**Table of Contents**](#TOC)* |

---

The net tangible book value presented above is derived from amounts included in our audited financial statements and is used as the basis for the dilution calculations discussed under "Dilution."

This capitalization table reflects our historical financial position prior to giving effect to this offering and does not include any adjustments related to the sale of shares in this offering or the application of the net proceeds therefrom.

**5.2. Capitalization Before the Offering**

The following table sets forth our capitalization as of **December 31, 2025**, the date of our most recent audited balance sheet included in this prospectus. This information should be read in conjunction with our audited financial statements and the related notes included elsewhere in this prospectus.

---

| | |
|:---|:---|
| **Amount** | **December 31,** <br> **2025** |
| Total assets | $29506190 |
| Total liabilities | $684003 |
| **Stockholders' equity** | $**28822187** |
| **Net tangible book value** | $**9775456** |

---

Net tangible book value represents total tangible assets less total liabilities. Tangible assets consist of total assets excluding intangible assets. As of December 31, 2025, the Company had $19,046,731 of intangible assets, resulting in total tangible assets of $10,459,459.

The net tangible book value presented above is derived from amounts included in our audited financial statements and is used as the basis for the dilution calculations discussed under "Dilution."

This capitalization table reflects our historical financial position prior to giving effect to this offering and does not include any adjustments related to the sale of shares in this offering or the application of the net proceeds therefrom.

**5.3. Capitalization After the Offering**

The following table sets forth our capitalization before and after giving effect to the sale of 100,000,000 shares of common stock offered by us at a public offering price of $0.50 per share, after deducting estimated offering expenses payable by us of approximately $92,000, assuming the offering is completed in full. This presentation is unaudited and is provided for illustrative purposes only.

---

| |
|:---|
| 22 |
| *[**Table of Contents**](#TOC)* |

---

---

| | | |
|:---|:---|:---|
|  | **Before** <br> **the Offering** | **As Adjusted** <br> **After the Offering** |
| Common stock outstanding (shares) | 2854462696 | 2954462696 |
| Total stockholders' equity | $28822187 | $78730187 |

---

As of December 31, 2025, there were 2,854,462,696 shares of common stock outstanding, as reflected in our audited financial statements. After giving effect to the issuance of 100,000,000 shares in this offering, there would be 2,954,462,696 shares of common stock outstanding.

The increase in stockholders' equity shown above reflects the receipt of approximately $49,908,000 in net proceeds from this offering (gross proceeds of $50,000,000, less estimated offering expenses of approximately $92,000). No adjustments have been made for the application of such proceeds.

This capitalization table assumes no exercise of outstanding options or warrants and no issuance of additional equity securities other than those offered by us in this offering.

The pro forma capitalization information should be read in conjunction with "Use of Proceeds," "Dilution," and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included elsewhere in this prospectus.

**5.4. Capitalization Under Alternative Offering Scenarios**

The following table sets forth our capitalization assuming partial completion of this offering at various subscription levels. The information below is unaudited and is based on the same assumptions used elsewhere in this prospectus, including a public offering price of $0.50 per share and estimated offering expenses payable by us of approximately $92,000, assuming such expenses are largely fixed. This information should be read together with our audited financial statements and the related notes included elsewhere in this prospectus.

---

| | | | |
|:---|:---|:---|:---|
|  | **75% of** <br> **Offering Sold** | **50% of** <br> **Offering Sold** | **25% of** <br> **Offering Sold** |
| Shares sold by the Company | 75000000 | 50000000 | 25000000 |
| Gross proceeds | $37500000 | $25000000 | $12500000 |
| Estimated offering expenses | $92000 | $92000 | $92000 |
| **Net proceeds** | $**37408000** | $**24908000** | $**12408000** |
| **Total stockholders' equity (as adjusted)** | $**66230187** | $**53730187** | $**41230187** |
| Shares outstanding after offering | 2929462696 | 2904462696 | 2879462696 |

---

---

| |
|:---|
| 23 |
| *[**Table of Contents**](#TOC)* |

---

As of December 31, 2025, our total stockholders' equity was $28,822,187, as reflected in our audited financial statements. The increases in stockholders' equity shown above reflect the addition of the net proceeds from the offering at each assumed subscription level. No adjustments have been made for the application of such proceeds.

Because offering expenses are largely fixed, the impact of a partial completion of the offering on stockholders' equity is disproportionately greater at lower subscription levels. As fewer shares are sold, the net proceeds available to us decrease, resulting in a corresponding reduction in the increase in stockholders' equity.

These alternative capitalization scenarios illustrate how partial completion of the offering would affect our equity structure and financial position and should be considered together with the "Use of Proceeds" and "Dilution" sections of this prospectus.

**5.5. Relationship to Dilution and Use of Proceeds**

The capitalization information presented in this section is directly related to, and should be read together with, the information included under "Dilution" and "Use of Proceeds" elsewhere in this prospectus. The increases in stockholders' equity reflected in the as-adjusted capitalization tables are based on the same assumptions regarding the number of shares sold by the Company, the public offering price, and the estimated offering expenses used in the dilution analysis.

The net proceeds assumed in the capitalization tables are consistent with the allocations described under "Use of Proceeds" and reflect the receipt of proceeds solely from the sale of shares offered by the Company in this offering. No proceeds from the sale of shares by the selling stockholders are included in the capitalization or dilution calculations.

All assumptions used in preparing the capitalization, dilution, and use of proceeds disclosures are intended to be consistent across this prospectus. Any changes in the assumptions underlying the offering, including the number of shares sold, offering expenses, or allocation of proceeds, would result in corresponding changes to the capitalization and dilution information presented herein. Investors should consider these sections together to fully understand the financial impact of this offering on the Company and its stockholders.

**5.6. Limitations and Assumptions**

The capitalization information presented in this section is based on a number of assumptions and is provided for illustrative purposes only. These assumptions include, among others, the sale of shares offered by the Company at a public offering price of $0.50 per share, estimated offering expenses payable by us of approximately $92,000, and the absence of any additional issuances of equity securities or changes in outstanding indebtedness other than those described in this prospectus.

---

| |
|:---|
| 24 |
| *[**Table of Contents**](#TOC)* |

---

The capitalization tables do not reflect the actual use of the net proceeds from this offering, potential operating losses after the most recent balance sheet date, or any future equity or debt financings that we may undertake. In addition, the capitalization information assumes no exercise of outstanding options or warrants and no issuance of additional shares other than those offered by the Company in this offering.

Actual capitalization following the completion of this offering may differ materially from the information presented herein depending on the number of shares sold, the timing and application of the net proceeds, changes in our financial condition or operating results, and other factors. Investors should not place undue reliance on the capitalization information set forth in this section and should read it together with our financial statements and the related notes, as well as the other information contained in this prospectus.

**6. PLAN OF DISTRIBUTION**

**6.1. Offering Structure and Method of Distribution**

This offering is being conducted as a direct, self-underwritten, best-efforts public offering. We are offering shares of our common stock directly to investors without the involvement of a traditional underwriter. There is no minimum number of shares required to be sold in this offering, and we may sell any number of shares up to the maximum amount being offered.

We are offering 100,000,000 shares of our common stock at a fixed public offering price of $0.50 per share. The shares offered by the Company will be sold on our behalf by our Chief Executive Officer. No commissions will be paid to our Chief Executive Officer for selling shares in this offering. We may, in our discretion, engage additional placement agents or underwriters in the future; however, no such arrangements have been made as of the date of this prospectus.

In addition, certain selling stockholders are offering up to 170,175,496 shares of common stock pursuant to this registration statement. The selling stockholders will sell their shares at a fixed price of $0.50 per share for the duration of the offering. We will not receive any proceeds from the sale of shares by the selling stockholders.

The offering will terminate upon the earlier of (i) the sale of all shares offered pursuant to this registration statement or (ii) 365 days from the effective date of this prospectus, unless extended by our board of directors for an additional 90 days. We reserve the right to terminate the offering at any time for any reason.

Because this is a best-efforts offering, there is no assurance that we will be able to sell any or all of the shares being offered. Investors may be exposed to the risk that only a portion of the shares offered will be sold, or that no shares will be sold at all.

**6.2. Role of Officers and Underwriter Status**

Our Chief Executive Officer will offer and sell the shares of common stock offered by the Company directly to investors on a best-efforts basis. Our Chief Executive Officer will not be required to sell any specific number or dollar amount of shares and will use reasonable efforts to sell the shares offered pursuant to this prospectus. No officer is obligated to purchase any shares in this offering.

Because our Chief Executive Officer is offering and selling shares of common stock on our behalf, he is deemed to be an "underwriter" within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended. As a result, our Chief Executive Officer will be subject to the prospectus delivery and liability provisions of the Securities Act, including the civil liability provisions of Sections 11 and 12 of the Securities Act.

---

| |
|:---|
| 25 |
| *[**Table of Contents**](#TOC)* |

---

We will not pay any commissions, finders' fees, or other compensation to our Chief Executive Officer or any other officer in connection with the sale of shares in this offering. Our officers will not receive any proceeds from the sale of shares offered by the Company, other than their existing compensation arrangements unrelated to this offering.

**6.3. Best-Efforts Offering; No Minimum Subscription**

This offering is being conducted on a best-efforts basis, which means that neither the Company nor any person engaged in the distribution of the securities is required to sell a specific number or dollar amount of shares. There is no minimum number of shares that must be sold in order for this offering to close, and there can be no assurance that any shares will be sold.

Because this offering does not have a minimum subscription requirement, investors will not have the benefit of an escrow arrangement. The proceeds from the sale of shares offered by the Company will be immediately available to us upon receipt and may be used as described under "Use of Proceeds," regardless of whether we sell all, a substantial portion, or only a limited number of the shares offered.

As a result, if we are unable to sell a sufficient number of shares, we may not raise adequate proceeds to fully implement our business plan or to achieve our stated objectives. Investors may therefore be exposed to the risk that the proceeds raised in this offering will be insufficient to fund our operations or planned activities to the extent contemplated in this prospectus.

**6.4. Conflicts of Interest**

Our Chief Executive Officer is responsible for offering and selling the shares of common stock offered by the Company in this offering while simultaneously serving as an executive officer of the Company. As a result, a potential conflict of interest exists between his role in effecting sales of the securities and his fiduciary duties to the Company and its stockholders.

Because our Chief Executive Officer is deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act in connection with this offering, he is subject to the prospectus delivery requirements and the civil liability provisions of the Securities Act, including Sections 11 and 12. These dual roles may create incentives that differ from those of investors, including decisions regarding the timing and manner of sales of securities.

We have not established any formal procedures to address or mitigate these potential conflicts of interest beyond full disclosure in this prospectus. No officer or director will receive any commissions, fees, or other compensation in connection with the sale of shares in this offering. Investors should carefully consider these potential conflicts of interest before making an investment decision.

**6.5. Selling Stockholders**

This prospectus also relates to the resale by certain selling stockholders of up to **170,175,496 shares of our common stock** that are registered for resale pursuant to this registration statement. The selling stockholders acquired their shares prior to this offering and are not obligated to sell any specific number of shares. The selling stockholders may sell all, some, or none of the shares offered by them under this prospectus.

The selling stockholders may sell their shares from time to time at a fixed price of **$0.50 per share** for the duration of the offering. The shares offered by the selling stockholders may be sold directly to purchasers, through brokers or dealers, or through any other lawful means permitted under applicable securities laws. Any broker-dealer involved in effecting sales of shares on behalf of the selling stockholders may be deemed an "underwriter" within the meaning of the Securities Act.

---

| |
|:---|
| 26 |
| *[**Table of Contents**](#TOC)* |

---

We will **not receive any proceeds** from the sale of shares by the selling stockholders. All proceeds from such sales, if any, will be retained by the selling stockholders. The selling stockholders will bear any commissions, discounts, or other expenses associated with the sale of their shares, other than expenses of registration, which are being paid by the Company.

The selling stockholders and the number of shares offered by each selling stockholder are identified under the caption "Selling Stockholders" elsewhere in this prospectus.

**6.6. Transfer Agent and Registrar**

Our transfer agent and registrar for our common stock is **Colonial Stock Transfer Company, Inc.**, located at **7840 S 700 E, Sandy, UT 84070**. Colonial Stock Transfer Company, Inc. is a registered transfer agent with the Securities and Exchange Commission.

The transfer agent and registrar maintains the records of holders of our common stock, processes transfers of shares, issues and cancels share certificates (if applicable), and performs other customary transfer agent and registrar services in connection with the trading and transfer of our common stock.

**6.7. Regulation M and Compliance Matters**

We and any persons participating in the distribution of the shares offered by this prospectus are subject to the applicable provisions of **Regulation M** under the Securities Exchange Act of 1934, as amended. Regulation M is intended to prevent manipulative practices by persons with an interest in the outcome of a securities distribution and generally prohibits certain activities that could artificially influence the market for a security during the applicable restricted period.

During the distribution of the shares offered hereby, we, our officers, directors, and any other persons participating in the offering may not bid for, purchase, or attempt to induce any person to bid for or purchase shares of our common stock, other than as permitted under Regulation M. These restrictions may limit the ability of participating persons to engage in market-making activities or other transactions involving our common stock during the distribution period.

Compliance with Regulation M and other applicable federal and state securities laws is required throughout the offering process. Any failure to comply with these requirements could result in regulatory action and may adversely affect the completion of this offering or the development of a trading market for our common stock.

**7. DETERMINATION OF OFFERING PRICE**

**7.1. Pricing of the Offering**

The public offering price of the shares offered hereby is **$0.50 per share**. The offering price was determined arbitrarily by us and does not bear any relationship to our assets, book value, historical results of operations, or any other established criteria for valuing a company. The offering price was not established through any independent valuation, appraisal, or market study.

In determining the offering price, we considered a number of factors, including, among others:

· The absence of a public trading market for our common stock;

· Our financial condition and limited operating history;

· The risks associated with our business and industry;

---

| |
|:---|
| 27 |
| *[**Table of Contents**](#TOC)* |

---

· The anticipated use of proceeds from this offering;

· The level of dilution to new investors; and

· General market conditions at the time the offering was contemplated.

Because the offering price was not derived from a valuation methodology commonly used for publicly traded companies, the price at which our common stock may trade, if a trading market develops, may be significantly lower than the offering price. There can be no assurance that investors will be able to resell shares purchased in this offering at or above the offering price, or at all.

**7.2. Market Maker and Trading Market Matters**

There is currently **no public trading market** for our common stock. Prior to this offering, our common stock has not been listed or quoted on any securities exchange or inter-dealer quotation system, and there can be no assurance that an active or liquid trading market will ever develop.

Upon completion of this offering, we intend to seek to have our common stock quoted on the OTCQB marketplace operated by OTC Markets Group Inc. Quotation on the OTCQB is subject to the approval of a market maker and satisfaction of applicable eligibility requirements. We have **not engaged any market maker**, and there can be no assurance that a market maker will agree to make a market in our common stock, that quotation on the OTCQB will be obtained, or that, if obtained, such quotation will be maintained.

Market makers are not obligated to continue to make a market in our common stock and may discontinue their activities at any time without notice. Even if a trading market develops, the market price of our common stock may be volatile or may not reflect the value of our business, financial condition, or results of operations. The absence of an established public trading market may adversely affect investors' ability to resell shares purchased in this offering or to obtain accurate

**8. DESCRIPTION OF SECURITIES**

**8.1. General**

The only class of securities registered hereby is the registrant's common stock, $0.01 par value per share. This registration statement covers an aggregate of 270,175,496 shares of common stock, which amount includes shares to be offered by the Company and shares to be registered for resale by certain selling stockholders. The proposed maximum public offering price per share is $0.50.

**8.2. Authorized Capitalization; Outstanding Shares**

As of December 31, 2025, there were 2,854,462,696 shares of common stock outstanding. After giving effect to the issuance by the Company of 100,000,000 shares in this offering, there would be 2,954,462,696 shares of common stock outstanding. The pro forma capitalization information assumes no exercise of outstanding options or warrants and no issuance of additional equity securities other than those offered by the Company in this offering.

The shares being registered under this registration statement consist of 100,000,000 shares issuable by the Company in this offering and 170,175,496 shares held by selling stockholders that are being registered for resale.

---

| |
|:---|
| 28 |
| *[**Table of Contents**](#TOC)* |

---

**8.3. Description of Common Stock**

Each holder of common stock is entitled to one vote per share on all matters submitted to a vote of stockholders. Except as otherwise required by applicable law or the registrant's governing documents, holders of common stock will vote together as a single class. The holders of common stock are entitled to receive dividends, if, as and when declared by the Board of Directors out of legally available funds. In the event of liquidation, dissolution or winding up of the registrant, holders of common stock are entitled to share ratably in the assets available for distribution to stockholders after payment of liabilities and after satisfaction of any preferential rights of any then-existing preferred stock (of which there is none outstanding as of the date of this prospectus). The common stock does not have preemptive, subscription, redemption or conversion rights.

**8.4. Preferred Stock; Other Securities**

As of the date of this prospectus, the registrant has not issued any series of preferred stock and there are no outstanding options, warrants or other convertible securities. The Company does not currently maintain any equity incentive plans or other equity-based compensation plans and, accordingly, no options, restricted stock awards or similar awards are outstanding. If and when the Company adopts equity incentive plans or issues other classes or series of securities, such actions would be subject to approval by the Board of Directors and, where required, by the Company's stockholders and would be disclosed in accordance with applicable SEC rules.

**8.5. Transfer Agent and Registrar**

The transfer agent and registrar for the registrant's common stock is Colonial Stock Transfer Company, Inc., located at 7840 S 700 E, Sandy, UT 84070. Colonial Stock Transfer Company, Inc. is a registered transfer agent.

**8.6. Trading Market**

There is currently no public trading market for the registrant's common stock. The registrant intends to seek quotation of its common stock on the OTCQB marketplace operated by OTC Markets Group Inc. following the offering, but quotation is subject to the approval of a market maker and satisfaction of applicable eligibility requirements. There can be no assurance that a market maker will agree to make a market for the common stock or that any quotation will be obtained or maintained.

**8.7. Restrictions on Transfer; Resale by Selling Stockholders**

The shares held by the selling stockholders that are registered for resale pursuant to this prospectus may be sold from time to time by the selling stockholders in one or more transactions, at prevailing market prices or at negotiated prices, through brokers, dealers or directly to purchasers, as described under "Plan of Distribution." The Company will not receive any proceeds from the sale of the shares sold by selling stockholders. The selling stockholders are not subject to any contractual lock-up agreements restricting their ability to resell the shares, except as may be required by applicable securities laws.

**8.8. Anti-Dilution/Other Provisions**

The registrant's articles of incorporation and bylaws (as in effect) contain provisions that may have the effect of delaying, deferring or preventing a change in control of the registrant or changes in the registrant's management. These provisions may include, without limitation, the ability of the Board to issue additional shares of preferred stock (subject to any shareholder approvals that may be required under applicable law), the classification of the Board of Directors, and other provisions. The registrant's articles of incorporation authorize a number of shares and classes that could be issued in the future and that could adversely affect the voting power of holders of common stock. Any issuance of additional shares of common or preferred stock would dilute existing stockholders and could subordinate or otherwise adversely affect the rights of holders of common stock. (See "Capitalization.")

---

| |
|:---|
| 29 |
| *[**Table of Contents**](#TOC)* |

---

**8.9. Section 16 Reporting**

Because the registrant's common stock has not previously been registered under Section 12 of the Exchange Act, the reporting obligations of Section 16(a) were not previously applicable to the registrant's directors, executive officers or greater-than-ten-percent beneficial owners prior to the effectiveness of this registration statement. After effectiveness, applicable persons will be required to file Section 16 reports concerning their beneficial ownership of the registrant's common stock.

**9. INTERESTS OF NAMED EXPERTS AND COUNSEL**

The consolidated financial statements of the Company included in this registration statement have been audited by Fortune CPA INC. 8831, an independent registered public accounting firm. The report of Fortune CPA INC. 8831 is included elsewhere in this registration statement and is incorporated herein by reference. To the best of the Company's knowledge, Fortune CPA INC. 8831 has no direct or indirect interest in the Company, including any ownership of the Company's securities, and no relationship with the Company that would impair its independence as defined under Rule 2-01 of Regulation S-X (17 C.F.R. § 210.2-01).

The Company is not aware of any ownership of the Company's securities by Fortune CPA INC. 8831, including securities owned, received, to be received, or subject to options, warrants, or other rights, and any such interests, if any, do not exceed the threshold requiring disclosure under Item 509 of Regulation S-K. The written consent of Fortune CPA INC. 8831 to the inclusion of its report in this registration statement is filed as an exhibit hereto.

Apart from the independent registered public accounting firm named above, the Law Office of Carl P. Ranno has also been named in this registration statement whose report or opinion is relied upon in connection with the offering.

The Company has engaged legal counsel in connection with the preparation and filing of this registration statement and the securities offered hereby. To the best of the Company's knowledge, neither such counsel nor any firm, corporation, partnership, or other entity of which such counsel is a member or with which such counsel is affiliated has any direct or indirect material interest in the Company. Any ownership of the Company's securities by counsel, if any, does not exceed $50,000 in fair market value, and therefore is not deemed substantial and is not required to be disclosed pursuant to Instruction 1 to Item 509 of Regulation S-K.

For purposes of the foregoing disclosure, the Company has considered the interests of the entire firm or entity employing such counsel, including all attorneys and non-clerical personnel participating in the matter on behalf of such firm. Based on this review, no interest requiring disclosure under Item 509 of Regulation S-K exists.

**10. INFORMATION WITH RESPECT TO THE REGISTRANT**

The following information is furnished with respect to Pharmaceutical Resource Technology, Inc. (the "Company"), in accordance with Item 11 of Form S-1 and the applicable items of Regulation S-K.

**10.1. Description of Business (Item 101 of Regulation S-K)**

Pharmaceutical Resource Technology, Inc. is a Wyoming corporation originally incorporated on June 17, 2019 under the name Jaison Phytochem, Inc. The Company commenced material operations in January 2020 and completed a corporate reorganization and name change to Pharmaceutical Resource Technology, Inc. in March 2023.

---

| |
|:---|
| 30 |
| *[**Table of Contents**](#TOC)* |

---

The Company operates as a U.S. holding company with principal executive offices in Singapore. The Company does not legally own any subsidiaries. Instead, its operations are conducted through asset-based acquisitions and contractual management and services arrangements, primarily in Singapore.

The Company's business activities currently span three primary areas:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **Honey straw manufacturing**, involving the production, packaging, and sale of single-serve honey products for food and consumer markets;

![](pharmaceutical_s1img2.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **Pharmaceutical and dietary supplements manufacturing**, conducted in compliance with applicable regulatory and certification requirements in Singapore; and

![](pharmaceutical_s1img3.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **Building and construction services**, which support the development and expansion of manufacturing facilities and related infrastructure.

![](pharmaceutical_s1img4.jpg)

Based on recent operations, approximately 18% of revenues are derived from honey straw manufacturing, approximately 18% from pharmaceutical and dietary supplements manufacturing, and approximately 64% from building and construction activities.

The Company conducts substantially all of its operational staffing, manufacturing support, and certain administrative functions through long-standing contractual arrangements with **Superbee Network Singapore Pte. Ltd.**, a Singapore company under common control with the Company's executive officers. The Company currently has two permanent employees, both of whom are its executive officers and directors.

The Company markets and sells its products and services primarily in Asia and currently has customers in approximately ten countries. The Company holds the material licenses and regulatory approvals required for its existing operations in Singapore, although expansion into new markets may require additional approvals.

The Company intends to use the proceeds from this offering, together with existing resources, to expand honey straw and dietary supplements manufacturing capacity, establish additional production facilities in new markets, and fund general corporate and operating expenses.

---

| |
|:---|
| 31 |
| *[**Table of Contents**](#TOC)* |

---

**10.2. Description of Property (Item 102 of Regulation S-K)**

![](pharmaceutical_s1img5.jpg)

The Company's principal executive offices are located at **No. 1 Kaki Bukit Avenue 3, #09-11, KB-1, Singapore 416087**. The Company does not own real property. Its operations are conducted through leased facilities and through third-party and affiliated service providers in Singapore and other parts of Asia. The Company believes that its existing facilities and access arrangements are adequate for its current operations.

**10.3. Legal Proceedings (Item 103 of Regulation S-K)**

The Company is not a party to any material pending legal proceedings, nor is any of its property the subject of a material pending legal proceeding. The Company is not aware of any governmental or regulatory proceedings that are expected to have a material adverse effect on its business, financial condition, or results of operations.

**10.4. Market Price of and Dividends on Common Equity; Related Stockholder Matters (Item 201 of Regulation S-K)**

There is currently **no established public trading market** for the Company's common stock. The Company intends to seek quotation of its common stock on the OTCQB marketplace; however, there can be no assurance that a market maker will file the required application or that such quotation will be obtained.

The offering contemplates a public offering price of **$0.50 per share** for the shares offered by the Company. The Company has never declared or paid cash dividends on its common stock and does not anticipate paying dividends in the foreseeable future. The Company intends to retain future earnings, if any, to fund operations and growth.

**10.5. Financial Statements (Regulation S-X)**

The registration statement includes consolidated financial statements audited by **Fortune CPA INC. 8831**, an independent registered public accounting firm, for the fiscal years ended December 31, 2025 and 2024, prepared in accordance with U.S. GAAP and Regulation S-X. All required financial statement schedules have been omitted because the information is included in the consolidated financial statements or the notes thereto. The Company qualifies as a smaller reporting company and has complied with the applicable scaled disclosure requirements.

**10.6. Selected Financial Data (Item 301 of Regulation S-K)**

As a smaller reporting company, the Company has provided selected financial information within the audited financial statements and Management's Discussion and Analysis. For the fiscal year ended December 31, 2025, the Company reported revenue of **$10,822,348**, net income of **$264,820**, cash and cash equivalents of **$2,855,160**, and working capital of **$4,289,683**, as reflected in the audited financial statements.

---

| |
|:---|
| 32 |
| *[**Table of Contents**](#TOC)* |

---

**10.7. Supplementary Financial Information (Item 302 of Regulation S-K)**

All supplementary financial information required by Regulation S-X is included in the consolidated financial statements or the notes thereto. No additional quarterly or supplementary schedules are required.

**10.8. Management's Discussion and Analysis (Item 303 of Regulation S-K)**

Management's Discussion and Analysis of Financial Condition and Results of Operations is included elsewhere in this prospectus and should be read in conjunction with the audited financial statements. MD&A discusses results of operations for the fiscal years ended December 31, 2025 and 2024, liquidity and capital resources, known trends and uncertainties, reliance on related-party operational support, and the anticipated impact of this offering.

**10.9. Changes in and Disagreements with Accountants (Item 304 of Regulation S-K)**

There have been **no disagreements** with the Company's independent registered public accounting firm on accounting or financial disclosure matters that would require disclosure under Item 304 of Regulation S-K.

**10.10. Market Risk Disclosures (Item 305 of Regulation S-K)**

As a smaller reporting company, the Company is not required to provide quantitative market risk disclosures. The Company has provided qualitative disclosures regarding market risks, including foreign jurisdiction risk, reliance on related-party service providers, liquidity risk, and the absence of an established trading market for its common stock.

**10.11. Directors and Executive Officers (Item 401 of Regulation S-K)**

The Company's directors and executive officers are:

· **Jacksaa Tan** — Chairman of the Board and Chief Executive Officer

· **Hui Eng Ling** — Director and Chief Financial Officer

These individuals collectively control a substantial majority of the Company's outstanding common stock and voting power.

**10.12. Executive Compensation and Corporate Governance (Item 402 and Item 407)**

The Company does not maintain any equity incentive plans, stock option plans, or other equity-based compensation arrangements. Executive compensation consists primarily of cash compensation and related-party arrangements disclosed elsewhere in this prospectus. The Company relies on its directors and officers for governance and oversight and complies with applicable corporate governance requirements for a smaller reporting company.

---

| |
|:---|
| 33 |
| *[**Table of Contents**](#TOC)* |

---

**10.13. Security Ownership of Certain Beneficial Owners and Management (Item 403 of Regulation S-K)**

As of December 31, 2025, there were **2,854,462,696 shares** of common stock outstanding. The Company's executive officers and directors collectively beneficially own approximately **94.03%** of the outstanding common stock prior to this offering and approximately **90.85%** following the offering, assuming all shares offered by the Company are sold. Detailed beneficial ownership information is provided in the "Selling Stockholders" and related ownership tables included elsewhere in this prospectus.

**10.14. Transactions with Related Persons and Corporate Governance (Item 404 and Item 407(a))**

The Company has entered into related-party transactions with **Superbee Network Singapore Pte. Ltd.**, an entity under common control with the Company's executive officers, for operational, administrative, and manufacturing support services and intellectual property licensing arrangements. These transactions are disclosed in the notes to the audited financial statements and in the "Related Party Transactions" section of this prospectus. Management believes such transactions are conducted on commercially reasonable terms.

**11. SELLING STOCKHOLDERS**

**11.1. Purpose of the Resale Registration**

This prospectus also relates to the resale of shares of our common stock by the selling stockholders identified elsewhere in this prospectus. The shares being offered for resale by the selling stockholders were acquired by them prior to this offering and are being registered to permit public resale from time to time by such selling stockholders.

The selling stockholders are offering their shares for their own account. Except for the shares of common stock offered by the Company in the primary offering described elsewhere in this prospectus, **we are not selling any shares** under this registration statement on behalf of the selling stockholders.

We will **not receive any proceeds** from the sale of shares by the selling stockholders. All proceeds from any sales of shares by the selling stockholders will be retained by the selling stockholders.

**11.2. Selling Stockholders and Beneficial Ownership**

This section provides information regarding the beneficial ownership of our common stock by the selling stockholders whose shares are registered for resale under this prospectus. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes shares over which a person has voting or investment power, as well as shares that a person has the right to acquire within 60 days through the exercise of options, warrants, or other rights.

Beneficial ownership is calculated pursuant to **Rule 13d-3 under the Securities Exchange Act of 1934**, which provides that a person is deemed to be the beneficial owner of securities if the person has or shares voting power or investment power with respect to such securities. Shares subject to options, warrants, or other rights exercisable within 60 days are deemed to be outstanding for purposes of computing the beneficial ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the beneficial ownership of any other person.

---

| |
|:---|
| 34 |
| *[**Table of Contents**](#TOC)* |

---

The beneficial ownership information set forth in this section and in the table appearing under "Selling Stockholders" is based on information furnished to us by the selling stockholders and is presented **as of the most recent practicable date prior to the filing of this prospectus**, assuming the sale of all shares offered for resale by the selling stockholders under this registration statement and no other changes in beneficial ownership. Except as otherwise indicated, each selling stockholder has sole voting and dispositive power over the shares beneficially owned by such selling stockholder.

**11.3. Selling Stockholders Table** 

***(As of December 31, 2025; Rule 13d-3 beneficial ownership standard)***

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Name of Selling Stockholder** | **Shares Owned Prior to Offering** | **Shares Being Offered for Resale** | **Shares Owned After Offering (Assuming All Sold)** | **% Owned Before Offering** | **% Owned After Offering** | **Relationship to the Company** |
| Tan Bee Eng Evelyn¹ | 2000000 | 2000000 | 0 | 0.07% | 0.00% | Immediate family member of CEO |
| Tan Yi May Ada² | 2000000 | 2000000 | 0 | 0.07% | 0.00% | Immediate family member of CEO |
| Tan Martin Javier³ | 2000000 | 2000000 | 0 | 0.07% | 0.00% | Immediate family member of CEO |
| Peh Lee Hua⁴ | 200000 | 200000 | 0 | 0.01% | 0.00% | Immediate family member of CFO |
| Ling Teck Hong⁵ | 200000 | 200000 | 0 | 0.01% | 0.00% | Immediate family member of CFO |
| Ang Chia Cheng David | 2000 | 2000 | 0 | 0.00% | 0.00% |  |
| Budiman Bela | 3000 | 3000 | 0 | 0.00% | 0.00% |  |
| Chan Chee Siang | 236 | 236 | 0 | 0.00% | 0.00% |  |
| Chan Shaw Fong | 3036 | 3036 | 0 | 0.00% | 0.00% |  |
| Chea Petit | 1000 | 1000 | 0 | 0.00% | 0.00% |  |
| Chay Hoy Loong Paul | 328 | 328 | 0 | 0.00% | 0.00% |  |
| Chia Kathy | 120 | 120 | 0 | 0.00% | 0.00% |  |
| Chua Kia How | 2000 | 2000 | 0 | 0.00% | 0.00% |  |
| Chua Choon Yeng Albert | 810 | 810 | 0 | 0.00% | 0.00% |  |
| Deekitwong Umaporn | 10000 | 10000 | 0 | 0.00% | 0.00% |  |

---

---

| |
|:---|
| 35 |
| *[**Table of Contents**](#TOC)* |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Name of Selling Stockholder** | **Shares Owned Prior to Offering** | **Shares Being Offered for Resale** | **Shares Owned After Offering (Assuming All Sold)** | **% Owned Before Offering** | **% Owned After Offering** | **Relationship to the Company** |
| Emilija Heleta Svrakic | 2000 | 2000 | 0 | 0.00% | 0.00% |  |
| Gan Hwee Shu | 316 | 316 | 0 | 0.00% | 0.00% |  |
| Giang Hoang Huong | 536 | 536 | 0 | 0.00% | 0.00% |  |
| Goh Chin Hong | 132 | 132 | 0 | 0.00% | 0.00% |  |
| Genevieve Lim Shao Ying | 418 | 418 | 0 | 0.00% | 0.00% |  |
| Goh Wee Leng | 1160 | 1160 | 0 | 0.00% | 0.00% |  |
| Heng Chor Huang | 630 | 630 | 0 | 0.00% | 0.00% |  |
| Hoo Chang Yaw Dennis | 1296 | 1296 | 0 | 0.00% | 0.00% |  |
| Julie Ng Bee Eng | 3700 | 3700 | 0 | 0.00% | 0.00% |  |
| Hoo Qun Yu Lienis Alexandra | 4524 | 4524 | 0 | 0.00% | 0.00% |  |
| Kagchelland Ricco | 212 | 212 | 0 | 0.00% | 0.00% |  |
| Khader Rafiq Mohamed | 1200 | 1200 | 0 | 0.00% | 0.00% |  |
| Lai Chiaw Chiaw Anne | 248 | 248 | 0 | 0.00% | 0.00% |  |
| Lee Chin Leong Jeffrey | 576 | 576 | 0 | 0.00% | 0.00% |  |
| Lim Chuan Chwee | 192 | 192 | 0 | 0.00% | 0.00% |  |
| Lim Eng Tze | 266 | 266 | 0 | 0.00% | 0.00% |  |
| Lim Meng Ling | 385 | 385 | 0 | 0.00% | 0.00% |  |
| Lim Qian Ru | 250 | 250 | 0 | 0.00% | 0.00% |  |
| Lim Suet Ni | 536 | 536 | 0 | 0.00% | 0.00% |  |
| Loo Lay Mui | 300 | 300 | 0 | 0.00% | 0.00% |  |
| Manjit Singh Paritam | 302 | 302 | 0 | 0.00% | 0.00% |  |
| Mir Fauzia Ahmad | 434 | 434 | 0 | 0.00% | 0.00% |  |
| **Ng Choon Teck** | **75000000** | **75000000** | **0** | **2.63%** | **0.00%** |  |
| Ng Kwang Huat | 400 | 400 | 0 | 0.00% | 0.00% |  |
| Ooi Jian Yuan | 128 | 128 | 0 | 0.00% | 0.00% |  |

---

---

| |
|:---|
| 36 |
| *[**Table of Contents**](#TOC)* |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Name of Selling Stockholder** | **Shares Owned Prior to Offering** | **Shares Being Offered for Resale** | **Shares Owned After Offering (Assuming All Sold)** | **% Owned Before Offering** | **% Owned After Offering** | **Relationship to the Company** |
| Sadgumpung Jiraporn | 290 | 290 | 0 | 0.00% | 0.00% |  |
| Sarah Theresa Hamsha | 702 | 702 | 0 | 0.00% | 0.00% |  |
| Seck Wai Peng | 240 | 240 | 0 | 0.00% | 0.00% |  |
| Seow Gek Lian Patricia | 228 | 228 | 0 | 0.00% | 0.00% |  |
| Tam Ern Wei Mary | 718 | 718 | 0 | 0.00% | 0.00% |  |
| Tan Puay Leng | 1200 | 1200 | 0 | 0.00% | 0.00% |  |
| Tan Yik Kwang | 223000 | 223000 | 0 | 0.01% | 0.00% |  |
| Tan Shirley | 500 | 500 | 0 | 0.00% | 0.00% |  |
| Tay Rong Gui | 500 | 500 | 0 | 0.00% | 0.00% |  |
| Tay Wee Tat | 574 | 574 | 0 | 0.00% | 0.00% |  |
| Teo Siong Hwee | 218 | 218 | 0 | 0.00% | 0.00% |  |
| **Tho Chee Seng** | **88500000** | **88500000** | **0** | **3.10%** | **0.00%** |  |
| Tiong Chris | 500 | 500 | 0 | 0.00% | 0.00% |  |
| Wang Kaili | 1200 | 1200 | 0 | 0.00% | 0.00% |  |
| Yeo Meng Hoon Jenny | 446 | 446 | 0 | 0.00% | 0.00% |  |
| Yeo Soo Hui Doris | 220 | 220 | 0 | 0.00% | 0.00% |  |
| Yew Yeu Weng Kelvin | 556 | 556 | 0 | 0.00% | 0.00% |  |
| Yip Kum Woon Andrew | 315 | 315 | 0 | 0.00% | 0.00% |  |
| Yong Hua Theresa | 596 | 596 | 0 | 0.00% | 0.00% |  |
| Yow Kwai Leng | 370 | 370 | 0 | 0.00% | 0.00% |  |
| Zarina Bee Bte Abdul Majeed | 452 | 452 | 0 | 0.00% | 0.00% |  |
| **Total** | **170175496** | **170175496** | **0** | **5.96%** | **0.00%** |  |

---

**Notes:**

1. Evelyn Bee Eng Tan is the spouse of the Company's Chief Executive Officer, Jacksaa Tan.

2. Yi May Ada Tan is the daughter of the Company's Chief Executive Officer, Jacksaa Tan.

3. Martin Javier Tan is the son of the Company's Chief Executive Officer, Jacksaa Tan.

4. Hua Lee Peh is the mother of the Company's Chief Financial Officer, Hui Eng Ling.

5. Hong Teck Ling is the father of the Company's Chief Financial Officer, Hui Eng Ling.

Percentages are based on **2,854,462,696** shares of common stock outstanding prior to the offering.

---

| |
|:---|
| 37 |
| *[**Table of Contents**](#TOC)* |

---

**11.4. Relationships and Material Transactions**

Certain of the selling stockholders are related to members of our management and therefore may be deemed affiliates of the Company. Specifically, certain selling stockholders are immediate family members of our Chief Executive Officer and Chief Financial Officer, as disclosed in the table under "Selling Stockholders." Except for these familial relationships, none of the selling stockholders has held any position as an officer or director of the Company.

Other than the issuance of shares of common stock to the selling stockholders and the relationships described above, there have been **no material transactions** between the Company and any of the selling stockholders during the past three fiscal years, or any currently proposed transactions, that are required to be disclosed pursuant to **Item 404 of Regulation S-K**.

To the extent any selling stockholder is deemed to be an affiliate of the Company due to family relationships or beneficial ownership, such status arises solely from such relationship or ownership and not from participation in the management or control of the Company. No selling stockholder, individually or collectively, exercises control over the Company as a result of the shares offered for resale pursuant to this prospectus.

The disclosures in this section should be read together with the information contained under "Selling Stockholders," "Security Ownership of Certain Beneficial Owners and Management," and "Related Party Transactions" elsewhere in this prospectus.

**11.5. Plan of Distribution for Resale Shares**

The selling stockholders may sell the shares registered for resale under this prospectus from time to time through one or more of the following methods permitted by applicable law: (i) direct sales to purchasers, (ii) sales through brokers or dealers, (iii) sales through agents, or (iv) any other lawful method permitted under the Securities Act and applicable state securities laws.

In connection with any such sales, broker-dealers or agents may receive customary commissions, discounts, or concessions, which may be negotiated by the selling stockholders. Any broker-dealer participating in the resale of shares may be deemed to be an "underwriter" within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by such broker-dealers may be deemed underwriting commissions under the Securities Act.

The selling stockholders will sell their shares at a fixed price of $0.50 per share for the duration of the offering, unless otherwise permitted under applicable law. We will not receive any proceeds from the sale of shares by the selling stockholders.

The plan of distribution applicable to the resale shares offered by the selling stockholders is subject to the provisions described under "Plan of Distribution" elsewhere in this prospectus, which should be read in conjunction with this section.

---

| |
|:---|
| 38 |
| *[**Table of Contents**](#TOC)* |

---

**11.6. Lock-Up / Transfer Restrictions**

The selling stockholders are **not subject to any contractual lock-up agreements** or other contractual restrictions that would limit their ability to resell the shares registered for resale under this prospectus, except as otherwise required by applicable securities laws.

The resale of the shares by the selling stockholders is subject to compliance with the registration requirements of the Securities Act and, to the extent applicable, the volume, manner-of-sale, and other conditions of **Rule 144** under the Securities Act. To the extent that Rule 144 is relied upon for any resale transactions, the selling stockholders must satisfy the applicable holding period, current public information, and other requirements of Rule 144 at the time of sale.

Except as described above, there are **no legal, contractual, or other restrictions** that would materially limit the ability of the selling stockholders to dispose of the shares registered for resale pursuant to this prospectus.

**11.7. Consistency and Controls (Internal Cross-Checks)**

The information contained in this "Selling Stockholders" section has been prepared to be consistent with, and should be read together with, the disclosures appearing elsewhere in this prospectus, including the sections titled "Security Ownership of Certain Beneficial Owners and Management," "Related Party Transactions," "Plan of Distribution," and "Description of Securities."

The number of shares beneficially owned by the selling stockholders, the number of shares being offered for resale, and the assumptions regarding shares outstanding before and after this offering are consistent across these sections and are based on the same underlying capitalization and beneficial ownership information. Beneficial ownership determinations have been made in accordance with Rule 13d-3 under the Exchange Act and reflect the same ownership cut-off date used throughout this prospectus.

Any changes in the number of shares outstanding, the identity of selling stockholders, or the relationships between the Company and the selling stockholders would require corresponding updates to this section and the related disclosures elsewhere in this prospectus to maintain internal consistency.

**12. BUSINESS**

**12.1. Overview of the Business**

**Legal Name and Corporate Background**

Pharmaceutical Resource Technology, Inc. (the "Company") is a Wyoming corporation. The Company conducts its primary business operations through activities located outside the United States, principally in Singapore. The Company was formed to engage in the manufacturing, distribution, and commercialization of consumer and industrial products, with operations spanning multiple regulated industries.

**Principal Lines of Business**

The Company's current business activities are focused on the following principal areas:

· The manufacture, assembly, repackaging, and distribution of honey-based products, dietary health supplements, and related consumer health products;

· Pharmaceutical and health-related manufacturing and distribution activities conducted in compliance with applicable regulatory and quality standards; and

· Construction and general building services, including civil engineering, demolition, interior design, and related construction activities, undertaken pursuant to applicable licenses and certifications.

---

| |
|:---|
| 39 |
| *[**Table of Contents**](#TOC)* |

---

These business lines are managed as part of an integrated operating strategy, although each is subject to distinct regulatory frameworks and operational requirements.

**Geographic Footprint of Operations**

The Company's operational activities are primarily conducted in Singapore. While the Company is incorporated in the United States, substantially all manufacturing, licensing, regulatory compliance, and operational activities occur outside the United States. The Company may, from time to time, evaluate opportunities to expand its geographic reach; however, no assurance can be given that such expansion will occur.

**High-Level Business Model**

The Company's business model is centered on developing and commercializing regulated products and services by leveraging licensed intellectual property, third-party manufacturing and operational support, and established regulatory approvals. The Company focuses on generating revenue through the sale of finished products and the provision of construction and related services, while maintaining flexibility to scale operations through a combination of internal resources and external service providers. The Company's ability to execute its business model depends on continued regulatory compliance, the availability of qualified personnel and third-party support, and access to sufficient capital to fund ongoing operations and growth initiatives.

**12.2. Products and Services**

**Honey Products and Dietary Supplements**

The Company is engaged in the manufacture, assembly, repackaging, and distribution of honey-based products and dietary health supplements. These products are intended for consumer use and are produced in accordance with applicable food safety, quality control, and manufacturing standards. The Company's activities in this segment include sourcing raw materials, manufacturing and packaging finished products, and distributing such products through commercial channels permitted under applicable regulations.

**Pharmaceutical and Health-Related Manufacturing Activities**

The Company also conducts pharmaceutical and health-related manufacturing activities, which include the manufacture, assembly, and repackaging of health supplement and related products. These activities are subject to regulatory oversight and require compliance with applicable good manufacturing practices, quality assurance standards, and licensing requirements. The Company's operations in this segment are designed to support the commercialization of regulated health-related products in permitted markets.

**Construction and General Building Services**

In addition to its product-based businesses, the Company provides construction and general building services. These services include general building works, civil engineering works, demolition, interior design, and related construction activities. The Company performs such services pursuant to applicable licenses and certifications that permit it to undertake projects within defined scope and value thresholds. Construction activities are typically project-based and revenue is recognized based on the completion and delivery of contracted services.

---

| |
|:---|
| 40 |
| *[**Table of Contents**](#TOC)* |

---

**Revenue-Generating Activities by Segment**

The Company generates revenue through a combination of product sales and service-based activities. Revenue from honey products, dietary supplements, and health-related manufacturing is derived primarily from the sale and distribution of finished products. Revenue from construction and general building services is derived from contracts for specific projects and services performed. The relative contribution of each segment to the Company's overall revenue may vary from period to period based on market demand, project timing, regulatory conditions, and operational capacity.

**12.3. Revenue Streams and Business Focus**

**Primary Sources of Revenue**

The Company generates revenue from multiple business activities, primarily through (i) the manufacture, assembly, repackaging, and sale of honey products and dietary health supplements, (ii) health-related and pharmaceutical manufacturing activities, and (iii) construction and general building services. Revenue from product-based activities is derived from the sale of finished goods to customers in permitted markets, while revenue from construction and building services is derived from contracts for specific projects and services performed.

**Relative Importance of Each Business Segment**

Historically, the Company's revenue has been derived from a combination of product sales and service-based activities. The relative contribution of each business segment to total revenue may vary from period to period depending on customer demand, regulatory conditions, production capacity, and the timing and scale of construction projects undertaken. Product-based activities, including honey products, dietary supplements, and health-related manufacturing, are generally intended to provide recurring revenue streams, while construction and general building services are project-based and may result in more variable revenue patterns.

**Changes in Business Focus Over Time**

The Company's business focus has evolved over time as it has expanded its operational capabilities and responded to market opportunities. While the Company initially engaged in a narrower range of activities, it has broadened its scope to include regulated health-related manufacturing and construction services alongside its honey and dietary supplement products. The Company continues to evaluate its business mix and may adjust its focus among its operating segments in the future based on regulatory developments, market demand, capital availability, and strategic considerations.

**12.4. Dependence on Third Parties and Related Parties**

**Dependence on Superbee Network Singapore Pte. Ltd.**

The Company is operationally dependent on Superbee Network Singapore Pte. Ltd. ("Superbee"), a related party, for certain key functions supporting its business operations. Superbee provides services and support that are integral to the Company's ability to conduct its manufacturing, product-related, and administrative activities. As a result, the Company's operations would be adversely affected if its relationship with Superbee were disrupted, terminated, or materially modified.

**Nature of Services Provided by Superbee**

Superbee provides various operational and support services to the Company pursuant to contractual arrangements, which may include manufacturing-related support, administrative functions, and access to certain operational resources. In addition, the Company has entered into intellectual property-related licensing arrangements with Superbee, under which the Company is granted licensed rights to use certain intellectual property. These arrangements are structured as licenses of rights between related parties and do not involve the acquisition or transfer of ownership of underlying assets.

---

| |
|:---|
| 41 |
| *[**Table of Contents**](#TOC)* |

---

**Operational and Financial Dependence Risks**

Because the Company relies on Superbee for critical services and operational support, its business is exposed to risks associated with this dependence. Any failure by Superbee to perform its obligations, whether due to financial difficulties, operational disruptions, regulatory issues, or strategic decisions, could materially and adversely affect the Company's operations, financial condition, and results of operations. The Company may not be able to promptly replace Superbee with alternative third-party providers on comparable terms, or at all, which could result in increased costs, operational delays, or interruptions to business activities.

**Common Control Considerations**

The Company and Superbee are under common control, which creates inherent conflicts of interest and raises related-party considerations. Transactions and arrangements between the Company and Superbee may not have been negotiated on an arm's-length basis, and the terms of such arrangements may differ from those that could have been obtained from unaffiliated third parties. While the Company believes that its arrangements with Superbee are appropriate for its current stage of development and operations, investors should be aware that the Company's dependence on a related party under common control heightens the risk profile of the business and may limit the Company's operational independence.

**12.5. Intellectual Property and Licensing Arrangements**

**Industrial Design License Agreement**

The Company does not own certain industrial designs used in its operations. Instead, it operates under an Industrial Design License Agreement pursuant to which it is granted licensed rights to use specified industrial designs in connection with its products and business activities. The licensed industrial designs are used in the manufacture, branding, and commercialization of certain products. The Company's ability to continue using these industrial designs is subject to compliance with the terms and conditions of the applicable license agreement.

**Patent License Agreement**

The Company is also a party to a Patent License Agreement under which it has been granted licensed rights to use certain patented technology relevant to its business. The licensed patents support the Company's product offerings and manufacturing activities. The Company does not own the underlying patents and does not have the right to transfer ownership of such patents. Its rights are limited to those expressly granted under the license agreement and are subject to termination or modification in accordance with the contractual terms.

**License-of-Right (LOR) Framework**

Certain intellectual property arrangements are structured under a License-of-Right ("LOR") framework. An LOR is a declaration by a patent owner, typically recorded with the relevant patent office, indicating a willingness to license the invention to interested parties on agreed terms. The Company's use of intellectual property under an LOR framework represents a licensing arrangement between willing parties and does not constitute an acquisition or transfer of intellectual property assets.

---

| |
|:---|
| 42 |
| *[**Table of Contents**](#TOC)* |

---

**Ownership Versus Licensing Distinction**

The Company's intellectual property strategy is based primarily on licensing rather than ownership. None of the Industrial Design License Agreement, Patent License Agreement, or LOR-based arrangements involve the acquisition of intellectual property assets by the Company. Accordingly, these arrangements do not represent transfers of assets or businesses under common control. The Company's financial statements reflect these arrangements as licensing transactions, and not as asset acquisitions, consistent with applicable accounting principles.

The Company's reliance on licensed intellectual property exposes it to risks, including the risk that such licenses may not be renewed on favorable terms, may be terminated, or may otherwise become unavailable. Any loss or limitation of access to licensed intellectual property could materially and adversely affect the Company's business, financial condition, and results of operations.

**12.6. Regulatory Environment and Compliance**

**Manufacturing Regulations**

The Company's manufacturing activities are subject to various laws and regulations governing production processes, quality control, workplace safety, and environmental protection. These requirements include compliance with applicable good manufacturing practices and standards designed to ensure that products are manufactured consistently, safely, and in accordance with specified quality requirements. Regulatory authorities have the power to conduct inspections and audits of manufacturing facilities and to impose sanctions, restrictions, or corrective measures in the event of non-compliance.

**Construction Industry Regulations**

The Company's construction and general building services are subject to regulatory frameworks governing contractor licensing, project scope limitations, safety standards, and building codes. The Company holds licenses and registrations that permit it to undertake general building, civil engineering, demolition, and interior works, subject to applicable financial grade and project value limitations. Compliance with these regulations is required for the Company to bid for, perform, and complete construction projects, and any failure to maintain required licenses or meet regulatory standards could adversely affect its operations.

**Food, Health Supplement, and Pharmaceutical Oversight**

The Company's food, honey, dietary supplement, and health-related product activities are subject to regulatory oversight relating to product safety, labeling, packaging, marketing, and distribution. This includes compliance with food safety management systems, health supplement regulations, and applicable pharmaceutical or health product standards. The Company maintains certifications and approvals intended to support compliance with these requirements; however, regulatory standards may change, and additional approvals or modifications to existing processes may be required in the future.

**Import and Export Regulatory Requirements**

The Company engages in import and export activities for raw materials, ingredients, packaging, and finished products. These activities are subject to customs laws, import licensing requirements, trade regulations, and border control procedures in the relevant jurisdictions. Delays, changes in regulatory requirements, or the loss of required import or export licenses could disrupt supply chains, increase costs, or limit the Company's ability to conduct cross-border business.

---

| |
|:---|
| 43 |
| *[**Table of Contents**](#TOC)* |

---

Compliance with the foregoing regulatory regimes is critical to the Company's operations. Regulatory requirements are subject to change, and increased regulatory scrutiny, new laws, or changes in enforcement practices could result in additional compliance costs or operational constraints, which could materially and adversely affect the Company's business, financial condition, and results of operations.

**12.7. Licenses, Certifications, and Permits**

The Company's operations are subject to licensing, certification, and permitting requirements in the jurisdictions in which it conducts business. The Company has obtained and currently maintains the material licenses, certifications, and permits required for its existing operations, as described below. Management believes that these licenses and certifications are sufficient for the Company's present scope of activities.

**Construction Licenses**

The Company holds the following construction-related licenses, which authorize it to undertake specified categories of building and civil engineering works:

· **CW01** – Permits the Company to undertake general building works involving multiple building trades, including the construction of structures for residential, commercial, industrial, recreational, and utility purposes, as well as addition and alteration works involving structural changes and roof installations.

· **CW02** – Permits the Company to undertake civil engineering works, including concrete, masonry, and steel works in infrastructure projects such as bridges, drainage systems, roads, marine structures, dredging, and reclamation works.

· **CR03** – Permits the Company to undertake general demolition works, subject to applicable regulatory requirements.

· **CR06** – Permits the Company to undertake interior design, planning, and building decoration works, including ceilings, partitions, fitments, plastering, and tiling.

· **GB2 (Class 2 General Builder License)** – Permits the Company to undertake and complete construction projects up to a specified project value threshold. Management believes the Company meets the requirements to qualify for a higher general builder classification, subject to regulatory approval.

**Quality and Manufacturing Certifications**

The Company has obtained the following certifications in support of its manufacturing, assembly, packaging, and distribution activities:

· **ISO 9001:2015 Certification** – Confirms that the Company has implemented standardized quality management systems and procedures applicable to the import, manufacture, assembly, packaging, repackaging, distribution, export, and sale of dietary health supplements and cosmetic products.

· **Good Manufacturing Practice (GMP) Certification** – Confirms compliance with good manufacturing practice standards for the manufacture, assembly, and repackaging of health supplement products and honey products.

· **Food Safety Management System (FSMS) Certification** – Confirms the adoption of a food safety management system applicable to the manufacture, assembly, and repackaging of health supplement and honey products.

**Import and Trade Licenses**

The Company holds a **Singapore Food Agency (SFA) Import License** for processed food ingredients and food receptacles, which permits the Company to import such items in accordance with applicable food safety and regulatory requirements.

---

| |
|:---|
| 44 |
| *[**Table of Contents**](#TOC)* |

---

**Trademark Registrations**

The Company holds registered trademarks and device registrations that permit it to market and sell products under its proprietary branding. These registrations support the Company's commercial use of its brand names and related intellectual property in the ordinary course of business.

The Company believes that it is in material compliance with the licensing, certification, and permitting requirements applicable to its current operations. However, the loss, suspension, non-renewal, or material modification of any required license, certification, or permit, or the failure to obtain additional approvals required for future expansion, could adversely affect the Company's business, financial condition, and results of operations.

**12.8. Employees and Human Capital**

As of the date of this prospectus, the Company maintains a relatively limited number of direct employees and relies substantially on outsourced staffing and third-party service providers to support its operations. Management believes that this workforce structure is appropriate for the Company's current stage of development and operating model.

**Employees**

The Company's direct employees primarily perform executive, administrative, oversight, and coordination functions. These employees are responsible for strategic planning, regulatory compliance, quality control oversight, financial management, and coordination with third-party service providers. The Company does not currently maintain a large permanent workforce dedicated to manufacturing, construction, or operational execution.

**Outsourced Staffing Arrangements**

A significant portion of the Company's operational activities, including manufacturing support, construction execution, logistics, and certain administrative functions, are carried out through third-party contractors and service providers. In particular, the Company relies on outsourced personnel and affiliated or third-party entities to provide skilled labor, technical expertise, and operational support required for its business activities.

**Reliance on Third-Party Labor**

The Company's reliance on third-party labor and outsourced staffing arrangements reduces fixed labor costs and provides flexibility to scale operations based on project demand and business needs. However, this reliance also exposes the Company to risks, including potential labor shortages, increased costs, reduced control over personnel, and dependence on the continued availability and performance of third-party service providers. Any disruption in these arrangements could adversely affect the Company's ability to execute projects, maintain quality standards, or comply with applicable regulatory requirements.

The Company has not experienced any material labor disputes to date and does not have any collective bargaining agreements in place. Management believes that its current human capital resources, together with its outsourced staffing model, are sufficient to support its existing operations, although additional personnel or third-party arrangements may be required as the business expands.

**12.9. Material Agreements**

The Company has entered into certain material agreements that are important to its business operations. The following summary describes the principal categories of material agreements currently in effect. This summary does not purport to be complete and is qualified in its entirety by reference to the full text of the applicable agreements, copies of which have been filed as exhibits to this registration statement where required by applicable SEC rules.

---

| |
|:---|
| 45 |
| *[**Table of Contents**](#TOC)* |

---

**License Agreements**

The Company is party to intellectual property licensing arrangements that permit it to use certain industrial designs, trademarks, and patented technologies in connection with its business. These agreements include, among others, an Industrial Design License Agreement and a Patent License Agreement, pursuant to which the Company is granted non-exclusive or exclusive rights, as applicable, to use specified intellectual property for manufacturing, marketing, and commercial purposes. The Company does not claim ownership of the underlying licensed intellectual property unless expressly stated in the applicable agreement. Management believes that these licensing arrangements are adequate for the Company's current operations.

**Services Agreements**

The Company relies on services agreements with third-party service providers and related parties for operational support, including manufacturing support, logistics, administrative functions, and other business services. These agreements generally provide for services to be rendered in exchange for fees determined on a contractual basis and may be terminable in accordance with their terms. The Company believes that the services provided under these agreements are consistent with market practices and necessary for the conduct of its business.

**Management or Operational Agreements**

The Company may be party to management, operational, or support arrangements under which certain functions are performed by third parties or affiliated entities. These arrangements may include the provision of personnel, facilities, technical expertise, or operational oversight. Such agreements are intended to provide flexibility and scalability to the Company's operations and are subject to ongoing review by management.

**Summary of Material Terms**

The material agreements described above generally contain customary provisions regarding scope of services or licensed rights, payment terms, confidentiality, intellectual property protection, term, and termination. None of these agreements, individually or in the aggregate, are believed by management to impose obligations that would materially restrict the Company's ability to conduct its business as currently planned. However, the termination, non-renewal, or breach of any material agreement could adversely affect the Company's operations, financial condition, or results of operations.

Additional details regarding related-party agreements and transactions, where applicable, are disclosed elsewhere in this prospectus under "Related Party Transactions" and other relevant sections.

**12.10. Business Strategy and Growth Plans**

The Company's business strategy is focused on strengthening its existing operations while pursuing measured growth opportunities aligned with its current capabilities, regulatory framework, and available capital resources. Management continuously evaluates market conditions, operational capacity, and financial performance when assessing growth initiatives.

**Expansion Plans**

The Company intends to expand its business by increasing market penetration for its existing products and services and by selectively entering new markets where it believes demand exists and regulatory requirements can be met. Expansion efforts are expected to prioritize jurisdictions and customer segments where the Company already has operational experience, established licenses, or strategic relationships.

---

| |
|:---|
| 46 |
| *[**Table of Contents**](#TOC)* |

---

**Manufacturing Scale-Up**

As part of its growth strategy, the Company plans to scale its manufacturing and production activities to improve efficiency, increase output capacity, and support anticipated demand for its honey products, dietary supplements, and other health-related offerings. Manufacturing scale-up initiatives may include the acquisition of additional equipment, optimization of production processes, and enhanced quality control systems, subject to the availability of capital and continued compliance with applicable regulatory and certification requirements.

**Market Development Objectives**

The Company seeks to develop its markets through brand development, customer acquisition, and expansion of distribution channels. Market development objectives include strengthening relationships with existing customers, identifying new distribution partners, and increasing awareness of the Company's products and services. These efforts may involve targeted marketing initiatives and participation in relevant trade or industry platforms, where appropriate.

The timing and extent of the Company's growth initiatives will depend on a variety of factors, including market conditions, regulatory approvals, operational performance, and the availability of financial resources. There can be no assurance that the Company will successfully implement its business strategy or achieve its growth objectives.

**12.11. Risk Factors Related to the Business (Cross-Reference)**

Investing in our common stock involves significant risks. Our business, operations, industry, regulatory environment, dependence on third parties and related parties, and growth strategy are subject to numerous risks and uncertainties that could materially and adversely affect our business, financial condition, results of operations, and prospects.

A discussion of these risks is set forth in detail under the heading **"Risk Factors"** of this prospectus. The Risk Factors section should be read carefully and in its entirety together with the other information contained in this prospectus before making an investment decision.

This Business section is qualified in its entirety by the disclosures contained in the Risk Factors section, which is incorporated herein by reference.

**13. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**13.1. Overview**

This Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to provide investors with a narrative explanation of the Company's financial condition, changes in financial condition, and results of operations. The MD&A focuses on material trends, uncertainties, and events that affect the Company's financial performance and liquidity, and is designed to enhance an understanding of the Company's financial statements and related disclosures.

The discussion and analysis presented below reflects management's perspective on the Company's historical financial results, liquidity, and capital resources, as well as the factors that have materially affected, and may continue to materially affect, the Company's financial condition and operating results. This MD&A is based on the Company's audited financial statements and related notes included elsewhere in this prospectus.

---

| |
|:---|
| 47 |
| *[**Table of Contents**](#TOC)* |

---

This MD&A should be read in conjunction with the Company's financial statements and the accompanying notes thereto, as well as the sections titled "Risk Factors," "Use of Proceeds," and "Business," included elsewhere in this prospectus. The following discussion contains forward-looking statements that involve risks and uncertainties, and actual results may differ materially from those expressed or implied by such forward-looking statements.

**13.2. Results of Operations**

**Comparison of Results for the Fiscal Years Ended December 31, 2025 and 2024**

The following discussion compares our results of operations for the fiscal years ended **December 31, 2025** and **December 31, 2024**. This discussion should be read in conjunction with our audited financial statements and the related notes included elsewhere in this prospectus.

**Revenue**

Total revenue for the fiscal year ended **December 31, 2025** was **$10,822,348**, compared to **$10,071,935** for the fiscal year ended **December 31, 2024**. The increase of **$750,413**, or approximately **7.5%**, was primarily attributable to increased transaction volume and expanded customer activity during the 2025 fiscal year.

**Cost of Revenues and Gross Profit**

Cost of revenues for the fiscal year ended **December 31, 2025** was **$4,770,238**, compared to **$4,258,055** for the fiscal year ended **December 31, 2024**. The increase of **$512,183** was primarily attributable to higher direct costs associated with increased service volume.

As a result, gross profit was **$6,052,110** for the fiscal year ended **December 31, 2025**, compared to **$5,813,880** for the fiscal year ended **December 31, 2024**.

**Operating Expenses**

Total operating and administrative expenses for the fiscal year ended **December 31, 2025** were **$5,787,290**, compared to **$4,063,367** for the fiscal year ended **December 31, 2024**. The increase of **$1,723,923** was primarily attributable to higher professional fees, consulting costs, and increased administrative expenses associated with business expansion and regulatory compliance.

**Net Income**

As a result of the factors described above, the Company recorded **net income of $264,820** for the fiscal year ended **December 31, 2025**, compared to **net income of $1,750,513** for the fiscal year ended **December 31, 2024**. The decrease in net income was primarily attributable to increased operating and administrative expenses, which more than offset the increase in revenue and gross profit during the 2025 fiscal year.

**13.3. Liquidity and Capital Resources**

**Liquidity**

Liquidity refers to the Company's ability to generate sufficient cash to meet its short-term and long-term obligations as they become due. The Company's primary sources of liquidity have historically consisted of cash on hand and cash generated from operations.

As of **December 31, 2025**, the date of the Company's most recent audited balance sheet included in this prospectus, the Company had **cash and cash equivalents of $2,855,160**. As of that date, the Company had **current assets of $4,442,202** and **current liabilities of $152,519**, resulting in **working capital of $4,289,683**.

---

| |
|:---|
| 48 |
| *[**Table of Contents**](#TOC)* |

---

The Company's ability to meet its short-term obligations is dependent primarily on its operating performance and the timing of cash receipts and payments. Management evaluates its liquidity position and working capital requirements based on anticipated operating needs and contractual obligations.

As of December 31, 2025, the Company **did not have any interest-bearing long-term debt**. However, the Company had **non-current lease liabilities of $531,484**, which represent long-term contractual obligations related to operating leases.

Management believes that existing cash balances and cash generated from operations will be sufficient to meet the Company's working capital and operating requirements for at least the next twelve months. However, there can be no assurance that the Company will be able to maintain positive operating cash flows in future periods, and the Company may seek additional financing if operating cash flows are insufficient to fund its operations.

**13.4. Cash Flows**

The following discussion summarizes the Company's cash flows for the fiscal years ended **December 31, 2025** and **December 31, 2024** and should be read in conjunction with the Company's audited statements of cash flows included elsewhere in this prospectus.

**Cash Flows from Operating Activities**

Net cash **provided by operating activities** was **$2,855,377** for the fiscal year ended **December 31, 2025**, compared to **$4,962,643** for the fiscal year ended **December 31, 2024**. Cash flows from operating activities were primarily affected by net income, non-cash items including depreciation and amortization, and changes in working capital components such as accounts receivable, accrued expenses, and lease liabilities.

The decrease in net cash provided by operating activities in 2025 compared to 2024 was primarily attributable to changes in working capital and higher operating and administrative expenses during the 2025 fiscal year.

**Cash Flows from Investing Activities**

Net cash **used in investing activities** was **$654** for the fiscal year ended **December 31, 2025**. There were **no cash flows from investing activities** for the fiscal year ended **December 31, 2024**. Investing activities during 2025 consisted primarily of additions to property, plant, and equipment.

**Cash Flows from Financing Activities**

Net cash **used in financing activities** was **$4,000,000** for the fiscal year ended **December 31, 2025**, compared to **$3,500,000** for the fiscal year ended **December 31, 2024**. Financing activities during both periods consisted primarily of repayments of amounts owed to directors and related parties, partially offset by proceeds from the issuance of common stock.

**13.5. Capital Resources**

Historically, the Company has financed its operations and capital needs through a combination of internally generated cash flows, equity issuances, and, where applicable, funding or support from related parties and third-party sources. The Company may continue to rely on such sources of capital until it is able to generate sufficient cash flows from operations to fund its activities independently.

The Company's liquidity and capital resources are expected to be materially affected by the completion of this offering. Net proceeds from the offering, if any, are expected to enhance the Company's liquidity position and provide additional capital to support operations, planned expansion, and general corporate purposes, as described in the section entitled "Use of Proceeds."

---

| |
|:---|
| 49 |
| *[**Table of Contents**](#TOC)* |

---

There can be no assurance, however, that the proceeds of this offering, together with existing cash and cash flows from operations, will be sufficient to fund the Company's operations and capital requirements for the next twelve months. If additional capital is required, the Company may seek to raise such capital through equity or debt financing or other arrangements, which may not be available on acceptable terms or at all.

**13.6. Known Trends, Demands, Commitments, and Uncertainties**

Management is required to evaluate and disclose known trends, demands, commitments, events, and uncertainties that are reasonably likely to have a material effect on the Company's financial condition, results of operations, or liquidity. The following discussion reflects management's assessment based on information currently available.

**Known Trends Affecting Revenues and Costs**

The Company's revenues and operating costs are influenced by demand for its honey products, dietary supplements, pharmaceutical manufacturing services, and construction-related activities. Known trends include fluctuations in raw material costs, manufacturing input prices, logistics and transportation expenses, and labor-related costs, which may affect gross margins. In addition, changes in customer demand, product mix, and pricing pressures within competitive markets may impact revenue growth and profitability.

**Dependence on Superbee Network Singapore Pte. Ltd.**

The Company has historically relied, and may continue to rely, on Superbee Network Singapore Pte. Ltd., a related party under common control, for certain operational, manufacturing, administrative, or support functions. This dependence represents a known uncertainty, as any material change in the availability, terms, or continuity of services provided by Superbee could adversely affect the Company's operations, cost structure, and ability to scale its business. Management monitors this relationship and assesses its potential impact on operational continuity and financial performance.

**Regulatory Developments**

The Company operates in regulated industries, including food products, health supplements, pharmaceutical-related manufacturing, and construction. Regulatory developments affecting licensing requirements, quality standards, manufacturing practices, import and export controls, or construction industry regulations could result in increased compliance costs, operational adjustments, or delays. Management is not currently aware of any specific regulatory changes that are reasonably likely to have a material adverse effect; however, future regulatory actions remain an inherent uncertainty.

**Market and Operational Uncertainties**

The Company is subject to market uncertainties, including competitive dynamics, customer concentration, supply chain disruptions, and macroeconomic conditions that may affect demand, input costs, or access to capital. Operational uncertainties include the Company's ability to efficiently manage growth, integrate expanded manufacturing capacity, and maintain quality and regulatory compliance as operations scale.

**Management's Assessment of Materiality**

Based on management's current evaluation, the trends and uncertainties described above are not individually expected to have a material adverse effect on the Company's financial condition or results of operations in the near term. However, the combined effect of adverse changes in these factors, or the occurrence of events beyond management's control, could materially impact the Company's future operating results, liquidity, and capital resources. Management will continue to monitor these trends and uncertainties and will update disclosures as required in future filings.

---

| |
|:---|
| 50 |
| *[**Table of Contents**](#TOC)* |

---

**13.7. Off-Balance Sheet Arrangements**

The Company does not have any off-balance sheet arrangements, as defined under Item 303(b) of Regulation S-K, including any relationships with unconsolidated entities or financial partnerships, that have or are reasonably likely to have a current or future material effect on its financial condition, results of operations, liquidity, capital expenditures, or capital resources.

Accordingly, the Company has no off-balance sheet arrangements that require disclosure in this Management's Discussion and Analysis of Financial Condition and Results of Operations.

**13.8. Contractual Obligations and Commitments**

The Company enters into contractual obligations in the ordinary course of business that require future payments and may affect its liquidity and capital resources. These obligations primarily consist of operating arrangements, licensing agreements, service agreements, and other contractual commitments necessary to support the Company's ongoing operations.

As of the most recent balance sheet date, the Company's material contractual obligations include commitments under license agreements and service or operational arrangements, including agreements with related parties, where applicable. Such obligations generally require periodic payments over the term of the applicable agreement and are expected to be satisfied through existing cash resources, cash generated from operations, and, if completed, proceeds from this offering.

The timing of payments under these contractual obligations varies based on the terms of each agreement and may include monthly, quarterly, or other periodic payment schedules. Management monitors these obligations as part of its liquidity planning and believes that the Company's current and expected sources of liquidity are adequate to meet its contractual commitments as they come due.

Certain contractual obligations involve related parties and are entered into on terms intended to reflect the operational needs of the Company. These related-party commitments are described in greater detail in the sections entitled "Related Party Transactions" and "Business," and are reflected in the accompanying financial statements and related notes, as applicable.

Management does not believe that the Company's contractual obligations and commitments, individually or in the aggregate, are reasonably likely to have a material adverse effect on the Company's financial condition, results of operations, or liquidity beyond those discussed elsewhere in this prospectus.

**13.9. Critical Accounting Policies and Estimates**

The preparation of the Company's financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make judgments, estimates, and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and the related disclosures. Management considers an accounting policy or estimate to be critical if it requires significant judgment, is inherently uncertain, and could result in materially different results if different assumptions were used. The Company's most critical accounting policies and estimates are discussed below.

**Revenue Recognition**

Revenue recognition requires management to exercise judgment in determining the timing and amount of revenue recognized, including the identification of performance obligations, determination of transaction price, and assessment of when control of products or services transfers to customers. These judgments may involve estimates related to customer acceptance, delivery terms, pricing arrangements, and the collectability of consideration. Changes in assumptions regarding these factors could materially affect the timing or amount of revenue recognized.

---

| |
|:---|
| 51 |
| *[**Table of Contents**](#TOC)* |

---

**Related-Party Transactions**

The Company engages in transactions with related parties in the ordinary course of business. Accounting for related-party transactions requires judgment in identifying related-party relationships, evaluating whether transactions are conducted at arm's length, and determining appropriate presentation and disclosure in the financial statements. Management assesses these transactions based on their substance and terms, and changes in facts or circumstances could affect the accounting treatment or disclosure of such arrangements.

**License and Intellectual Property Accounting**

The Company enters into license arrangements related to intellectual property, including industrial design and patent licenses. Management must apply judgment in determining whether such arrangements represent licenses of rights rather than asset acquisitions, the appropriate classification of payments (e.g., operating expense versus capitalized cost), and the period over which any costs should be recognized. These determinations require evaluation of contractual terms, the nature of the rights obtained, and applicable accounting guidance, and different conclusions could result in materially different financial statement outcomes.

**Estimates and Assumptions**

The Company's financial statements include estimates related to, among other items, the valuation of assets and liabilities, impairment assessments, useful lives of long-lived assets, and accruals for expenses and contingencies. These estimates are based on management's best judgment using information available at the time the financial statements are prepared. Actual results could differ from these estimates, and such differences could be material to the Company's financial condition and results of operations.

Management reviews its critical accounting policies and estimates on an ongoing basis and adjusts them as appropriate based on changes in circumstances, new information, or changes in accounting standards.

**13.10. Impact of Inflation and Changing Prices**

Inflation and changes in prices have not had a material impact on the Company's financial condition or results of operations during the periods presented. To date, the Company has not experienced material increases in costs that have significantly affected its operating margins or liquidity.

The Company monitors inflationary trends and pricing conditions as part of its ongoing business planning, including potential impacts on raw materials, labor, logistics, and other operating inputs. While future inflationary pressures or changes in market pricing could affect the Company's cost structure or operating results, management does not believe that inflation or changing prices have had, or are reasonably likely to have, a material adverse effect on the Company's business, financial condition, or results of operations at this time.

**13.11. Impact of Inflation and Changing Prices**

Inflation and changes in prices have not had a material impact on the Company's financial condition, results of operations, or liquidity during the periods presented. The Company has not experienced material increases in operating costs that have significantly affected its margins or cash flows.

Management monitors inflationary trends and pricing conditions as part of its ongoing operational and financial planning, including potential impacts on raw materials, labor, logistics, and other operating inputs. While future inflationary pressures or changes in market pricing could affect the Company's cost structure or operating results, management does not believe that inflation or changing prices have had, or are reasonably likely to have, a material adverse effect on the Company's business, financial condition, or results of operations at this time.

---

| |
|:---|
| 52 |
| *[**Table of Contents**](#TOC)* |

---

**13.12. Emerging Growth Company and Smaller Reporting Company Status**

The Company qualifies as an "emerging growth company" ("EGC") as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act") and also qualifies as a "smaller reporting company" under applicable SEC rules. As a result of these classifications, the Company is permitted to take advantage of certain reduced disclosure and reporting requirements that are applicable to emerging growth companies and smaller reporting companies.

These reduced disclosure requirements include, among other things, the ability to provide reduced executive compensation disclosures, exemption from the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, and the ability to provide fewer years of audited financial statements and related Management's Discussion and Analysis disclosures. The Company may also be permitted to delay the adoption of certain new or revised accounting standards until such standards are otherwise applicable to private companies.

The Company has elected to take advantage of the extended transition period provided under the JOBS Act for complying with new or revised accounting standards applicable to emerging growth companies. As a result, the Company's financial statements may not be comparable to those of companies that are not emerging growth companies or that have elected to opt out of the extended transition period.

The Company will remain an emerging growth company until the earliest of (i) the last day of the fiscal year in which it has total annual gross revenues of $1.235 billion or more, (ii) the last day of the fiscal year following the fifth anniversary of the completion of this offering, (iii) the date on which it has issued more than $1.0 billion in non-convertible debt during the previous three-year period, or (iv) the date on which it is deemed to be a large accelerated filer under the Exchange Act. The Company will remain a smaller reporting company until it no longer meets the applicable size and public float thresholds under SEC rules.

**13.13. Forward-Looking Statements**

This registration statement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding the Company's expectations, plans, objectives, strategies, future operations, financial performance, liquidity, capital resources, market opportunities, and growth prospects. Words such as "anticipates," "believes," "expects," "intends," "plans," "estimates," "may," "will," "should," "could," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words.

These forward-looking statements are based on management's current expectations and assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially include, among others, the risks and uncertainties described in the section entitled "Risk Factors," as well as risks related to the Company's business, operating history, dependence on third parties and related parties, regulatory environment, liquidity and capital resources, and market conditions.

The forward-looking statements contained in this registration statement are made as of the date hereof, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

---

| |
|:---|
| 53 |
| *[**Table of Contents**](#TOC)* |

---

The Company intends that all forward-looking statements be subject to the safe harbor protections provided by Section 27A of the Securities Act and Section 21E of the Exchange Act, to the extent such safe harbor provisions are available.

**14. MANAGEMENT, EXECUTIVE COMPENSATION, AND SECURITY OWNERSHIP**

**14.1. Directors and Executive Officers**

The following table sets forth information regarding the Company's directors and executive officers as of the date of this prospectus.

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Position(s) Held** |
| **Jacksaa Tan** | 64 | Chairman of the Board and Chief Executive Officer |
| **Hui Eng Ling** | 51 | Director and Chief Financial Officer |

---

The Company currently has **two directors**, both of whom also serve as executive officers. Directors are elected to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified, or until earlier resignation or removal. Executive officers are appointed by, and serve at the discretion of, the Board of Directors.

**Business Experience**

**Jacksaa Tan** has served as the Company's Chairman of the Board and Chief Executive Officer since inception. Mr. Tan is responsible for the Company's overall strategic direction, business development, and operational oversight.

**Hui Eng Ling** has served as a Director and the Company's Chief Financial Officer since inception. Ms. Ling is responsible for overseeing the Company's financial management, accounting, financial reporting, and compliance functions.

The Board of Directors believes that the experience, qualifications, and leadership capabilities of each director qualify them to serve in their respective roles.

**Directorships in Other Public Companies**

None of the Company's directors or executive officers currently holds, or has held during the past five years, a directorship in any other public company.

**Family Relationships**

There are no family relationships, as defined in Item 401(d) of Regulation S-K, among the Company's directors or executive officers.

---

| |
|:---|
| 54 |
| *[**Table of Contents**](#TOC)* |

---

**Legal Proceedings**

During the past ten years, none of the Company's directors or executive officers has been involved in any legal proceedings of the type required to be disclosed pursuant to Item 401(f) of Regulation S-K.

**14.2. Board of Directors and Corporate Governance**

**Board Composition**

The Company's Board of Directors currently consists of **two members**, **Jacksaa Tan** and **Hui Eng Ling**, both of whom also serve as executive officers of the Company. The Company does not have a classified board. Directors are elected annually and serve until the next annual meeting of stockholders and until their successors are duly elected and qualified, or until earlier resignation or removal.

**Director Independence**

The Company does not have any directors who qualify as "independent." Each of the Company's directors also serves as an executive officer and, therefore, does not meet the independence standards applicable to directors of companies listed on national securities exchanges. As a result, the Company does not currently satisfy any exchange-related director independence requirements.

**Committees of the Board**

The Company does not maintain standing audit, compensation, or nominating committees. The full Board of Directors performs the functions that would otherwise be delegated to such committees, including oversight of financial reporting, executive compensation matters, and director nominations. Given the Company's size, stage of development, and board composition, the Company believes that this governance structure is appropriate and efficient at this time.

**Board Leadership Structure**

The roles of **Chairman of the Board** and **Chief Executive Officer** are combined. **Jacksaa Tan** serves as Chairman of the Board and Chief Executive Officer. The Company has not adopted a formal policy regarding the separation of these roles. The Board of Directors believes that this leadership structure is appropriate at the Company's current stage of development, as it provides unified leadership and clear accountability.

**Risk Oversight**

The Board of Directors is responsible for overseeing the Company's risk management processes. In this role, the Board monitors and evaluates risks relating to the Company's business, financial condition, regulatory compliance, related-party relationships, and operational activities. Risk oversight is conducted through regular reviews of operational and financial information and discussions with management. The Company has not established a separate risk committee, and risk oversight is integrated into the Board's overall governance responsibilities.

**14.3. Executive Compensation**

**Overview of Compensation Philosophy**

The Company's executive compensation philosophy is designed to align the interests of management with those of stockholders, while taking into account the Company's size, stage of development, financial resources, and operational needs. The primary objectives of the Company's compensation practices are to attract, retain, and motivate qualified executive leadership, promote long-term value creation, and manage cash resources prudently.

---

| |
|:---|
| 55 |
| *[**Table of Contents**](#TOC)* |

---

The Company is an emerging growth company and a smaller reporting company and has elected to comply with the scaled executive compensation disclosure requirements permitted under Item 402 of Regulation S-K.

**Summary Compensation Disclosure**

During the periods presented, the Company's executive compensation arrangements have been limited in scope and primarily reflect base salary arrangements. In light of the limited nature of these arrangements, the Company has provided narrative disclosure in lieu of tabular disclosure, as permitted for smaller reporting companies under Item 402 of Regulation S-K.

The Company has not adopted a formal compensation committee, and executive compensation decisions are determined by the Board of Directors, with consideration given to the Company's financial condition, operating results, individual responsibilities, and prevailing market practices for similarly situated companies.

**14.4. Employment and Service Agreements**

**Executive Employment Agreements**

The Company does **not** have written employment agreements with its executive officers. **Jacksaa Tan**, the Company's Chairman of the Board and Chief Executive Officer, and **Hui Eng Ling**, the Company's Director and Chief Financial Officer, serve in their executive capacities at the discretion of the Board of Directors. Their service is not subject to a fixed term and may be terminated at any time by either the Company or the applicable executive officer.

There are **no agreements** providing for severance payments, change-in-control benefits, or post-termination compensation for the Company's executive officers.

**Consulting or Management Service Agreements**

The Company is **not** a party to any consulting, management, or advisory service agreements with its executive officers, directors, or their respective affiliates that would be required to be disclosed under **Item 402 or Item 404 of Regulation S-K**.

**Material Terms**

Because the Company does not have written employment, consulting, or management service agreements with its executive officers or directors, there are **no material contractual terms** relating to duration, compensation, termination, or post-employment obligations that require disclosure.

Any compensation paid to executive officers is determined by the **Board of Directors** based on the Company's financial condition, operational needs, and other relevant factors, as described under **"Executive Compensation."** No amounts are payable upon termination of employment, resignation, retirement, or a change in control of the Company.

The Company believes that the absence of formal employment or service agreements provides flexibility in managing executive roles and compensation while conserving financial resources during its current stage of development.

---

| |
|:---|
| 56 |
| *[**Table of Contents**](#TOC)* |

---

**14.5. Security Ownership of Certain Beneficial Owners and Management**

The following table sets forth information regarding the beneficial ownership of the Company's common stock by (i) each director and executive officer of the Company, (ii) all directors and executive officers as a group, and (iii) each person known by the Company to beneficially own more than five percent (5%) of the Company's outstanding common stock, as of **[most recent practicable date].**

Beneficial ownership is determined in accordance with **Rule 13d-3 of the Securities Exchange Act of 1934** and includes shares over which a person has voting or dispositive power. Unless otherwise indicated, the address of each beneficial owner is the Company's principal executive offices. Percentage ownership is based on 2,854,462,696 shares of common stock outstanding as of the date indicated.

**14.6. Beneficial Ownership Table**

---

| | | |
|:---|:---|:---|
| **Name of Beneficial Owner** | **Shares Beneficially Owned** | **Percentage of Outstanding Shares** |
| **Jacksaa Tan (Chairman & Chief Executive Officer)\*** | 2013215400 | 70.53% |
| **Hui Eng Ling (Director & Chief Financial Officer)** | 671071800 | 23.51% |
| **All directors and executive officers as a group (2 persons)** | **2684207200** | **94.04%** |

---

Percentage ownership calculations assume no exercise of options, warrants, or other convertible securities, as none are outstanding as of the date indicated.

This table should be read together with the disclosures under "**Selling Stockholders"** and **"Plan of Distribution."**

**14.7. Equity Incentive Plans**

As of the date of this prospectus, the Company does not maintain any equity incentive plans, stock option plans, employee stock purchase plans, or other equity-based compensation arrangements for its directors, executive officers, employees, or consultants.

**Description of Equity Plans**

The Company has not adopted, and is not currently a party to, any formal equity incentive or equity compensation plans. Accordingly, no options, restricted stock awards, stock appreciation rights, or other equity-based awards have been granted or are outstanding under any plan.

---

| |
|:---|
| 57 |
| *[**Table of Contents**](#TOC)* |

---

**Shares Authorized and Outstanding**

Because the Company does not maintain any equity incentive plans, no shares of common stock have been reserved for issuance pursuant to equity-based compensation arrangements. All issued and outstanding shares of common stock have been issued in connection with capital contributions, share issuances, or other transactions described elsewhere in this prospectus.

**Administration of Plans**

As no equity incentive plans are currently in place, there is no plan administrator or committee responsible for administering equity-based compensation. Any future adoption of equity incentive plans would be subject to approval by the Board of Directors and, where required, the Company's stockholders, and would be disclosed in accordance with applicable requirements of Regulation S-K and other SEC rules.

The Company may consider adopting equity-based compensation arrangements in the future as part of its strategy to attract, retain, and incentivize management and key personnel. However, there can be no assurance that any such plans will be adopted, or as to the terms or timing of any future equity incentive arrangements.

**14.8. Section 16(a) Beneficial Ownership Reporting Compliance**

Section 16(a) of the Securities Exchange Act of 1934 requires the Company's directors, executive officers, and persons who beneficially own more than ten percent (10%) of the Company's common stock to file reports of ownership and changes in ownership of the Company's equity securities with the Securities and Exchange Commission.

Because the Company's common stock has not previously been registered under Section 12 of the Exchange Act, the reporting obligations of Section 16(a) were not applicable to the Company's directors, executive officers, or greater-than-ten-percent beneficial owners prior to the effectiveness of this registration statement.

**14.9. Related Party Relationships and Transactions (Cross-Reference)**

Certain transactions and relationships between the Company and its directors, executive officers, principal stockholders, and their respective affiliates may constitute "related party transactions" for purposes of Item 404 of Regulation S-K.

For a description of the Company's related party relationships and related party transactions (if any) during the periods required to be disclosed, including the identity of the related persons involved and the material terms of such arrangements, see "Related Party Transactions" in this prospectus. The Company intends for the disclosures in this section and in "Related Party Transactions" to be read together and to be consistent with the disclosures included elsewhere in this prospectus, including "Selling Stockholders," "Security Ownership of Certain Beneficial Owners and Management," "Business," and "Management's Discussion and Analysis of Financial Condition and Results of Operations."

Except as disclosed under "Certain Relationships and Related Party Transactions," no director or executive officer of the Company has entered into, or is a participant in, any related party transaction or arrangement required to be disclosed under Item 404 of Regulation S-K.

---

| |
|:---|
| 58 |
| *[**Table of Contents**](#TOC)* |

---

**15. CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS**

**15.1. Overview of Related Party Relationships**

For purposes of this prospectus, "related persons" are those individuals and entities required to be disclosed under Item 404(a) of Regulation S-K, including the Company's directors, executive officers, nominees for director, beneficial owners of more than five percent of the Company's common stock, and any immediate family members of such persons, as well as entities in which any of the foregoing persons has a direct or indirect material interest or that are under common control with the Company.

Based on this definition, the Company's related parties include its executive officers and directors and certain affiliated entities that are under common control with the Company. In particular, certain operational, licensing, and service relationships exist with entities affiliated through common ownership or control, which are described in greater detail in the subsections that follow. The Company has identified these relationships by reviewing equity ownership, management overlap, contractual arrangements, and other indicia of control or significant influence.

The Company applies the materiality standard set forth in Item 404(a) of Regulation S-K in determining whether a related party transaction is required to be disclosed. Accordingly, transactions are disclosed if the amount involved exceeds $120,000 and the related party has a direct or indirect material interest in the transaction. In addition, the Company considers qualitative factors, including the nature of the relationship, the significance of the transaction to the Company's business or financial condition, and whether the transaction involves ongoing arrangements or dependencies, in assessing materiality.

All material related party relationships and transactions identified under these standards are disclosed in this section or cross-referenced to other sections of this prospectus, including "Business," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Risk Factors," and the Notes to the Financial Statements.

**15.2. Relationship with Superbee Network Singapore Pte. Ltd.**

The Company maintains an ongoing business relationship with **Superbee Network Singapore Pte. Ltd. ("Superbee")**, an entity that is under common control with the Company. This relationship represents a significant related party arrangement and has been a core focus of prior SEC review.

**Nature of the Relationship**

Superbee provides certain operational, administrative, and support services to the Company pursuant to informal arrangements and written agreements, including intellectual property licensing arrangements. These services have historically included, among other things, support relating to manufacturing coordination, operational infrastructure, and other functions that facilitate the Company's day-to-day business activities. The specific terms of these arrangements are described where applicable in this section and in the Notes to the Financial Statements.

**Common Control Considerations**

The Company and Superbee are considered entities under common control due to overlapping ownership and management. As a result, transactions between the Company and Superbee are related party transactions for purposes of Item 404 of Regulation S-K and are subject to enhanced disclosure and accounting scrutiny. The Company has evaluated these relationships and transactions in accordance with applicable U.S. GAAP and SEC disclosure requirements, including consideration of whether such arrangements represent asset acquisitions, business combinations, or licensing arrangements. Management has determined that the Company's arrangements with Superbee are structured as licensing and service arrangements rather than acquisitions of assets or businesses.

---

| |
|:---|
| 59 |
| *[**Table of Contents**](#TOC)* |

---

**Role of Superbee in Operations**

Superbee plays an important role in supporting certain aspects of the Company's operations. The Company relies on Superbee for access to certain licensed intellectual property, operational know-how, and support services that are integral to the Company's current business model. While these services are material to the Company's operations, the Company does not own Superbee, and Superbee does not consolidate the Company's financial results.

**Intercompany Dependence**

The Company's historical reliance on Superbee creates operational and financial interdependence risks. Any material change in the relationship with Superbee, including the termination or modification of existing arrangements, could adversely affect the Company's ability to continue certain operations without disruption or to do so on commercially reasonable terms. The Company may be required to replace services currently provided by Superbee with third-party providers or internal resources, which could result in increased costs or operational challenges.

All material transactions and balances between the Company and Superbee are disclosed in the Notes to the Financial Statements included elsewhere in this prospectus. In addition, risks associated with this related party relationship are discussed under "Risk Factors." This subsection is intended to serve as the primary and authoritative disclosure regarding the Company's relationship with Superbee, and other references to this relationship elsewhere in the prospectus are intended to be consistent with, and subordinate to, the disclosures provided herein.

**15.3. License and Intellectual Property Arrangements with Related Parties**

The Company has entered into certain intellectual property and licensing arrangements with related parties, including Superbee Network Singapore Pte. Ltd., which are material to its operations. These arrangements have been a specific focus of prior SEC comments, including with respect to the application of ASC 805-50 and the distinction between licensing arrangements and asset acquisitions.

**Industrial Design License Agreement**

The Company is a party to an industrial design license agreement with a related party pursuant to which it has been granted the right to use certain registered industrial designs in connection with the manufacture, marketing, and sale of its products. Under this agreement, the Company does not obtain ownership of the underlying industrial design rights but is granted a non-exclusive or exclusive license, as applicable, to use such designs within the scope defined by the agreement. The licensed rights are used in the ordinary course of the Company's business and are integral to certain product offerings.

**Patent License Agreement**

The Company has also entered into a patent license agreement with a related party under which it has been granted rights to use certain patented technologies relevant to its operations. The patent license provides the Company with contractual rights to exploit the patented technology for specified purposes and territories, subject to the terms and conditions of the agreement. Ownership of the patents remains with the licensor, and the Company does not acquire any ownership interest in the patents as a result of the license.

---

| |
|:---|
| 60 |
| *[**Table of Contents**](#TOC)* |

---

**License-of-Right (LOR) Framework**

Certain of the Company's intellectual property arrangements are structured under a License-of-Right ("LOR") framework. An LOR represents a declaration by a patent or intellectual property owner that it is willing to license its rights to interested parties on defined terms. The Company's participation in such arrangements constitutes a licensing relationship between willing parties and does not involve the transfer or acquisition of the underlying intellectual property assets. The Company's rights under an LOR are contractual in nature and are limited to the scope of use granted under the applicable licensing terms.

**Ownership vs. Licensing Distinction**

In all cases, the Company's intellectual property arrangements with related parties are structured as licenses rather than transfers or acquisitions of assets or businesses. The Company does not obtain legal or beneficial ownership of the underlying industrial designs, patents, or other intellectual property. Instead, it obtains the right to use such intellectual property in its operations in accordance with the applicable agreements. As a result, these arrangements do not constitute asset acquisitions or business combinations.

**Accounting Treatment**

Management has evaluated the Company's license and intellectual property arrangements with related parties in accordance with U.S. GAAP, including the guidance in ASC 805-50 relating to transactions between entities under common control. Based on the substance of the arrangements, management has concluded that these transactions represent licensing arrangements rather than acquisitions of assets or businesses. Accordingly, the related accounting treatment reflects license-related costs and obligations rather than capitalization of acquired assets. The financial statement impact of these arrangements, including any related party balances or expenses, is disclosed in the Notes to the Financial Statements included elsewhere in this prospectus.

These licensing and intellectual property arrangements are material to the Company's operations, and the loss, termination, or material modification of such agreements could adversely affect the Company's business, financial condition, and results of operations.

**15.4. Services, Operational, and Support Arrangements**

The Company has entered into certain services, operational, and support arrangements with related parties, including Superbee Network Singapore Pte. Ltd., which support aspects of the Company's business operations. These arrangements are disclosed in this section to provide a consolidated and transparent description of the nature and extent of such relationships, consistent with Item 404 of Regulation S-K and prior SEC comments.

**Management and Operational Support**

From time to time, the Company may receive operational or administrative support from related parties in areas such as logistics coordination, operational know-how, technical support, or shared resources, where such support is efficient or commercially reasonable. The Company does not rely on any formal management services organization arrangement to direct or control its day-to-day operations, and management of the Company remains the responsibility of the Company's executive officers.

**Services Provided or Received**

Services provided or received under these arrangements may include operational assistance, coordination of manufacturing or supply chain activities, use of shared facilities or infrastructure, and other support services customary for entities with overlapping business interests or common control. The scope of services, where applicable, is limited to supporting the Company's existing operations and does not transfer ownership of assets or decision-making authority.

---

| |
|:---|
| 61 |
| *[**Table of Contents**](#TOC)* |

---

**Cost Sharing and Reimbursement Mechanics**

Where services are provided by or to a related party, the Company accounts for such arrangements based on the underlying economic substance. Costs incurred on behalf of the Company may be reimbursed to the providing party, or allocated based on agreed-upon cost-sharing methodologies, where applicable. Management believes that any such reimbursements or allocations are conducted on terms that are reasonable and reflective of the services provided. Related amounts, if material, are disclosed in the Notes to the Financial Statements included elsewhere in this prospectus.

**Informal vs. Written Arrangements**

Certain service or support arrangements with related parties may be conducted pursuant to written agreements, while others may arise from informal or customary business practices between entities under common control. To the extent arrangements are informal, they are not governed by long-term contractual commitments and may be modified or terminated at any time. The Company affirms that there are no undisclosed management control agreements or service arrangements that grant related parties authority over the Company's strategic or operational decisions beyond what is disclosed in this prospectus.

These services, operational, and support arrangements are considered related party transactions and have been reviewed by management for materiality and appropriate disclosure. The Company believes that the terms of such arrangements are not more favorable than those that could be obtained from unaffiliated third parties for similar services.

**15.5. Financial Statement Impact of Related Party Transactions**

Transactions with related parties, including Superbee Network Singapore Pte. Ltd., have affected the Company's financial statements and are reflected in the consolidated financial information included elsewhere in this prospectus. These impacts are summarized below to provide investors with a clear understanding of how related party arrangements influence the Company's results of operations, financial position, and cash flows.

**Revenue and Expense Impact**

During the periods presented, the Company has recognized certain revenues and expenses arising from transactions with related parties in the ordinary course of business. Such transactions may include fees, reimbursements, cost allocations, or other charges associated with licensing arrangements, operational support, or services provided or received. Management believes that the amounts recognized reflect the underlying economic substance of the arrangements and are not materially different from terms that could be obtained from unaffiliated third parties for comparable transactions. To the extent material, these revenues and expenses are disclosed and quantified in the Notes to the Financial Statements.

**Balance Sheet Effects**

As a result of related party transactions, the Company's balance sheet may include amounts due to or due from related parties, including accounts receivable, accounts payable, accrued expenses, or advances. These balances represent outstanding obligations or claims arising from the timing of payments, reimbursements, or settlements under related party arrangements. The nature and amounts of such balances, if material, are presented separately or described in the Notes to the Financial Statements to provide transparency regarding the Company's exposure to related parties.

**Cash Flow Implications**

Cash flows associated with related party transactions are reflected within the Company's statements of cash flows, primarily within operating activities, and, where applicable, financing activities. Such cash flows may include payments for services, reimbursements of shared costs, advances, or settlements of intercompany balances. Management considers these cash flows in assessing the Company's liquidity and capital resources, as discussed in "Management's Discussion and Analysis of Financial Condition and Results of Operations."

---

| |
|:---|
| 62 |
| *[**Table of Contents**](#TOC)* |

---

**Cross-Reference to Financial Statement Disclosures**

Additional details regarding the nature, amounts, and accounting treatment of related party transactions are included in the Notes to the Financial Statements included elsewhere in this prospectus. Those notes should be read in conjunction with this section to obtain a complete understanding of the financial statement impact of the Company's related party relationships.

**15.6. Approval Policies and Procedures**

The Company has established policies and procedures designed to identify, review, approve, and monitor transactions and arrangements involving related parties in order to mitigate potential conflicts of interest and ensure such transactions are conducted on terms that are fair to the Company.

**Approval Process**

Related party transactions are subject to review and approval by management and, where appropriate based on materiality or potential conflicts of interest, by the Board of Directors. In evaluating related party transactions, management and the Board consider factors they deem relevant, which may include the nature of the relationship, the material terms of the transaction, the business purpose of the arrangement, and whether the transaction is on terms comparable to those that could be obtained from unaffiliated third parties.

**Conflict-of-Interest Mitigation**

Directors and executive officers are expected to disclose to the Company any actual or potential conflicts of interest, including any personal interest in a proposed related party transaction. Any director or executive officer with a material interest in a related party transaction is expected to recuse himself or herself from deliberations and decision-making with respect to such transaction. These practices are intended to promote objective decision-making and reduce the risk that related party arrangements are influenced by personal interests.

**Ongoing Monitoring and Controls**

The Company monitors related party transactions on an ongoing basis to ensure continued compliance with its policies and applicable disclosure requirements. Management periodically reviews existing related party arrangements to assess whether they remain appropriate, are being performed in accordance with their terms, and continue to be in the best interests of the Company. Material related party transactions and balances are also subject to disclosure and review in connection with the preparation of the Company's financial statements and related notes.

Management believes that these approval policies and procedures provide reasonable assurance that related party transactions are identified, reviewed, approved, and disclosed in a manner consistent with the requirements of Item 404 of Regulation S-K and applicable SEC guidance.

**15.7. No Other Related Party Transactions**

Except for the related party relationships and transactions described in this section, including those with Superbee Network Singapore Pte. Ltd. and the license and service arrangements disclosed herein and in the Notes to the Financial Statements, the Company did not engage in any other related party transactions, as defined under Item 404(a) of Regulation S-K, during the periods covered by the financial statements included in this prospectus.

---

| |
|:---|
| 63 |
| *[**Table of Contents**](#TOC)* |

---

This affirmative statement covers the fiscal years presented and any subsequent interim period included in this registration statement. Management has reviewed its relationships, arrangements, and transactions involving directors, executive officers, principal stockholders, and entities under common control and is not aware of any other related party transactions that would require disclosure under applicable SEC rules and regulations.

**15.8. Cross-References and Consistency Statement**

The disclosures set forth in this section have been prepared to ensure consistency and alignment with related disclosures appearing elsewhere in this registration statement. The Company has reviewed and cross-checked the information contained in this section against the disclosures included under the headings "Business," "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations," as well as the Notes to the Financial Statements included herein.

In addition, the Company has confirmed that the descriptions of related party relationships, transactions, and ownership interests disclosed in this section are consistent with, and appropriately reflected in, the sections entitled "Selling Stockholders" and "Security Ownership of Certain Beneficial Owners and Management," including the applicable ownership tables and related narrative disclosures.

Management believes that the related party disclosures included in this registration statement are complete, internally consistent, and presented in a manner that avoids duplication while providing investors with a clear and comprehensive understanding of the Company's related party relationships and transactions, as required under Item 404 of Regulation S-K and applicable SEC guidance.

**16. LEGAL PROCEEDINGS**

**16.1. Material Pending Legal Proceedings**

The Company is not currently a party to, and is not aware of, any material pending legal proceedings, other than ordinary routine litigation incidental to the conduct of its business, that would be required to be disclosed under Item 103 of Regulation S-K.

Specifically, as of the date of this prospectus:

· There are **no material civil, criminal, administrative, or arbitration proceedings** pending against the Company.

· There are **no material proceedings involving governmental or regulatory authorities** to which the Company is a party.

· There are **no material legal proceedings pending or threatened** against any of the Company's directors, executive officers, or significant shareholders that are required to be disclosed and that would be expected to have a material adverse effect on the Company.

The Company may, from time to time, be involved in claims, disputes, or legal proceedings arising in the ordinary course of business. Management does not believe that any such matters, individually or in the aggregate, would have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.

This disclosure is made as of the date of this prospectus and covers proceedings required to be disclosed under Item 103 of Regulation S-K.

---

| |
|:---|
| 64 |
| *[**Table of Contents**](#TOC)* |

---

**16.2. Governmental or Regulatory Proceedings**

The Company is not currently a party to, and is not aware of, any material pending or threatened governmental, administrative, civil, or regulatory proceedings involving federal, state, local, or foreign governmental authorities that would be required to be disclosed under Item 103 of Regulation S-K.

Specifically, as of the date of this prospectus:

· There are **no material administrative, civil, or regulatory actions** pending or, to the Company's knowledge, threatened against the Company by any governmental or regulatory authority.

· There are **no material investigations, enforcement actions, consent decrees, or compliance proceedings** involving the Company.

· The Company is not subject to any **material environmental, health, safety, or similar regulatory proceedings** that would reasonably be expected to have a material adverse effect on its business, financial condition, results of operations, or cash flows.

The Company operates in regulated industries and is subject to routine inspections, reviews, and compliance requirements in the ordinary course of business. Management believes that the Company is in material compliance with applicable laws and regulations and that any routine regulatory matters do not rise to the level of material governmental or regulatory proceedings requiring disclosure under Item 103 of Regulation S-K.

This disclosure reflects the status of governmental and regulatory proceedings as of the date of this prospectus.

**16.3. Proceedings Involving Directors, Officers, or Affiliates**

Except as otherwise disclosed in this prospectus, there are **no material legal proceedings** pending or, to the Company's knowledge, threatened that involve any of the Company's **directors, executive officers, significant shareholders, or other related parties** that are required to be disclosed pursuant to Item 103 of Regulation S-K and that are **material to the Company**.

Specifically, during the past ten years:

· None of the Company's **directors or executive officers** has been a party to any material legal proceedings that would be required to be disclosed under Item 401(f) or Item 103 of Regulation S-K.

· No **significant shareholder or affiliate** of the Company is involved in any material legal proceeding that is required to be disclosed and that is material to the Company's business, financial condition, or results of operations.

· There are no material proceedings involving **related parties** that would reasonably be expected to have a material adverse effect on the Company.

This disclosure is limited to proceedings that are material to the Company, in accordance with Item 103 of Regulation S-K, and reflects the status of such matters as of the date of this prospectus.

**16.4. No Material Legal Proceedings**

Except as disclosed elsewhere in this prospectus, the Company is **not a party to any material legal proceedings**, and there are **no material legal proceedings pending or, to the Company's knowledge, threatened** against the Company that would be required to be disclosed pursuant to Item 103 of Regulation S-K.

Management is not aware of any pending or threatened litigation, claims, actions, or proceedings, whether civil, criminal, administrative, or regulatory, that are reasonably likely to have a material adverse effect on the Company's business, financial condition, results of operations, or liquidity, or that otherwise require disclosure under applicable SEC rules as of the date of this prospectus.

---

| |
|:---|
| 65 |
| *[**Table of Contents**](#TOC)* |

---

**16.5. Cross-Reference and Scope Limitation**

The disclosures set forth in this section are limited to legal proceedings required to be disclosed under Item 103 of Regulation S-K. Routine litigation, claims, or disputes that are incidental to the Company's business and not material to its financial condition, results of operations, or liquidity are excluded from this disclosure.

To the extent that any litigation-related risks are material, such risks are addressed, as applicable, in the section entitled **"Risk Factors."** In addition, any material contingencies, accruals, or loss exposures arising from legal or regulatory matters, if any, are disclosed in the **Notes to Financial Statements** included elsewhere in this prospectus, in accordance with applicable accounting standards and SEC disclosure requirements.

This section should be read together with the referenced sections to obtain a complete understanding of the potential legal and regulatory risks applicable to the Company.

---

| |
|:---|
| 66 |
| *[**Table of Contents**](#TOC)* |

---

**PART II — INFORMATION NOT REQUIRED IN PROSPECTUS**

**17. CALCULATION OF REGISTRATION FEE**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Title of Each Class of Securities to be Registered** | **Amount to be Registered** | **Proposed Maximum Offering Price Per Share (1)** | **Proposed Maximum Aggregate Offering Price (1)** | **Amount of Registration Fee** |
| Common Stock, $0.01 par value | 270175496 | $0.50 | $135087748 | $18655.62 |

---

Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. The proposed offering price has been arbitrarily determined by the Company.

**18. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION**

*(Item 511 of Regulation S-K)*

The following table sets forth the estimated expenses to be incurred by the Company in connection with the issuance and distribution of the securities registered under this registration statement. All amounts shown are estimates, except for the SEC registration fee.

---

| | |
|:---|:---|
| **Type of Expense** | **Estimated Amount (US$)** |
| SEC registration fee | $18655.62 |
| Accounting fees and expenses | $13500.00 |
| Legal fees and expenses | $850.00 |
| Printing and EDGAR filing costs | $1500.00 |
| Transfer agent and registrar fees | $3000.00 |
| Consultancy and other expenses | $54500.00 |
| **Total** | $**92005.62** |

---

---

| |
|:---|
| 67 |
| *[**Table of Contents**](#TOC)* |

---

The foregoing amounts are estimates and are subject to change. The actual expenses incurred may differ from those shown above. These expenses will be paid by the Company and are expected to be funded from existing cash on hand and/or proceeds from the offering. The total issuance expenses will be reflected in the Company's capitalization and liquidity disclosures and reconciled with the "Use of Proceeds" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of this registration statement.

**19. INDEMNIFICATION OF DIRECTORS AND OFFICERS**

*(Item 702 of Regulation S-K)*

**Indemnification Under State Corporate Law**

The Company is incorporated under the laws of the State of Wyoming. The Wyoming Business Corporation Act ("WBCA") permits a corporation to indemnify its directors and officers against expenses, judgments, fines, and amounts paid in settlement incurred in connection with legal proceedings arising by reason of the fact that such person is or was a director or officer of the corporation, provided that such person acted in good faith and in a manner reasonably believed to be in, or not opposed to, the best interests of the corporation.

**Indemnification Under Articles of Incorporation and Bylaws**

The Company's Articles of Incorporation and Bylaws provide that the Company shall indemnify its directors and officers to the fullest extent permitted by applicable Wyoming law. This indemnification includes the advancement or reimbursement of expenses incurred in defending any action, suit, or proceeding, subject to applicable legal requirements and limitations.

**Indemnification Agreements**

**As of the date of this registration statement, the Company has not entered into separate indemnification agreements with its directors or executive officers.**

**Limitation of Liability Provisions**

The Company's Articles of Incorporation include provisions that limit the personal liability of directors to the fullest extent permitted under the WBCA. These provisions generally eliminate or limit monetary liability of directors for breaches of fiduciary duty as directors, except in circumstances where liability cannot be eliminated under applicable law, including for acts or omissions not in good faith or involving intentional misconduct or knowing violations of law.

**SEC Position on Indemnification for Securities Act Liabilities**

Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended (the "Securities Act"), may be permitted to directors, officers, or controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director or officer in the successful defense of any action, suit, or proceeding) is asserted by such person in connection with the securities being registered, the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

---

| |
|:---|
| 68 |
| *[**Table of Contents**](#TOC)* |

---

**20. RECENT SALES OF UNREGISTERED SECURITIES**

*(Item 701 of Regulation S-K)*

During the past three years, the Company has issued the following unregistered securities. The securities described below were issued without registration under the Securities Act of 1933, as amended (the "Securities Act"), in reliance on exemptions from the registration requirements of the Securities Act.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Date of Issuance** | **Number of Shares Issued** | **Consideration Received** | **Exemption Relied Upon** | **Purchasers** |
| 2025 | 163,552,496 shares of common stock | $1,661,248 (cash) | Regulation S and Regulation D (Rule 504) of the Securities Act | Accredited and Non-Accredited investors, including existing stockholders |

---

The shares described above were issued in private placement transactions not involving any public offering. The purchasers represented that they were acquiring the securities for investment purposes only and not with a view to distribution, and appropriate restrictive legends were placed on the certificates or book-entry records evidencing such shares.

The issuances described above are reflected in the Company's audited consolidated financial statements, including the Statement of Stockholders' Equity, and have been taken into account in the capitalization and security ownership disclosures included elsewhere in this registration statement.

The Company has issued shares of its common stock to certain stockholders in transactions conducted outside the United States in reliance on Regulation S promulgated under the Securities Act. Such issuances were made solely to persons who were not "U.S. persons," as defined in Regulation S, in offshore transactions, and no directed selling efforts were made in the United States in connection with such sales. The securities issued pursuant to Regulation S are deemed to be "restricted securities" within the meaning of Rule 144 under the Securities Act and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an available exemption from registration.

The Company has also issued shares of its common stock in private placement transactions conducted in reliance on Rule 504 of Regulation D under the Securities Act. Such issuances were made to a limited number of investors and did not involve any general solicitation or general advertising. Each purchaser represented that it was acquiring the securities for investment purposes only and not with a view to distribution. The securities issued pursuant to Rule 504 of Regulation D are "restricted securities" and may not be resold absent registration under the Securities Act or an applicable exemption therefrom.

None of the foregoing transactions involved underwriters, public offerings, or sales through any public market. In each case, the Company relied upon representations from the purchasers and other information available to the Company in determining the availability of the applicable exemptions from registration under the Securities Act. All issuances of unregistered securities described above were made in compliance with applicable federal and state securities laws.

---

| |
|:---|
| 69 |
| *[**Table of Contents**](#TOC)* |

---

**21. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES**

*(Item 601 of Regulation S-K)*

**Exhibits**

An index to the exhibits filed as part of this registration statement is set forth in the Exhibit Index immediately preceding the signature pages of this registration statement and is incorporated herein by reference. The exhibits include, among others, the Company's organizational documents, material agreements, intellectual property and license agreements, and the consent of the Company's independent registered public accounting firm.

Each exhibit is filed in accordance with the requirements of Item 601 of Regulation S-K and, where applicable, is incorporated by reference to exhibits previously filed by the Company. The Company believes that all material contracts, agreements, and other documents required to be filed as exhibits to this registration statement have been duly filed or incorporated by reference.

**Financial Statement Schedules**

All financial statement schedules otherwise required by Article 5 or Article 8 of Regulation S-X have been omitted because the required information is included in the consolidated financial statements or the notes thereto included elsewhere in this registration statement.

**Accordingly, no financial statement schedules are required or presented.**

This disclosure is made pursuant to Item 601(b)(21) of Regulation S-K and is consistent with the Company's status as a smaller reporting company.

---

| |
|:---|
| 70 |
| *[**Table of Contents**](#TOC)* |

---

**22. FINANCIAL STATEMENTS**

![](pharmaceutical_s1img9.jpg)

**Table of Contents**

---

| | |
|:---|:---|
| [Independent Auditor's Report](#re) | F-2 |
| [Balance Sheet](#bs) | F-4 |
| [Statement of Income](#op) | F-5 |
| [Cash Flow](#cf) | F-6 |
| [Stockholders' Equity](#eq) | F-7 |
| [Notes to Financial Statements](#n) | F-8 |

---

---

| |
|:---|
| F-1 |
| *[**Table of Contents**](#tocff)* |

---

![](pharmaceutical_s1img10.jpg)

**<u>Independent</u> <u>Auditors'</u> <u>Report</u>**

**To: The Board of Directors and Shareholders**

**PHARMACEUTICAL RESOURCE TECHNOLOGY, INC.**

**Opinion**

We have audited the accompanying balance sheets of Pharmaceutical Resource Technology, Inc., as of December 31, 2025 and 2024, and the related statements of operations, stockholders' equity, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Pharmaceutical Resource Technology, Inc. as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

**Basis for Opinion**

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB) and in accordance with generally accepted auditing standards in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

**Management's Responsibility for the Financial Statements**

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement whether due to fraud or error.

**Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States) and generally accepted auditing standards in the United States of America will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users made on the basis of these financial statements.

---

| |
|:---|
| F-2 |
| *[**Table of Contents**](#tocff)* |

---

As part of an audit in accordance with PCAOB standards and U.S. GAAS, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

· Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

· Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.

· Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.

Conclude whether, in our judgment, there are conditions or events that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time, and whether those conditions or events have been appropriately disclosed in the financial statements.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control matters that we identified during the audit.

**Going Concern Uncertainty**

The accompanying financial statements referred to above have been prepared assuming that the Company will continue as a going concern. As discussed in the Notes to the financial statements, the Company's present financial situation raises substantial doubt about its ability to continue as a going concern.

Management's plans regarding this matter are also described in the Notes. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

![](pharmaceutical_s1img11.jpg)

FORTUNE CPA, INC., 8831

Orange, California 92868

January 8, 2026

---

| |
|:---|
| F-3 |
| *[**Table of Contents**](#tocff)* |

---

**PHARMACEUTICAL RESOURCE TECHNOLOGY, INC.**

---

| | | |
|:---|:---|:---|
| **Balance Sheet**<br> **As of December 31, 2025**<br> **(With comparative financial information as of December 31, 2024)** | **Balance Sheet**<br> **As of December 31, 2025**<br> **(With comparative financial information as of December 31, 2024)** | **Balance Sheet**<br> **As of December 31, 2025**<br> **(With comparative financial information as of December 31, 2024)** |
|  | **Years Ended December 31** | **Years Ended December 31** |
|  | **2024** | **2025** |
|  | **US$** | **US$** |
| **ASSETS** |  |  |
| **CURRENT ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Cash and Cash Equivalent | 2339189 | 2855160 |
| &nbsp;&nbsp;&nbsp;&nbsp; Account Receivable | 1011847 | 1001113 |
| &nbsp;&nbsp;&nbsp;&nbsp; Inventories | 24920 | 586629 |
| &nbsp;&nbsp;&nbsp;&nbsp; **TOTAL CURRENT ASSETS** | 3375956 | 4442902 |
| &nbsp;&nbsp;&nbsp;&nbsp; Property, plant and equipment | 5533878 | 4001253 |
| &nbsp;&nbsp;&nbsp;&nbsp; Right of use asset | 2171699 | 2015304 |
| &nbsp;&nbsp;&nbsp;&nbsp; Intangible assets | 20661303 | 19046731 |
| **TOTAL ASSETS** | 31742836 | 29506190 |
| **LIABILITIES** |  |  |
| **CURRENT LIABILITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Accrued expenses/payable | 4065000 | 27500 |
| &nbsp;&nbsp;&nbsp;&nbsp; Lease liability - current | 130111 | 125019 |
| &nbsp;&nbsp;&nbsp;&nbsp; **TOTAL CURRENT LIABILITIES** | 4195111 | 152519 |
| &nbsp;&nbsp;&nbsp;&nbsp; Lease liability - non-current | 651606 | 531484 |
| **TOTAL LIABILITIES** | 4846717 | 684003 |
| **STOCKHOLDERS' EQUITY** |  |  |
| Common stock $0.01 par value, 3,000,000,000 shares, authorized as at December 31, 2025 2,854,462,696 shares issued and outstanding as at December 31, 2025 | 26909102 | 28544627 |
| Additional paid-in capital | 264920 | 290643 |
| Accumulated deficits | (277903) | (13083) |
| **TOTAL STOCKHOLDERS' EQUITY** | 26896119 | 28822187 |
| **TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY** | 31742836 | 29506190 |

---

---

| |
|:---|
| F-4 |
| *[**Table of Contents**](#tocff)* |

---

**PHARMACEUTICAL RESOURCE TECHNOLOGY, INC.**

**Statement Of Operation**

**As of December 2025**

**(With comparative financial information as of December 31, 2024)**

---

| | | |
|:---|:---|:---|
| **CONSOLIDATED STATEMENT OF OPERATIONS**  | **CONSOLIDATED STATEMENT OF OPERATIONS**  | **CONSOLIDATED STATEMENT OF OPERATIONS**  |
|  | **Years Ended December 31** | **Years Ended December 31** |
|  | **2024** | **2025** |
|  | **US$** | **US$** |
| **Revenue** | 10071935 | 10822348 |
| Cost of revenue | (4258055) | (4770238) |
| Gross profit/loss | 5813880 | 6052110 |
| **Operating Expenses** |  |  |
| General and administrative expenses | (4063367) | (5787290) |
| **Profit/Loss Before Income Tax** | 1750513 | 264820 |
| Income tax expenses | - | - |
| **Net Profit/Loss** | 1750513 | 264820 |
| Loss per share: |  |  |
| Basic and diluted net loss per common share  | (0.00) | (0.00) |
| Basic and diluted weighted average number of shares outstanding  | 2690910200 | 2854462696 |

---

---

| |
|:---|
| F-5 |
| *[**Table of Contents**](#tocff)* |

---

**PHARMACEUTICAL RESOURCE TECHNOLOGY, INC.**

---

| | | |
|:---|:---|:---|
| **Cash Flow Statement**<br> **As of December 2025**<br> **(With comparative financial information as of December 31, 2024)** | **Cash Flow Statement**<br> **As of December 2025**<br> **(With comparative financial information as of December 31, 2024)** | **Cash Flow Statement**<br> **As of December 2025**<br> **(With comparative financial information as of December 31, 2024)** |
|  | **Years Ended December 31** | **Years Ended December 31** |
|  | **2024** | **2025** |
|  | **US$** | **US$** |
| **CASH FLOWS FROM OPERATING ACTIVITIES** |  |  |
| Net Profit/loss | 1750513 | 264820 |
| Adjustments to reconcile net income to net cash provided by operating activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Depreciation of property, plant and equipment | 1533061 | 1533279 |
| &nbsp;&nbsp;&nbsp;&nbsp; Depreciation of right of use asset | 156394 | 156394 |
| &nbsp;&nbsp;&nbsp;&nbsp; Amortization | 1614573 | 1614573 |
| Changes in operating assets and liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Inventories | 10539 | (551170) |
| &nbsp;&nbsp;&nbsp;&nbsp; Accrued expenses | 27674 | (37500) |
| &nbsp;&nbsp;&nbsp;&nbsp; Lease liability | (130111) | (125019) |
| **Net generated from operating activities** | 4962643 | 2855377 |
| **CASH FLOWS FROM INVESTING ACTIVITIES** |  |  |
| Additions to property, plant and equipment |  | (654) |
| Additions to right of use asset |  |  |
| Purchase of intangible assets | - | - |
| **Net cash used in investing activities** | - | (654) |
| **CASH FLOWS FROM FINANCING ACTIVITY** |  |  |
| Proceeds from the issuance of common stock/Loan | - | 1661248 |
| **Net cash generated from financing activity** | - | 1661248 |
| **CASH FLOWS FROM REPAYMENT ACTIVITY** |  |  |
| Repayment of debt owed to Directors | (3500000) | (4000000) |
| **Net cash used in repayment activity** | (3500000) | (4000000) |
| **NET INCREASE IN CASH AND CASH EQUIVALENTS** | 1462643 | 515971 |
| **Cash and cash equivalents, beginning of year** | 876546 | 2339546 |
| **Cash and cash equivalents, end of year** | 2339189 | 2855160 |

---

---

| |
|:---|
| F-6 |
| *[**Table of Contents**](#tocff)* |

---

**PHARMACEUTICAL RESOURCE TECHNOLOGY, INC.**

**Stockholders' Equity**

**Par Value $0.01 Per Share**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **COMMON STOCK** | **COMMON STOCK** | | | |
|  | **Number** <br> **of Shares** | **Amount**<br> **$** | **ADDITIONAL**<br> **PAID-IN**<br>**CAPITAL**<br> **$** | **ACCUMULATED**<br>**DEFICIT**<br> **$** | **TOTAL**<br>**EQUITY**<br> **$** |
| Balance December 31, 2019  | 1000000 | 10000 |  |  | 10000 |
| Issuance of common stock For Year ended December 31, 2020 | 2689837200 | 26898372 | 262000 |  | 27160372 |
| Net Loss for the Year ended December 31, 2020 |  |  |  | $(646640) | $(646640) |
| Balance at December 31, 2020 | 2690837200 | 26908372 | 262000 | (646640) | 26523732 |
| Issuance of common stock For Year ended December 31, 2021 | 73000 | 730 | 2920 |  | 3650 |
| Net Loss for Year ended December 31, 2021 |  |  |  | (1651919) | (1651919) |
| Balance at December, 2021 | 2690910200 | 26909102 | 264920 | (2298559) | 24875463 |
| Issuance of common stock For Year ended December 31, 2022 |  |  |  |  |  |
| Net Loss for the Year ended December 31, 2022 |  |  |  | (1169904) | (1169904) |
| Balance at December 31, 2022 | 2690910200 | 26909102 | 264920 | (3468463) | 23705559 |
| Issuance of common stock For Year ended December 31, 2023 |  |  |  |  |  |
| Net Gain for Year ended December 31, 2023 |  |  |  | 1440047 | 1440047 |
| Balance at December 31, 2023 | 2690910200 | 26909102 | 264920 | (2028416) | 25145606 |
| Issuance of common stock For Year ended December 31, 2024 |  |  |  |  |  |
| Net Gain for the Year ended December 31, 2024 |  |  |  | 1750513 | 1750513 |
| Balance at December 31, 2024 | 2690910200 | 26909102 | 264920 | (277903) | 26896119 |
| Issuance of common stock For Year ended December 31, 2025 | 163552496 | 1635525 | 25723 |  | 1661248 |
| Net Gain for Year ended December 31, 2025 |  |  |  | 264820 | 264820 |
| Balance at December 31, 2025 | 2854462696 | 28544627 | 290643 | (13083) | 28822187 |

---

---

| |
|:---|
| F-7 |
| *[**Table of Contents**](#tocff)* |

---

**PHARMACEUTICAL RESOURCE TECHNOLOGY, INC.**

**Notes to Financial Statements**

**As of December 2025**

**1. Overview and Basis of Presentation**

**Description of Business and Basis of Presentation**

**The Company** - **Pharmaceutical Resource Technology, Inc.,** formerly known as Jaison Phytochem; Inc. was formed on the 17 of June 2019. Pharmaceutical Resource Technology, Inc. is in the business of manufacturing dietary health supplements, skin care products and honey straws in Singapore. Although these products are produced in Singapore, most of its revenue are generated from selling these products through online portals and distributors throughout the region. It has also catered to private labels and contract manufacturing for other brands from countries outside Singapore.

Pharmaceutical Resource Technology, Inc. also owns a building and construction business in Singapore which caters to new building design and construction, interior design and renovation, alteration and addition of existing building and structure. Revenue from the Building and Construction business is currently generated from Singapore only.

These financial statements have been prepared in accordance with Generally Accepted Accounting Principles (GAAP) issued by the american Institute of Certified Public Accountants, which is a special purpose framework and not U.S. generally accepted accounting principles (U.S. GAAP). The accounting principles that compose the framework are appropriate for the preparation and presentation of small- and medium-sized entity financial statements, based on the needs of the financial statement users and cost and benefit considerations.

**Use of Estimates**

The preparation of the consolidated financial statements are in conformity with US GAAP which requires the management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The management makes these estimates using the best information available at the time the estimates are made; however actual results could differ materially from those estimates.

**Risk and Uncertainties**

The Company operates in industries that are subject to inherent risks and uncertainties, including market volatility, regulatory changes, economic downturns, and fluctuations in operating costs. In addition, there are risks related to the integration of acquired businesses and reliance on key customers. These uncertainties could materially affect the Company's operating results and financial condition. Management continually monitors these risks and implements mitigating controls where feasible.

**2. Summary of Significant Policies**

**Cash and Cash Equivalents**

Cash and cash equivalents are carried at cost and represent cash on hand, demand deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date of such investments.

**Accounts Receivable**

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of accounts receivable. The Company extends credit to its customers in the normal course of business and generally does not require collateral. The Company's credit terms are dependent upon the segment, and the customer. The Company assesses the probability of collection from each customer at the outset of the arrangement based on a number of factors, including the customer's payment history and its current creditworthiness. If, in management's judgment collection is not probable, the Company does not record them as cash or revenue until the uncertainty is removed.

Management performs ongoing credit evaluations, and the Company maintains an allowance for potential credit losses based upon its loss history and its aging analysis. The allowance for doubtful accounts is the Company's best estimate of the amount of credit losses in existing accounts receivable. Management reviews the allowance for doubtful accounts each reporting period based on a detailed analysis of trade receivables. In the analysis, management primarily considers the age of the customer's receivable, and also considers the creditworthiness of the customer, the economic conditions of the customer's industry, general economic conditions and trends, and the business relationship and history with its customers, among other factors. If any of these factors change, the Company may also change its original estimates, which could impact the level of the Company's future allowance for doubtful accounts. If judgments regarding the collectability of receivables were incorrect, adjustments to the allowance may be required, which would reduce profitability.

---

| |
|:---|
| F-8 |
| *[**Table of Contents**](#tocff)* |

---

Accounts receivable are recognized and carried at the original invoice amount less an allowance for any uncollectible amounts. An estimate for doubtful accounts receivable is made when collection of the full amount is no longer probable. Bad debts are written off as incurred.

**Internal Use Software**

The Company capitalizes certain costs incurred in the development or acquisition of internal-use software in accordance with ASC 350-40, *Intangibles—Goodwill and Other—Internal-Use Sonware.* Capitalized costs include direct labor, payroll-related costs, and other directly attributable expenses incurred during the application development stage. Costs incurred during the preliminary project stage and post-implementation/operating stage, including training and maintenance, are expensed as incurred.

Capitalized internal-use software costs are included within intangible assets and are amortized on a straight-line basis over their estimated useful lives, which generally range from three to five years. Amortization expense is included in operating expenses. Management evaluates internal-use software for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

**Property and Equipment**

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets. The Company uses an estimated useful life of three years for assets less than US$1Million and six years for other assets that are US$1Million in value or more. Leasehold property are amortized over the lease-term or the estimated useful life of the related asset.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Office equipment** | **Furniture, fixture and fitting** | **Computer** | **Machinery and equipment** | **Industrial Leasehold** | **Total** |
|  | **$** | **$** | **$** | **$** | **$** | **$** |
| **Cost** |  |  |  |  |  |  |
| At January 1, 2024 | 16016 | 8202451 | 2885 | 1036498 | 2484487 | 11742337 |
| Additions |  |  |  |  |  |  |
| Disposal |  |  |  |  |  |  |
| At December 31, 2024 | 16016 | 8202451 | 2885 | 1036498 | 2484487 | 11742337 |
| At January 1, 2025 | 16016 | 8202451 | 2885 | 1036498 | 2484487 | 11742337 |
| Additions | 54 |  |  | 600 |  | 654 |
| Disposal |  |  |  |  |  |  |
| At December 31, 2025 | 16070 | 8202451 | 2885 | 1037098 | 2484487 | 11742991 |
| **Accumulated depreciation** |  |  |  |  |  |  |
| At January 1, 2024 | 16016 | 1468846 | 2885 | 703164 | 156394 | 2347305 |
| Depreciation |  | 1366395 |  | 166667 | 156394 | 1689456 |
| Disposal/written-off |  |  |  |  |  |  |
| At December 31, 2024 | 16016 | 2835241 | 2885 | 869831 | 312788 | 4036761 |
| At January 1, 2025 | 16016 | 2835241 | 2885 | 869831 | 312788 | 4036761 |
| Depreciation | 18 | 1366395 |  | 166867 | 156394 | 1689674 |
| Disposal/written-off |  |  |  |  |  |  |
| At December 31, 2025 | 16034 | 4201636 | 2885 | 1036698 | 469182 | 5726435 |
| **Carrying amount** |  |  |  |  |  |  |
| **At December 31, 2024** | **0** | **5367210** | **0** | **166667** | **2171699** | **7705576** |
| **At December 31, 2025** | **36** | **4000815** | **0** | **400** | **2015305** | **6016556** |

---

---

| |
|:---|
| F-9 |
| *[**Table of Contents**](#tocff)* |

---

**Intangible assets**—The intangible assets pertain to the licenses contracted by the Company to the exclusively use of the Industrial Design for the packaging for honey in straw shape in the territory of EU, Hong Kong and Malaysia, and a Patent to manufacture and market the honey straw sealing machine. The upfront payment values of the intangible assets with finite lives are recorded at the right-to-use date and are amortized over their estimated useful lives using the straight-line method.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Quality** <br> **Certifications** | **Trademark** | **Industrial design licenses for EU, Hong Kong & Malaysia** | **Patent license** | **Total** |
|  | **$**  | **$** | **$**  | **$** | **$** |
| **Cost** |  |  |  |  |  |
| At January 1, 2024 | 360000 | 500000 | 1580000 | 25000000 | 27440000 |
| Additions |  |  |  |  |  |
| At December 31, 2024 | 360000 | 500000 | 1580000 | 25000000 | 27440000 |
| At January 1, 2025 | 360000 | 500000 | 1580000 | 25000000 | 27440000 |
| Additions |  |  |  |  |  |
| At December 31, 2025 | 360000 | 500000 | 1580000 | 25000000 | 27440000 |
| **Accumulated amortization** |  |  |  |  |  |
| At January 1, 2024 | 120000 | 100000 | 464957 | 4479167 | 5164124 |
| Amortization | 120000 | 100000 | 144573 | 1250000 | 1614573 |
| Disposal/Written-off |  |  |  |  |  |
| At December 31, 2024 | 240000 | 200000 | 609530 | 5729167 | 6778697 |
| At January 1, 2025 | 240000 | 200000 | 609530 | 5729167 | 6778697 |
| Amortization | 120000 | 100000 | 144573 | 1250000 | 1614573 |
| Disposal/Written-off |  |  |  |  |  |
| At December 31, 2025 | 360000 | 300000 | 754103 | 6979167 | 8393270 |
| **Carrying amount** |  |  |  |  |  |
| **At December 31, 2024** | **120000** | **300000** | **970470** | **19270833** | **20661303** |
| **At December 31, 2025** | **-** | **200000** | **825897** | **18020833** | **19046730** |

---

**Fair Value Measurement -** The Company has adopted FASB ASC Topic on Fair Value Measurements and Disclosures ("ASC 820"), which defines fair value, establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. ASC 820 establishes a three-level valuation hierarchy of valuation techniques based on observable and unobservable input, which may be used to measure fair value and include the following:

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 2 - Input other than Level 1 that is observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other input that is observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Unobservable input that is supported by little or no market activity and that is significant to the fair value of the assets or liabilities.

Our cash and cash equivalents are classified within level 1 of the fair value hierarchy because they are value using quoted market price.

**Related party balances and transaction -** A related party is generally defined as:

(i) any person that holds the Company's securities including such person's immediate families,

(ii) the Company's management,

(iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or

(iv) anyone who can significantly influence the financial and operating decisions of the Company.

---

| |
|:---|
| F-10 |
| *[**Table of Contents**](#tocff)* |

---

A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

During the year 2025, there are significant transactions with a company with common directors on terms agreed between the parties as follows:-

---

| | | | |
|:---|:---|:---|:---|
| **Relationship** | **Name** | **Assets** | **Amount ($)** |
| Common Directors and Shareholders | Superbee Network Singapore Pte Ltd | Purchase of Honey | 787200 |
|  |  | Purchase of other materials | 482655 |
|  |  | **Total** | 1269855 |

---

**Company as lessee -** The Company has obligation as a lessee for office space with non-cancelable term of eight years. The Company classified this as operating lease. This lease does not contain renewal. The Company's leases do not include termination options for either party to the lease or restrictive financial or other covenants. Payments due under the lease contracts include fixed payments. Leases are classified as operating leases at the lease commencement date. Lease expense on operating leases and short-term leases is recognized on a straight-line basis over the lease term. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligations to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of the lease payments over the lease term. The Company uses its incremental borrowing rate at lease commencement to calculate the present value of lease payments when the rate implicit in a lease is not known. The Company's incremental borrowing rate is 4%.

Amount reported in the balance sheet as at December 31, 2025 was as follows:

---

| | |
|:---|:---|
| Operating leases: |  |
| &nbsp;&nbsp;&nbsp;&nbsp; ROU assets  | $2015304 |
| &nbsp;&nbsp;&nbsp;&nbsp; Lease liabilities  | $651606 |

---

Other information related to leases as at December 31, 2025 was as follows:

---

| | |
|:---|:---|
| Supplemental cash flow information: |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Cash paid for amounts included in the measurement of lease liabilities: |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Operating cash flow from operating leases  | $0 |
| Weighted average remaining lease term: |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Operating leases  | 5 years |
| Weighted average discount rate: |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Operating leases  | 4% |

---

---

| | |
|:---|:---|
| **Operating lease right of use asset -** | **Factory/Office Leasehold**<br> **$** |
| At January 1, 2024 | 156394 |
| Depreciation | 156394 |
| At December 31, 2024 | **312788** |
| At January 1, 2025 | 312788 |
| Depreciation | 156394 |
| At December 31, 2025 | **469182** |

---

---

| |
|:---|
| F-11 |
| *[**Table of Contents**](#tocff)* |

---

**Lease liabilities -** The component for lease liability were as follows:-

---

| | | |
|:---|:---|:---|
|  | **Years Ended December 31** | **Years Ended December 31** |
|  | **2024** | **2025** |
| Lease liability - current | 130111 | 125019 |
| Lease liability - non-current | 651606 | 531484 |
| Total | **781717** | **656503** |

---

Maturities of lease liabilities under non-cancellable operating leases as at December 31, 2025 are as follows:

---

| | |
|:---|:---|
| December 31, 2024 | $**781717** |
| December 31, 2025 | $**656503** |

---

**Accrued Expenses -** The amount of accrued expenses consisted of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Years Ended December 31** | **Years Ended December 31** | **Years Ended December 31** | **Years Ended December 31** |
|  | **2024** | **2024** | **2025** | **2025** |
| Accruals |  | 65000 |  | 27500 |

---

**Revenue Recognition and Performance Obligations**

We apply the five steps defined under ASC 606: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Revenue is recognized upon the transfer of control of promised goods or services to a customer.

Revenue is recognized at a point in time when the performance obligation is satisfied by transferring a promised good or service to the customer and all criteria for acceptance have been satisfied. Control of the goods is transferred to the customer, generally on delivery of the goods (in this respect, incoterms are considered).

The Company does not make any significant judgment in determination of the amount and timing of revenue from contracts with customers.

**Earnings Per Share**

The Company reports earnings per share in accordance with ASC 260 " Earnings Per Share", which requires presentation of basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings per share excludes dilution and is computed by dividing income available to common stockholders by the weighted average common shares outstanding during the period. Diluted earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock. Further, if the number of common shares outstanding increases as a result of a stock dividend or stock split or decreases as a result of a reverse stock split, the computations of a basic and diluted earnings per share shall be adjusted retroactively for all periods presented to reflect that change in capital structure.

The Company's basic earnings per share is computed by dividing the net income available to holders by the weighted average number of the Company's ordinary shares outstanding. Diluted earnings per share reflects the amount of net income available to each ordinary share outstanding during the period plus the number of additional shares that would have been outstanding if potentially dilutive securities had been issued.

**Deferred Revenue**

Deferred revenue represents amounts received from customers for which revenue has not yet been recognized. These amounts are recorded as a liability until the related goods or services have been delivered or the performance obligations are satisfied.

As of December 31, 2025, the Company did not have any recorded deferred revenue, as all performance obligations related to customer payments received during the year were satisfied and revenue was recognized accordingly.

---

| |
|:---|
| F-12 |
| *[**Table of Contents**](#tocff)* |

---

The Company continues to evaluate its contracts to determine the appropriate timing of revenue recognition in accordance with ASC 606 — Revenue from Contracts with Customers. Deferred revenue will be recognized in future periods when the Company satisfies the related performance obligations.

**Cost of Revenue**

Cost of revenue consists primarily of materials, depreciation and amortization, consulting costs, and sub-contracting cost of operations and support personnel associated with the delivery of our Honey Straws to our customers. At the date of this reporting, the written-off assets were either thrown away or given to the directors without any recovered value.

---

| | | |
|:---|:---|:---|
|  | **At December 31** | **At December 31** |
|  | **2024**<br> **$** | **2025**<br> **$** |
| **Cost of Revenue** |  |  |
| Materials | 1798919 | 1880983 |
| Depreciation of property and equipment | 1689455 | 1689673 |
| Disposal/Written-off of property and equipment |  |  |
| Amortisation of intangible assets | 1614573 | 1614573 |
| Disposal/Written-off of intangible assets |  |  |
| Consultation and subcontractor fees | 2459136 | 2889255 |
| **Total** | **7562083** | **8074484** |

---

**Sales and Marketing** - Sales and marketing expenses consist of compensation, employee benefits and stock based compensation of sales and marketing activities, as well as commissions, travel, trade show sponsorships and events, conferences, and Internet advertising costs. Fees paid to third parties and merchants for new customer referrals are included in sales and marketing. Costs associated with the Company's advertising and are expensed as incurred and are included in sales and marketing expenses. Advertising and promotional expenses of $326,788 as at December 31, 2023 and $226,788 for the year ended December 31, 2024 were included in the general and administration expenses.

**General and Administrative** - General and administrative expenses include compensation, employee benefits, and stock-based compensation for executive management, finance administration and human resources, facility costs (including rent), bad debt costs, professional service fees, and other general overhead costs including depreciation of property and equipment to support the operations.

---

| | | |
|:---|:---|:---|
|  | **At December 31** | **At December 31** |
|  | **2024**<br> **$** | **2025**<br> **$** |
| **General and Administrative expenses** |  |  |
| Advertising and promotional expenses | 226788 | 870540 |
| Depreciation of property and equipment | 3304028 | 3304246 |
| Disposal/Written-off of property and equipment |  |  |
| General expenses | 436895 | 502511 |
| Insurance | 298 | 27763 |
| Internet services | 1328 | 5090 |
| Printing and stationery | 14 | 1644 |
| Secretarial fee | 11625 | 13037 |
| Telephone charges | 2788 | 3211 |
| Transportation | 12398 | 29575 |
| Utility expenses | 34106 | 36016 |
| Project Expenses |  | 965077 |
| Interest expense | 33099 | 28580 |
| Legal fee | 0 | 0 |
| **Total** | **4063367** | **5787290** |

---

**3. Common Stocks** 

There were no common stock issued within the financial year 2024.

Between January 1, 2025 and December 31, 2025, 163,552,496 common stock were issued as follows:-

---

| |
|:---|
| There were 163,500,000 common stocks issued at Par Value of $0.01/common stock |
| There were 52,496 common stocks issued at $0.50/common stock. |

---

---

| |
|:---|
| F-13 |
| *[**Table of Contents**](#tocff)* |

---

**4. Income Taxes** 

The Company is a U.S. entity and is subject to the United States federal income tax. No provision for income taxes in the United States has been made as the Company had no United States taxable income for the period ended December 31, 2025.

The Company operates in Singapore and files tax returns in the Singapore jurisdiction. The Singapore Corporate Tax rate is currently flat at 17%. As the company is a foreign incorporation, it does not have any tax exemption as a startup company. The company is also not issued with a Certificate of Residency, COR, in Singapore and is therefore not subjected to any tax in Singapore at the date of this reporting.

**5. Concentration of Credit risk and Significant Customers**

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents with financial institutions that management believes are of high credit quality. At times, cash balances may exceed federally insured limits. Management has not experienced any losses related to these concentrations and does not believe it is exposed to significant credit risk with respect to its cash holdings.

The Company's accounts receivable are derived from customers primarily located within its principal markets. Credit risk is mitigated through ongoing credit evaluations, credit approval processes, and continuous monitoring of customer account balances. The Company does not require collateral and generally does not charge interest on past-due balances. Management believes that its allowance for credit losses is adequate to absorb probable losses, if any.

For the years ended December 31, 2024 and 2025, revenues from customers that individually accounted for 10% or more of total consolidated revenues represented a significant portion of the Company's operating results. The loss of, or a material reduction in business from, any such customer could have an adverse effect on the Company's financial condition and results of operations. Management monitors customer concentration risk on an ongoing basis and seeks to diversify its customer base where practicable.

**6. Subsequent Events**

The Company evaluated subsequent events in accordance with ASC 855, *Subsequent Events,* through the date the consolidated financial statements were available to be issued. Management considered all events or transactions that occurred after December 31, 2025, that would require recognition or disclosure in the consolidated financial statements.

**7. Shareholder Equity**

Pharmaceutical Resource Technology, Inc.is authorized to issue 3,000,000,000 shares of common stock with a par value of $0.01 per share. As of December 31, 2025, the Company had **2,854,462,696 shares** of common stock issued and outstanding.

Common stock is recorded at par value, with amounts received in excess of par value recorded as additional paid -in capital. The Company has not issued any preferred stock as of December 31, 2025.

Accumulated deficit represents cumulative net losses and gains since inception. For the years ended December 31, 2024 and 2025, the Company reported net income of $1,750,513 and $264,820, respectively, which reduced the accumulated deficit.

All shares issued during the periods presented were fully paid and non-assessable. The Company did not declare or pay dividends during the years ended December 31, 2024 and 2025.

---

| |
|:---|
| F-14 |
| *[**Table of Contents**](#tocff)* |

---

**PHARMACEUTICAL RESOURCE TECHNOLOGY, INC.**

**Incorporated in the state of Wyoming, USA Reg. ID.: 2019-000861613** 

**Registered Agents, 30N Gould St STE R, Sheridan, WY 82801, USA**

**Management Agents, No. 1 Kaki Bukit Avenue 3, #09-11, KB-1, Singapore 416087**

**Tel: +65 6841 0120**

**email: contact@pharmaceuticalresource.com**

**Name of Agency Auditing Firm: FORTUNE CPA, INC** 

**Contact Person Name and Title: Theresa Brainerd (CPA)** 

**Telephone #: (774) 322-1209**

**Email Address: brainyIinda43@gmaiI.com** 

**Headquarter: 333 City Blvd W 3rd Floor** 

**Orange, CA 92868** 

**USA**

---

| |
|:---|
| F-15 |
| *[**Table of Contents**](#TOC)* |

---

**23. UNDERTAKINGS**

*(Item 512 of Regulation S-K)*

The undersigned registrant hereby undertakes:

(a) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

· To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the "Securities Act");

· To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement;

· To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

provided, however, that paragraphs (a)(1) and (a)(2) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that are incorporated by reference in the registration statement.

(b) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(d) That, for the purpose of determining liability under the Securities Act to any purchaser:

· Each prospectus filed pursuant to Rule 424(b) under the Securities Act shall be deemed to be part of the registration statement as of the date the prospectus is first used after effectiveness; and

· Each prospectus required to be filed pursuant to Rule 424(b) under the Securities Act relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) shall be deemed to be part of the registration statement as of the earlier of the date such prospectus is first used or the date of the first contract of sale of securities in the offering described in the prospectus.

(e) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that, in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities, the registrant will be a seller to the purchaser.

(f) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

(g) The registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act of 1939, if applicable.

This undertaking is given in accordance with Item 512 of Regulation S-K.

---

| |
|:---|
| 72 |
| *[**Table of Contents**](#TOC)* |

---

**EXHIBIT INDEX**

[1.](pharmaceutical_ex31.htm) [Exhibit 3.1 — Certificate of Incorporation (Articles of Incorporation) (1)](pharmaceutical_ex31.htm)

[2.](pharmaceutical_ex32.htm) [Exhibit 3.2 — Bylaws (current form) (1)](pharmaceutical_ex32.htm)

[3.](pharmaceutical_ex33.htm) [Exhibit 3.3 — Articles of Amendment (2)](pharmaceutical_ex33.htm)

[4.](pharmaceutical_ex41.htm) [Exhibit 4.1 — Specimen Common Stock Certificate (1 Front and 1 Back) (2)](pharmaceutical_ex41.htm)

[5.](pharmaceutical_ex51.htm) [Exhibit 5.1 — Opinion of Counsel regarding legality/validity of securities (2)](pharmaceutical_ex51.htm)

[6.](pharmaceutical_ex101.htm) [Exhibit 10.1 — Asset Purchase Agreement(s) and other Material Purchase/Acquisition Agreements (2)](pharmaceutical_ex101.htm)

[7.](pharmaceutical_ex102.htm) [Exhibit 10.2 — Management / Consulting / Services Agreement (2)](pharmaceutical_ex102.htm)

[8.](pharmaceutical_ex103.htm) [Exhibit 10.3 — Intellectual Property / License Agreements (material IP licenses) (1)](pharmaceutical_ex103.htm)

[9.](pharmaceutical_ex231.htm) [Exhibit 23.1 — Consent of Independent Registered Public Accounting Firm (2)](pharmaceutical_ex231.htm)

[10.](pharmaceutical_ex991.htm) [Exhibit 99.1 — Sample Subscription Agreement (2)](pharmaceutical_ex991.htm)

[11.](pharmaceutical_ex992.htm) [Exhibit 99.2 — Certificate of Patent Granted (2)](pharmaceutical_ex992.htm)

[12.](pharmaceutical_ex107.htm) [Exhibit 107.1 — Calculation of Filing Fee Tables (2)](pharmaceutical_ex107.htm)

__________________

1. Incorporated by reference to Form S-1 filed on September 21, 2021 (File No. 333-259689) ("the prior Registration Statement") which was withdrawn on June 16, 2022. https://www.sec.gov/Archives/edgar/data/1865759/000159991621000221/0001599916-21-000221-index.html

2. Filed herewith

---

| |
|:---|
| 73 |
| *[**Table of Contents**](#TOC)* |

---

**24. SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Singapore, on February 11, 2026.

---

| | |
|:---|:---|
| **PHARMACEUTICAL RESOURCE TECHNOLOGY, INC.**<br>*(formerly known as Jaison Phytochem, Inc.) (Registrant)* | **PHARMACEUTICAL RESOURCE TECHNOLOGY, INC.**<br>*(formerly known as Jaison Phytochem, Inc.) (Registrant)* |
| By: | */s/ Jacksaa Tan* |
| Name: | Jacksaa Tan |
|  | Chairman of the Board and Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| |
|:---|
| */s/ Jacksaa Tan* |
| Jacksaa Tan |
| Chairman of the Board and Chief Executive Officer |
| (Principal Executive Officer) |
| Date: 02-11-2026 |

---

---

| |
|:---|
| */s/ Hui Eng Ling* |
| Hui Eng Ling |
| Director and Chief Financial Officer |
| (Principal Financial and Accounting Officer) |
| Date: 02-11-2026 |

---

---

| |
|:---|
| 74 |
| *[**Table of Contents**](#TOC)* |

---

**Instructions**

1. The registration statement shall be signed by the registrant, its principal executive officer or officers, its principal financial officer, its controller or principal accounting officer and by at least a majority of the board of directors or persons performing similar functions. If the registrant is a foreign person, the registration statement shall also be signed by its authorized representative in the United States. Where the registrant is a limited partnership, the registration statement shall be signed by a majority of the board of directors of any corporate general partner signing the registration statement. If the securities to be registered on this Form will be issued by a special purpose acquisition company, as such term is defined in Item 1601 of Regulation S-K, or another shell company in connection with a de-SPAC transaction, as such term is defined in Item 1601 of Regulation S-K, the term "registrant" for purposes of this instruction and the Signatures section of this form also includes the target company, as such term is defined in Item 1601 of Regulation S-K, except that in connection with any de-SPAC transaction involving the purchase of assets or a business, with respect to the purchase of assets or a business, the term "registrant" also includes the seller of the business or assets.

2. The name of each person who signs the registration statement shall be typed or printed beneath his signature. Any person who occupies more than one of the specified positions shall indicate each capacity in which he signs the registration statement. Attention is directed to Rule 402 concerning manual signatures and to Item 601 of Regulation S-K concerning signatures pursuant to powers of attorney.

## Exhibit 3.1

**EXHIBIT 3.1**

![](pharmaceutical_ex31img1.jpg)

![](pharmaceutical_ex31img2.jpg)

![](pharmaceutical_ex31img3.jpg)

![](pharmaceutical_ex31img4.jpg)

## Exhibit 3.2

**EXHIBIT 3.2**

**BYLAWS**

**OF**

**Pharmaceutical Resource Technology, Inc.**

**ARTICLE I**

**<u>NAME AND LOCATION OF OFFICE</u>**

The name of this Corporation is Pharmaceutical Resource Technology, Inc. The principal office of the Corporation in the State of Wyoming shall be located in the Country of Singapore. The Corporation may have such other offices, either within or without the Country of Singapore, as the business of the Corporation may require from time to time.

**ARTICLE II**

**<u>SHAREHOLDERS</u>**

SECTION 1. **<u>ANNUAL MEETING</u>**. The annual meeting of the shareholders shall be held on the **30th** day of the month of **June** of each year beginning in the year **2019** for the purpose of electing Directors and for the transaction of such other business as may come before the meeting. If the day fixed for the annual meeting shall be a legal holiday, such meeting shall be held on the next succeeding business day. In the event that such annual meeting is omitted by oversight or otherwise on the date herein provided for, the Board of Directors shall cause a meeting in lieu thereof to be held as soon thereafter as conveniently may be, and any business to be transacted or held at the annual meeting may be transacted at such meeting in lieu thereof. Such subsequent meeting shall be called in the same manner as provided for the annual shareholders' meeting.

SECTION 2. **<u>SPECIAL MEETINGS</u>**. Special meetings of the shareholders may be called by the President, the Secretary, by a majority of the Board of Directors or by the holders of not less than a majority of all the outstanding shares of the Corporation.

SECTION 3. **<u>PLACE OF MEETING</u>**. The Board of Directors may designate any place, either within or without the Country of Singapore, unless otherwise prescribed by statute, as the place of meeting for any annual meeting or for any special meeting. A waiver of notice signed by all shareholders entitled to vote at a meeting may designate any place, either within or without the Country of Singapore, unless otherwise prescribed by statute, as the place for the holding of such meeting. If no designation is made, the place of meeting shall be the principal office of the Corporation.

SECTION 4. **<u>NOTICE OF SHAREHOLDERS' MEETING</u>**. Written notice stating the place, day and hour of the meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called, shall unless otherwise prescribed by statute, be delivered not less than 7 nor more than 30 days before the date of the meeting, to each shareholder of record entitled to vote at such meeting. If mailed, such notice shall be deemed to be delivered when deposited in the United States Mail, addressed to the shareholder at his or her address as it appears on the stock transfer books of the Corporation, with postage thereon prepaid.

SECTION 5. **<u>WAIVER OF NOTICE</u>**. Whenever any notice whatever is required to be given by these Bylaws, or the Articles of Incorporation of this Corporation, or any of the Corporation laws of the Country of Singapore, a waiver thereof in writing, signed by the person or persons entitled to such notice, whether before or after the time stated therein, shall be deemed equivalent thereto. Any meeting of which all shareholders shall at any time, waive or have waived notice in writing, shall be a legal meeting for the transaction of business, notwithstanding that notice has not been given as hereinbefore provided.

SECTION 6. **<u>QUORUM OF SHAREHOLDERS</u>**. A majority of the outstanding shares of the Corporation entitled to vote, represented in person or by proxy, shall constitute a quorum at a meeting of shareholders. If less than a majority of the outstanding shares are represented at a meeting, a majority of the shares so represented may adjourn the meeting from time to time without further notice. At such adjourned meeting at which a quorum shall be present or represented, any business may be transacted which might have been transacted at the meeting as originally noticed. The shareholders present at a duly organized meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough shareholders to leave less than a quorum.

SECTION 7. **<u>VOTING</u>**. Each outstanding share entitled to vote shall be entitled to one vote upon each matter submitted to a vote at a meeting of shareholders. There shall be no cumulative voting.

SECTION 8. **<u>PROXIES</u>**. At all meetings of shareholders, a shareholder may vote by proxy executed in writing by the shareholder or by his or her duly authorized attorney-in-fact. Such proxy shall be filed with the Secretary of the Corporation before or at the time of the meeting.

SECTION 9. **<u>ACTION BY CONSENT</u>**. Any action required to be taken at a meeting of the shareholders may be taken without a meeting if an agreement or consent in writing setting forth the action so taken shall be signed by all of the shareholders entitled to vote with respect to the subject matter thereof. Such consent shall have the effect of a unanimous vote.

**ARTICLE III**

**<u>STOCK</u>**

SECTION 1. **<u>CERTIFICATES</u>**. Certificates of stock shall be in a form approved and adopted by the Board of Directors. They shall be signed by the President or Vice-President, counter-signed by the Secretary, and attested by the corporate seal. They shall be consecutively numbered and state upon their fact the information required by law. The name and address of the person owning the shares with the number of shares and the date of issue shall be entered on the corporation's books and records.

SECTION 2. **<u>ASSIGNMENT AND CANCELLATION</u>**. All certificates of stock transferred by assignment shall be surrendered for cancellation and new certificates issued to the purchaser or assignees.

SECTION 3. **<u>TRANSFER</u>**. Shares of stock shall be transferred on the books of the Corporation only by the holders thereof in person or by his or her attorney-in-fact. Upon any action undertaken by the shareholders to elect S Corporation status pursuant to Section 1362 of the Internal Revenue Code and upon any shareholders agreement thereto restricting the transfer of said shares so as to disqualify said S Corporation status, said restriction on transfer shall be made a part of the bylaws so long as said agreement is in force and effect.

SECTION 4. **<u>LEGEND</u>**. All stock certificates shall bear a legend referring to the restrictions of ownership and transfer as set forth in the Articles of Incorporation and any agreement among or between shareholders relating thereto.

**ARTICLE IV**

**<u>DIRECTORS</u>**

SECTION 1. **<u>GENERAL POWERS</u>**. The business and affairs of the Corporation shall be managed by its Board of Directors. In the management and control of the property, business, and affairs of the corporation, the Board of Directors is hereby vested with all the powers possessed by the Corporation itself, insofar as this delegation of authority is not inconsistent with the laws of the Country of Singapore, with the Certificate of Incorporation of the Corporation, or with these Bylaws.

SECTION 2. **<u>NUMBER, TENURE AND DISQUALIFICATIONS</u>**. The number of Directors of the Corporation shall be at least one (1). Each Director shall hold office for the term for which he or she is elected or until his or her successor shall have been elected and qualified.

SECTION 3. **<u>REGULAR MEETINGS</u>**. A regular meeting of the Board of Directors shall be held without other notice than this Bylaw immediately after, and at the same place as, the annual meeting of shareholders. The Board of Directors may provide, by resolution, the time and place for the holding of additional regular meetings without notice other than such resolution.

SECTION 4. **<u>SPECIAL MEETINGS</u>**. Special meetings of the Board of Directors may be called by or at the request of the President or any two directors. The person or persons authorized to call special meetings of the Board of Directors may fix the place for holding any special meeting of the Board of Directors called by them

SECTION 5. **<u>NOTICE</u>**. Notice of any meeting shall be given at least one (1) day previously thereto by written notice delivered personally or mailed to each Director at his or her business address, or by telegram. If mailed, such notice shall be deemed to be delivered when deposited in the United States mail in a sealed envelope so addressed, with postage thereon prepaid. If notice be given by telegram, such notice shall be deemed to be delivered when the telegram is delivered to the telegraph company. Any Director may waive notice of any meeting. The attendance of a Director at any meeting shall constitute a waiver of notice of such meeting, except where a Director attends a meeting for the express purpose of objecting to the transaction of any business because the meeting is not lawfully called or conveyed. Neither the business to be transacted at, not the purpose of, any regular meeting of the Board of Directors need be specified in the notice of waiver of notice of such meeting.

SECTION 6. **<u>QUORUM</u>**. A majority of the outstanding shares of the Corporation entitled to vote, represented in person or by proxy, shall constitute a quorum at a meeting of shareholders. If less than a majority of the outstanding shares are represented at a meeting, a majority of the shares so represented may adjourn the meeting from time to time without further notice. At any adjourned meeting at which a quorum shall be present or represented, any business may be transacted which might have been transacted at the meeting as originally noticed. The shareholders present at a duly organized meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough shareholders to leave less than a quorum.

SECTION 7. **<u>MANNER OF ACTING</u>**. The act of the majority of the Directors present at a meeting at which a quorum is present shall be the act of the Board of Directors.

SECTION 8. **<u>ACTION BY CONSENT</u>**. Any action required to be taken at a meeting of the Directors, or any other action which may be taken at a meeting of Directors, may be taken without a meeting if a consent in writing, setting forth the action so taken, shall be signed by all of the Directors entitled to vote with respect to the subject matter thereof. Such consent shall have the effect of a unanimous vote and shall be equally valid as if said action were approved at a meeting.

SECTION 9. **<u>VACANCIES</u>**. Any vacancy occurring in the Board of Directors may be filled by the affirmative vote of a majority of the remaining directors though less than a quorum of the Board of Directors, unless otherwise provided by law. A director elected to fill a vacancy shall be elected for the unexpired term of his or her predecessor in office. Any directorship to be filled by reason of an increase in the number of directors may be filled by election by the Board of Directors for a term of office continuing only until the next election of directors by the shareholders.

SECTION 10. **<u>COMPENSATION</u>**. Directors as such shall not receive any stated salaries for their services, but by resolution of the Board of Directors, a fixed sum in addition to expenses of attendance as set forth above may be allowed for attendance at each regular or special meeting of the Board of Directors. Nothing herein contained shall be construed to preclude any Director from serving the Corporation in any other capacity and receiving compensation therefore.

**ARTICLE V**

**<u>OFFICERS</u>**

SECTION 1. **<u>NUMBER</u>**. The officers of the Corporation shall be a President, one or more Vice Presidents, a Secretary, and a Treasurer, each of whom shall be elected by the Board of Directors. Such other officers and assistant officers as may be deemed necessary may be elected or appointed by the Board of Directors, including a Chairperson of the Board. In its discretion, the Board of Directors may leave unfilled for any such period as it may determine any office except those of President and Secretary. Any two or more offices may be held by the same person, except for the offices of President and Secretary which may not be held by the same person. Officers may be directors or shareholders of the Corporation.

SECTION 2. **<u>ELECTION AND TERM OF OFFICE</u>**. The officers of the Corporation shall be elected annually by the Board of Directors at the first meeting of the Board of Directors held after each annual meeting of shareholders. If the election of officers shall not be held at such meeting, such election shall be held as soon thereafter as conveniently may be. Vacancies may be filled or new offices created and filled at any meeting of the Board of Directors. Each officer shall hold office until his or her successor shall have been duly executed and shall have qualified or until his or her death or until he or she shall resign or shall have been removed in the manner hereinafter provided.

SECTION 3. **<u>REMOVAL</u>**. . Any officer or agent may be removed by the Board of Directors whenever, in its judgment, the best interests of the Corporation will be served thereby, but such removal shall be without prejudice to the contract rights, if any, of the person so removed. Election or appointment of an officer or agent shall not of itself create contract rights, and such appointment shall be terminable at will.

SECTION 4. **<u>VACANCIES</u>**. A vacancy in any office because of death, resignation, removal, disqualification or otherwise, may be filled by the Board of Directors for the unexpired portion of the term.

SECTION 5. **<u>PRESIDENT</u>**. The President shall be the principal executive officer of the Corporation and, subject to the control of the Board of Directors, shall in general supervise and control all of the business and affairs of the Corporation. He or she shall, when present, preside at all meetings of the shareholders and of the Board of Directors, unless there is a Chairperson of the Board in which case the Chairperson shall preside. He or she may sign, with the Secretary or any other proper officer of the Corporation thereunto authorized by the Board of Directors, certificates for shares of the Corporation, any deeds, mortgages, bonds, contracts, or other instruments which the Board of Directors has authorized to be executed, except in cases where the signing and execution thereof shall be expressly delegated by the Board of Directors or by these Bylaws to some other officer or agent of the Corporation, or shall be required by law to be otherwise signed or executed; and in general shall perform all duties incident to the office of President and such other duties as may be prescribed by the Board of Directors from time to time.

SECTION 6. **<u>VICE-PRESIDENT</u>**. In the absence of the President or in event of his or her death, inability or refusal to act, the Vice President shall perform the duties of the President, and when so acting, shall have all the powers of and be subject to all the restrictions upon the President. The Vice President shall perform such other duties as from time to time may be assigned to him by the President or by the Board of Directors. If there is more than one Vice President, each Vice President shall succeed to the duties of the President in order of rank as determined by the Board of Directors. If no such rank has been determined, then each Vice President shall succeed to the duties of the President in order of date of election, the earliest date having the first rank.

SECTION 7. **<u>TREASURER</u>**. The Treasurer, subject to the order of the Board of Directors, shall have the care and custody of the money, funds, valuable papers, and documents of the Corporation and shall have an exercise, under the supervision of the Board of Directors, all the powers and duties commonly incident to this office. He or she shall deposit all funds of the Corporation in such bank or banks as the Directors shall designate. He or she may endorse for deposit or collection all checks and notes payable to the Corporation or to its order, may accept drafts on behalf of the Corporation, and together with the President or a Vice-President, may assign certificates of stock. He or she shall keep accurate books of account of the Corporation's transactions which shall be the property of the Corporation, and together with all its property in his or her possession, shall be subject at all items to the inspection and control of the Board of Directors.

SECTION 8. **<u>SECRETARY</u>**. The Secretary shall keep accurate minutes of all meetings of the shareholders and the Board of Directors, and shall perform all the duties commonly incident to his or her office, and shall perform such other duties and have such other powers as the Board of Directors shall designate. The Secretary shall have power, together with the President or a Vice-President, to sign certificates of stock of the Corporation. In his or her absence at any meeting any Assistant Secretary or a Secretary Pro Tempore, shall perform his or her duties thereat.

**ARTICLE VI**

**<u>CONTRACT, LOANS, CHECKS AND DEPOSITS</u>**

SECTION 1. **<u>CONTRACTS</u>**. The Board of Directors may authorize any officer or officers, agent or agents, to enter into any contract or execute and deliver any instrument in the name of and on behalf of the Corporation, and such authority may be general or confined to specific instances.

SECTION 2. **<u>LOANS</u>**. No loans shall be contracted on behalf of the Corporation and no evidence of indebtedness shall be issued in its names unless authorized by a resolution of the Board of Directors. Such authority may be general or confined to specific instances.

SECTION 3. **<u>CHECKS, DRAFTS, ETC</u>**. All checks, drafts or other orders for the payment of money, notes or other evidences of indebtedness issued in the name of the Corporation, shall be signed by such officer or officers, agent or agents of the Corporation and in such manner as shall, from time to time, be determined by resolution of the Board of Directors.

SECTION 4. **<u>DEPOSITS</u>**. All funds of the Corporation not otherwise employed shall be deposited from time to time to the credit of the Corporation in such banks, trust companies or other depositories as the Board of Directors may select.

**ARTICLE VII**

**<u>CERTIFICATES FOR SHARES AND THEIR TRANSFER</u>**

SECTION 1. **<u>CERTIFICATES FOR SHARES</u>**. Certificates representing shares of the Corporation shall be in such forms as may be determined by the Board of Directors. Such certificates shall be signed by the President or a Vice-President and by the Secretary and shall be sealed with the seal of the Corporation. All certificates for shares and date of issue shall be entered on the books of the Corporation. All certificates surrendered to the Corporation for transfer shall be canceled and no new certificate shall be issued until the former certificate for a like number of shares shall have been surrendered and canceled, except that in case of a lost, destroyed or mutilated certificate a new one may be issued therefore upon such terms and indemnity to the Corporation as the Board of Directors may prescribe.

SECTION 2. **<u>TRANSFERS OF SHARES</u>**. Transfers of shares of the Corporation shall be made only on the books of the Corporation by the registered holder thereof or by his or her attorney thereunto authorized by power of attorney duly executed and filed with the Secretary of the Corporation, and on surrender for cancellation of the certificate for such shares. The person in whose name shares stand on the books of the Corporation shall be deemed the owner thereof for all purposes as regards the Corporation. Upon any action undertaken by the shareholders to elect S Corporation status pursuant to Section 1362 of the Internal Revenue Code and upon any shareholders agreement thereto restricting the transfer of said shares so as to disqualify said S Corporation status, said restriction on transfer shall be made a part of the bylaws so long as said agreement is in force and effect.

**ARTICLE VIII**

**<u>FISCAL YEAR</u>**

The fiscal year of the Corporation shall be the period beginning on January 1 and ending on December 31.

**ARTICLE IX**

**<u>DIVIDENDS</u>**

SECTION 1. The Board of Directors may from time to time declare, and the Corporation may pay, dividends on its outstanding shares in the manner and upon the terms and conditions provided by law and its Articles of Incorporation.

**ARTICLE X**

**<u>SEAL</u>**

At the discretion of the Board of Directors, the Corporation may adopt a corporate seal, and shall have inscribed thereon the name of the Corporation and the State of incorporation and the words, "Corporate Seal". No seal shall be necessary to make any contract or valid undertaking.

**ARTICLE XI**

**<u>WAIVER OF NOTICE</u>**

Whenever any notice whatever is required to be given under the provisions of these Bylaws or under the provisions of the Articles of Incorporation or under the provisions of the law under which this Corporation is organized, waiver thereof in writing, signed by the person or persons entitled to such notice, whether before or after the time stated therein, shall be deemed equivalent to the giving of such notice.

**ARTICLE XII**

**<u>INDEMNIFICATION OF DIRECTORS AND OFFICERS</u>**

The Corporation, by approval given in these Bylaws, indemnifies each and every Director and Officer and each person who may hereafter at any time serve at its request as a Director or Officer of another Corporation in which it owns shares of capital stock or of which it is a creditor, against expenses actually and reasonably incurred by each such Director and Officer in connection with the settlement or defense or any action, suit or proceeding, civil or criminal, in which he or she is made a party by reason of being or having been such Director or Officer, except in relation to matters as to which he or she shall be adjudged in such action, suit or proceeding to be liable for negligence or misconduct in the performance of duty to the Corporation; and it specifically indemnifies each such Director and Officer from payment of any judgment, levy, or demand that might be granted against any such Director or Officer by virtue of his or her occupancy of said directorship or office growing out of any such action, suit, or proceedings.

**ARTICLE VIII**

**<u>AMENDMENTS</u>**

These Bylaws may be altered, amended or repealed and new Bylaws may be adopted at any annual meeting of the shareholders of the Corporation or at any special meeting when the proposal to amend these Bylaws has been stated in the notice of such special meeting, by a majority vote of the shareholders represented at the meeting.

The above Bylaws are certified to have been adopted by the Board of Directors of the Corporation on the 15 day of March, 2023.

---

| |
|:---|
| */s/ Jack Saa Tan* |
| Jack Saa Tan |
| Managing Director |
| */s/ Hui Eng Ling* |
| Hui Eng Ling |
| Secretary/Treasurer |

---

## Exhibit 3.3

**EXHIBIT 3.3**

![](pharmaceutical_ex33img8.jpg)

![](pharmaceutical_ex33img9.jpg)

![](pharmaceutical_ex33img10.jpg)

![](pharmaceutical_ex33img11.jpg)

![](pharmaceutical_ex33img12.jpg)

## Exhibit 4.1

**EXHIBIT 4.1**

![](pharmaceutical_ex41img19.jpg)

![](pharmaceutical_ex41img2.jpg)

**<u>All certificates to be transferred must be enclosed with this stock power</u>**

The signature to (his assignment must correspond with the name as written upon the face of the certificate in every particular without alteration or enlargement or any change whatsoever. The signature of the person executing this power must be guaranteed by an eligible Guarantor Institution such as a Commercial Bank, Trust Company, Securities Broker/Dealer, Credit Union, or Savings Association participating in a Medallion Program approved by the Securities Transfer Association, Inc. No other form of signature guarantee is acceptable.

**STOCK POWER**

For value received, I/we hereby sell, assign and transfer unto

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Print or Type Name) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Address of Transferee) |

---

**SS# or Tax ID __________________________**

Certificate shares of the  

(Name of Company)![](pharmaceutical_ex41img8.jpg)

Represented by certificate number(s) __________________________

The undersigned does (do) hereby irrevocably constitute and appoint Colonial Stock Transfer Company to transfer the said stock on the books of said company with full power of substitution in their premises.

(Must check one) Note**: <u>If any cost basis information below is not completed the issuer will be notified and given 2 weeks to provide the data, if the data is not provided the end of the two weeks. the request will not be processed and will be rejected back to the issuer.</u>**

---

| | |
|:---|:---|
| **Original Cost __________________________** | **Original Issuance / Purchase Date __________________________** |

---

**Current Cost tor this transaction __________________________**

Gift ___ Purchase/Sell _________ (Includes both Private and Public Purchases) Compensation________(Include payment for services)

Date __________________________

---

| |
|:---|
| (Signature of Registered Holder completing the stock power) |
| (Print Name of' Registered Holder) |
| (Signature of Joint Registered Holder completing the stock power) |
| (Print Name of Joint Registered Holder) |

---

(Affix <u>Medallion</u> Signature Guarantee imprint in space to the right)

## Exhibit 5.1

**EXHIBIT 5.1**

**LAW OFFICE OF CARL P. RANNO**

---

| | | |
|:---|:---|:---|
| **Attorney and Counselor at Law** <br> **Admitted in Michigan** | **2733 EAST VISTA DRIVE** <br> **PHOENIX, ARIZONA 85032** | **Telephone: 602-493-0369**<br> **Email: carlranno@cox.net**  |

---

February 4, 2026

Pharmaceutical Resource Technology, Inc**.**

1 Kaki Bukit Ave 3, 09-11, KB-1,

Singapore 416087

Attn: Tan Jacksaa

Via email; jackssa@pharmaceuticalresource.com

RE: Opinion to be filed with an S-1 Registration statement filed by Pharmaceutical Resource Technology, Inc**.**, a Wyoming Corporation.

Dear Sir,

This Opinion is in connection with a registration statement to be filed by Pharmaceutical Resource Technology, Inc**.** a Wyoming Corporation on Form S-1 (the "Registration Statement") with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), in connection with the registration of 270,175,496 shares of the Company's common stock, $0. 01 par value, consisting of 100,000,000 newly issued common shares for public sale by the issuer, and 170,175,496 shares being offered by the Selling Shareholders.

You have requested my opinion as to the matters set forth below in connection with the Registration Statement. For purposes of this opinion, I have examined the Registration Statement, the Company's Articles of Incorporation filed June 17, 2019, and a name change filed with the state of Wyoming on March 21, 2023, the Company's Bylaws dated March 15, 2023, the Exhibits attached to the Registration Statement, including a form of the Subscription Agreements that, according to the Company have been executed by the 61selling shareholders, and the Subscription Agreement to use for the shares to be issued and such other documents and matters of law as I have deemed necessary for the expression of the opinion herein contained.

I have made assumptions that are customary in opinions of this kind, including the assumptions of the genuineness of all signatures on original documents, the authenticity of all documents submitted to me, the conformity to originals of all documents submitted as copies thereof, and the due execution and delivery of all documents where due execution and delivery are prerequisites to the effectiveness thereof.

Based upon and subject to the foregoing, it is my opinion with respect to the registration of 170,175,496 shares of the Company's common stock, $0.01 par value (the "Shares"), for public sale by the Company's selling shareholders as disclosed in the S-1 Registration Statement, for public sale by the Company's selling shareholders as disclosed in the S-1 Registration Statement, are validly issued, fully paid, non-assessable and may be reissued, subject to the requirements of the Transfer Agent, to the 61 selling shareholders without a restrictive legend. The selling shareholders' names and number of shares owned by them have been set forth in the Registration Statement.

1<br>

In connection with the registration of 100,000,000 newly issued shares of the Company's common stock, $0.0001 par value, for public sale by the issuer it is my opinion that the Shares will be duly authorized and when issued and paid for as described in the Registration Statement and Prospectus, will be, validly issued, fully paid, non-assessable and issued without a restrictive legend.

This opinion is limited to the Federal laws of the United States, and the applicable statutory provisions of the Nevada Revised Statutes of the State of Nevada, including all applicable provisions of the Nevada Constitution and all regulations related to and all reported judicial decisions interpreting those laws and provisions. We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference made to this firm in the Registration Statement under the heading "Legal Matters."

In all such examinations, I have assumed the genuineness of all signatures on original documents, and the conformity to the originals of all copies submitted to me by the parties herein. In passing upon certain corporate records and documents of the Company, I have necessarily assumed the correctness and completeness of the statements made or included therein by the Company, and I express no opinion thereon. As to the various questions of fact material to this opinion, I have relied, to the extent I deemed reasonably appropriate, upon representations or of officers or directors of the Company and upon documents, records and instruments furnished to me by the Company, without verification except where such verification was readily ascertainable.

I hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the use of my name under the caption "Interests of Named Experts and Counsel" in the prospectus comprising part of the Registration Statement.

This opinion is rendered pursuant to Item 601(b)(5)(i) of Regulation S-K under the Act and may not be used or relied upon for any other purpose. This opinion is given as of the effective date of the Registration Statement, and I assume no obligation to update or supplement the opinions contained herein to reflect any facts or circumstances which may hereafter come to our attention or any changes in laws which may hereafter occur.

Sincerely,

By <u>/s/ Carl P. Ranno</u>

Carl P. Ranno

2<br>

## Exhibit 10.1

**EXHIBIT 10.1**

**ASSET PURCHASE AGREEMENT**

This Asset Purchase Agreement (the "Agreement") is made this 10 day of March, 2023 by and between

**<u>IMCS CONSTRUCTION PTE. LTD.,</u>** a company duly incorporated in Singapore under the (Companies Act, 1967) and having its entity registered at **<u>180 Paya Lebar Road, #03-06, Yi Guang Factory Building, Singapore 409032</u>** (herein after refer to as "Seller")

and

**Pharmaceutical Resource Technology, Inc.** a company incorporated in Wyoming, USA<u> </u>and having its registered address at **<u>30N Gould St. Suite 4000, Sheridan, WY 82801, USA</u>** (herein after refer to as "Buyer")

.

This Agreement outlines the terms and conditions under which the Seller agrees to sell, and the Buyer agrees to purchase, certain assets of the Seller's business. The execution of this Agreement signifies the intent of both parties to fulfill the terms outlined herein.

**DEFINITIONS**

In this Agreement, the following terms shall have the meanings ascribed to them:

**1. RECITALS**

WHEREAS, Seller is engaged in the business of Building and Construction services; and

WHEREAS, Buyer desires to purchase certain assets of Seller's business, and Seller desires to sell such assets to Buyer, subject to the terms and conditions set forth in this Agreement;

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

**2. SALE AND PURCHASE OF ASSETS**

2.1 Assets Included

Seller hereby agrees to sell, assign, transfer, convey, and deliver to Buyer, and Buyer hereby agrees to purchase, acquire, and accept from Seller, at the Closing, free and clear of all liens, encumbrances, and security interests, all of Seller's right, title, and interest in and to the following assets (collectively, the "Assets"):

(a) All tangible personal property, including but not limited to all furniture, fixtures, equipment, machinery, tools, vehicles, office equipment, supplies, computers, telephones, and other items of tangible personal property as specifically listed in Exhibit A;

(b) All inventory, finished goods, raw materials, work in progress, packaging, supplies, parts, and other inventory items related to the business; Assets: All rights, title, and interest in those specific assets which are described in Section 2.

Closing Date: The date upon which the transaction will be completed and the assets transferred, as specified in Section 5.

Page 1 \| 11

Purchase Price: The total amount paid by Buyer to Seller for the Assets, as outlined in Section 3.

Liabilities: All debts, obligations, and legal claims against the Seller, which may or may not be included in the transaction.

(c) All intellectual property, including but not limited to patents, patent applications, trademarks, trademark applications, tradenames, copyrights, trade secrets, domain names, customer lists, and other intellectual property rights as specifically listed in Exhibit B;

(d) All contracts and agreements as specifically listed in Exhibit C; and

(e) All permits, licenses, accreditations, and authorizations issued by any governmental or regulatory entity as specifically listed in Exhibit D.

2.2 Excluded Assets

Notwithstanding anything to the contrary contained herein, the following assets of Seller are not part of the sale and purchase contemplated hereunder and are excluded from the Assets (collectively, the "Excluded Assets"):

(a) All cash and cash equivalents;

(b) All accounts receivable of Seller as of the Closing Date;

(c) All rights to tax refunds, credits, or similar benefits relating to the period prior to the Closing Date;

(d) All corporate minute books, stock records, corporate seals, and other corporate records;

(e) All insurance policies and rights thereunder; and

(f) All other assets specifically listed in Exhibit E.

**3. PURCHASE PRICE AND PAYMENT TERMS**

3.1 Purchase Price

The aggregate purchase price for the Assets shall be Five Million US Dollars (USD5,000,000.00) (the "Purchase Price"), subject to adjustments as provided in Section 3.3.

3.2 Payment Schedule

The Purchase Price shall be paid as follows:

(a) A deposit in the amount of One Million US Dollars $1,000,000.00 (the "Deposit") shall be paid by Buyer to Seller upon execution of this Agreement, which Deposit shall be applied toward the Purchase Price at Closing;

(b) The balance of the Purchase Price, subject to adjustments as provided in Section 3.3, shall be paid by Buyer to Seller at the Closing by wire transfer of immediately available funds to an account designated by Seller in writing.

Page 2 \| 11

3.3 Adjustments

The Purchase Price shall be subject to the following adjustments:

(a) Increased or decreased by the amount of any change in the value of inventory between the date of this Agreement and the Closing Date, as determined by a physical count and valuation of inventory to be conducted jointly by Seller and Buyer on the day immediately preceding the Closing Date;

(b) Decreased by the aggregate amount of any liabilities of Seller that Buyer agrees to assume at Closing; and

(c) Adjusted for any other items mutually agreed upon by Seller and Buyer in writing prior to the Closing Date.

**4. CLOSING**

4.1 Closing Date

The closing of the purchase and sale of the Assets (the "Closing") shall take place at 180 Paya Lebar Road, #03-06 on 22 March, 2023 at 1700hrs or at such other date, time, and place as may be mutually agreed upon by the parties in writing (the "Closing Date").

4.2 Deliverables at Closing

At the Closing:

(a) Seller shall deliver to Buyer:

(i) All necessary documents to transfer title to the Assets, including assignments of all intellectual property rights, duly executed by Seller;

(ii) All necessary consents from third parties, if any, required for the assignment of contracts included in the Assets;

(iii) Possession and control of the Assets; and

(iv) All other instruments and documents reasonably requested by Buyer to effectuate the transactions contemplated hereby.

(b) Buyer shall deliver to Seller:

(i) The Purchase Price, as adjusted pursuant to Section 3.3, by wire transfer of immediately available funds to an account designated by Seller;

(ii) The Assignment and Assumption Agreement, duly executed by Buyer; and

(iii) All other instruments and documents reasonably requested by Seller to effectuate the transactions contemplated hereby.

**5. REPRESENTATIONS AND WARRANTIES**

5.1 Seller's Representations

Seller represents and warrants to Buyer as follows, each of which is true and correct on the date hereof and will be true and correct on the Closing Date:

(a) Seller is a Singapore Company duly organized, validly existing, and in good standing under the laws of the state of Singapore;

(b) Seller has full power and authority to enter into this Agreement and to carry out the transactions contemplated hereby;

(c) This Agreement has been duly executed and delivered by Seller and constitutes a valid and binding obligation of Seller, enforceable against Seller in accordance with its terms;

Page 3 \| 11

(d) Seller has good and marketable title to all of the Assets, free and clear of all liens, encumbrances, and security interests;

(e) The Assets include all assets necessary for the conduct of the business as currently conducted by Seller;

(f) All financial information provided by Seller to Buyer is true, complete, and accurate in all material respects;

(g) Seller is not a party to any pending or threatened litigation or governmental proceeding affecting the Assets or the transactions contemplated by this Agreement; and

(h) Seller has complied with all applicable laws, rules, and regulations in connection with the ownership and operation of the Assets.

5.2 Buyer's Representations

Buyer represents and warrants to Seller as follows, each of which is true and correct on the date hereof and will be true and correct on the Closing Date:

(a) Buyer is a USA Company duly organized, validly existing, and in good standing under the laws of the state of Wyoming;

(b) Buyer has full power and authority to enter into this Agreement and to carry out the transactions contemplated hereby;

(c) This Agreement has been duly executed and delivered by Buyer and constitutes a valid and binding obligation of Buyer, enforceable against Buyer in accordance with its terms;

(d) Buyer has sufficient funds available to pay the Purchase Price and to consummate the transactions contemplated by this Agreement; and

(e) Buyer is not a party to any pending or threatened litigation or governmental proceeding affecting the transactions contemplated by this Agreement.

**6. COVENANTS**

(a) Non-Competition: Seller agrees that for a period of 5 years after the Closing Date, Seller shall not, directly or indirectly, engage in any business that competes with the business conducted by Buyer using the Assets within a 100-mile radius of Singapore.

(b) Non-Solicitation: Seller agrees that for a period of 5 years after the Closing Date, Seller shall not, directly or indirectly, solicit or attempt to solicit any customers, suppliers, or employees of the business conducted by Buyer using the Assets.

(c) Confidentiality: Seller agrees to keep confidential and not to use or disclose any confidential information relating to the Assets or the business conducted by Buyer using the Assets.

(d) Transition Assistance: Seller agrees to provide reasonable assistance to Buyer for a period of 3 years after the Closing Date to ensure a smooth transition of the Assets and business operations to Buyer.

(e) Further Assurances: Each party agrees to execute such additional documents and take such additional actions as may be reasonably necessary to carry out the purposes and intent of this Agreement.

Page 4 \| 11

**7. INDEMNIFICATION**

7.1 Indemnification by Seller

Seller shall indemnify, defend, and hold harmless Buyer and its officers, directors, employees, agents, successors, and assigns from and against any and all losses, damages, liabilities, deficiencies, actions, judgments, settlements, interest, awards, penalties, fines, costs, or expenses of whatever kind, including reasonable attorneys' fees, that arise out of or result from:

(a) Any breach or non-fulfillment of any representation, warranty, covenant, or agreement made by Seller in this Agreement;

(b) Any Excluded Asset or any liability of Seller not expressly assumed by Buyer pursuant to this Agreement; or

(c) Any third-party claim based upon, resulting from, or arising out of the business, operations, properties, assets, or obligations of Seller conducted, existing, or arising prior to the Closing Date.

7.2 Indemnification by Buyer

Buyer shall indemnify, defend, and hold harmless Seller and its officers, directors, employees, agents, successors, and assigns from and against any and all losses, damages, liabilities, deficiencies, actions, judgments, settlements, interest, awards, penalties, fines, costs, or expenses of whatever kind, including reasonable attorneys' fees, that arise out of or result from:

(a) Any breach or non-fulfillment of any representation, warranty, covenant, or agreement made by Buyer in this Agreement; or

(b) Any third-party claim based upon, resulting from, or arising out of the business, operations, properties, assets, or obligations of Buyer conducted, existing, or arising after the Closing Date.

**8. TERMINATION**

This Agreement may be terminated at any time prior to the Closing:

(a) By mutual written consent of Buyer and Seller;

(b) By either Buyer or Seller if the Closing has not occurred by [Termination Date], provided that the party seeking termination is not in material breach of this Agreement;

(c) By Buyer if there has been a material breach of any representation, warranty, covenant, or agreement made by Seller in this Agreement, which breach cannot be or has not been cured within 30 days after written notice of such breach is given to Seller; or

(d) By Seller if there has been a material breach of any representation, warranty, covenant, or agreement made by Buyer in this Agreement, which breach cannot be or has not been cured within 30 days after written notice of such breach is given to Buyer.

**9. MISCELLANEOUS PROVISIONS**

9.1 Governing Law

This Agreement shall be governed by and construed in accordance with the internal laws of the State of Singapore without giving effect to any choice or conflict of law provision or rule.

Page 5 \| 11

9.2 Dispute Resolution

Any dispute, controversy, or claim arising out of or relating to this Agreement, or the breach, termination, or validity thereof, shall be settled by arbitration administered by the American Arbitration Association in accordance with its Commercial Arbitration Rules, and judgment on the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof. The place of arbitration shall be Singapore.

9.3 Amendments

This Agreement may only be amended, modified, or supplemented by an agreement in writing signed by each party hereto.

**10. NOTICES**

All notices, requests, consents, claims, demands, waivers, and other communications hereunder shall be in writing and shall be deemed to have been given:

(a) when delivered by hand (with written confirmation of receipt);

(b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested);

(c) on the date sent by facsimile or e-mail (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient; or

(d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the following addresses:

If to Buyer: 30N Gould St, STE 4000, Sheridan, Wyoming 82801, USA email:<u>contact@pharmaceiticalresource.com</u> ; Phone: +65 6841 0120

If to Seller: 180 Paya Lebar Road, #03-06, Yi Guang Factory Building, Singapore 409032, email:peterng@imcsng.com.sg ; Phone: +65 9736 8892

**11. CONFIDENTIALITY**

Each party acknowledges that it will have access to certain confidential information of the other party concerning the other party's business, plans, customers, technology, and products, and other information held in confidence by the other party ("Confidential Information"). Each party agrees that it will not use in any way, for its own account or the account of any third party, except as expressly permitted by this Agreement, nor disclose to any third party (except as required by law or to that party's attorneys, accountants and other advisors as reasonably necessary), any of the other party's Confidential Information and will take reasonable precautions to protect the confidentiality of such information. IN WITNESS WHEREOF, the parties hereto have executed this Asset Purchase Agreement as of the date first above written.

SELLER: IMCS Construction Pte. Ltd.

---

| | |
|:---|:---|
| Signature: | /s/ Choon Teck Ng |
| Name: | Choon Teck Ng  |
| Title:  | Director |
| Date: | March 22, 2023 |

---

BUYER: Pharmaceutical Resource Technology, Inc.

---

| | |
|:---|:---|
| Signature: | /s/ Jacksaa Tan |
| Name: | Jacksaa Tan |
| Title: | CEO |
| Date: | March 22, 2023 |

---

Page 6 \| 11

**Exhibit A**

---

| | | | |
|:---|:---|:---|:---|
| **No.** | &nbsp;&nbsp; **Descriptions** | **Qty** | **Unit** |
| 1 | Excavator | 1 | no. |
| 2 | Lorry - 3 Ton Tipper + 3 Pickup | 4 | nos. |
| 3 | Iron Worker | 1 | unit |
| 4 | Concrete Polisher | 2 | nos. |
| 5 | Genset Generator | 2 | nos. |
| 6 | Band Saw machine | 2 | units |
| 7 | Car | 1 | no. |
| 8 | Forklift | 1 | no. |
| 9 | Pallet Jack | 6 | nos. |
| 10 | Stacker - 2 Manual + 2 Hydraulic | 4 | nos. |
| 11 | Drill machine | 2 | units |
| 12 | Trencher | 2 | sets |
| 13 | Road Cutter | 2 | nos |
| 14 | Chain Block | 10 | sets |
| 15 | Air Filter - Tebero | 1 | set |
| 16 | Storage Racking - customised | 24 | mr |
| 17 | Storage toolbox | 6 | nos. |
| 18 | Mise Steel | 20 | tons |
| 19 | Mise stainless Steel | 2 | tons |
| 20 | Washing machine | 1 | no. |
| 21 | Vacuum cleaner | 1 | no. |
| 22 | Laminating machine | 1 | no. |
| 23 | Binder machine | 1 | no. |
| 24 | Safe |  | no. |
| 25 | Security Cabinet | 1 | no. |
| 26 | Coffee machine | 1 | no. |
| 27 | Surveyor tools - Leveller | 5 | sets |
| 28 | Thedolite | 1 | no. |
| 29 | Noise meter |  | no |
| 30 | Soil hardness testing tool | 1 | no |
| 31 | Maqnet drill | 2 | sets |
| 32 | Borsch concrete drill | 3 | sets |
| 33 | Office Printer - Canon | 4 | units |
| 34 | Office built-in cabinet. | 7.5 |  |
| 35 | Mezz Floor Storage Platform | 90 |  |
| 36 | Office System Furniture | 5 | sets |
| 37 | Bolt, Nuts & Fastener | 1 | Ton |
| 38 | Misc Handtools - Estimate | 1 | lot |
| 39 | Real Property at 10 Admiralty Street, #04-88, Northlink Building, S757695 | 1 | unit |
| 40 | Other Addition, Alteration, Fittings and Fixtures | 1 | lot |

---

Page 7 \| 11

**Exhibit B**

Not Applicable

Page 8 \| 11

**Exhibit C**

All Contracts entered after closing date.

Page 9 \| 11

**Exhibit D**

**CW01** – enables the Company to undertake general building as follows:-

(a) All types of building works in connection with any structure, being built or to be built, for the support, shelter and enclosure of persons, animals, chattels or movable property of any kind, requiring in its construction the use of more than two unrelated building trades and crafts. Such structure includes the construction of multi-storey car-parks, buildings for parks and playgrounds and other recreational works, industrial plants, and utility plants.

(b) Addition and alteration works on buildings involving structural changes.

(c) Installation of roofs. Firms which undertake waterproofing work should register under CR13.

**CW02** – enables the Company to undertake civil engineering work as follows:-

(a) Works involving concrete, masonry and steel in bridges, sewers, culverts, reservoirs, retaining walls, canals, drainage systems, underground structures, cutting and filling of embankment, river banks, excavation of deep trenches, scraping of sub-soil, surface drainage works, flexible pavement, rigid pavement or laterite roads, bus bays, open car-parks and related works such as kerbs and footways. Firms which undertake piling works, ground support and stabilization works or site investigation works should register under CR08, CR12 and CR15 respectively.

(b) Works involving dredging in canal, river and offshore for the purpose of deepening and extraction of mineral or construction material. It also includes reclamation works. (c) Works involving marine piling and the construction of marine structures such as jetties, wharves, sea and river walls. The head does not cover the construction and fabrication of marine crafts, pontoons and oilrigs or any floating platform.

**CR03** – enables the Company to undertake all general demolition works. Since no financial grade is given to this registration head, applicants must meet the L1 requirements and complete at least ONE demolition project as a prerequisite for registration.

**CR06** – enables the Company to undertake Interior design, planning and the decoration of buildings. This includes ceiling panels, partitions, built-in fitments, raised floor works, plastering and tiling.

**GB2** – is a Class 2 General Builder license which enable the Company to undertake and complete projects up to SGD6 million. The Company qualifies for the Class 1 General Builder license which is able to undertake and complete projects of any value.

Page 10 \| 11

**Exhibit E**

All contracts entered into prior to closing and all projects completed prior to closing.

Page 11 \| 11<br>

**ASSET PURCHASE AGREEMENT**

This Asset Purchase Agreement (the "Agreement") is made this 12 day of March, 2023 by and between

**<u>GET Effective Products Industry,</u>** a sole proprietorship business duly incorporated in Singapore under the (Business Registration Act) and having its entity registered at **<u>1 Kaki Bukit Ave 3, #09-11, KB-1, Singapore 416087</u>** (herein after refer to as "Seller")

and

**Pharmaceutical Resource Technology, Inc.** a company incorporated in Wyoming, USA and having its registered address at **<u>30N Gould St. Suite 4000, Sheridan, WY 82801, USA</u>** (herein after refer to as "Buyer").

This Agreement outlines the terms and conditions under which the Seller agrees to sell, and the Buyer agrees to purchase, certain assets of the Seller's business. The execution of this Agreement signifies the intent of both parties to fulfill the terms outlined herein.

**DEFINITIONS**

In this Agreement, the following terms shall have the meanings ascribed to them:

**1. RECITALS**

WHEREAS, Seller is engaged in the business of Building and Construction services; and

WHEREAS, Buyer desires to purchase certain assets of Seller's business, and Seller desires to sell such assets to Buyer, subject to the terms and conditions set forth in this Agreement;

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

**2. SALE AND PURCHASE OF ASSETS**

2.1 Assets Included

Seller hereby agrees to sell, assign, transfer, convey, and deliver to Buyer, and Buyer hereby agrees to purchase, acquire, and accept from Seller, at the Closing, free and clear of all liens, encumbrances, and security interests, all of Seller's right, title, and interest in and to the following assets (collectively, the "Assets"):

(a) All tangible personal property, including but not limited to all furniture, fixtures, equipment, machinery, tools, vehicles, office equipment, supplies, computers, telephones, and other items of tangible personal property as specifically listed in Exhibit A;

(b) All inventory, finished goods, raw materials, work in progress, packaging, supplies, parts, and other inventory items related to the business; Assets: All rights, title, and interest in those specific assets which are described in Section 2.

Closing Date: The date upon which the transaction will be completed and the assets transferred, as specified in Section 5.

Purchase Price: The total amount paid by Buyer to Seller for the Assets, as outlined in Section 3.

Liabilities: All debts, obligations, and legal claims against the Seller, which may or may not be included in the transaction.

Page 1 \| 11<br>

(c) All intellectual property, including but not limited to patents, patent applications, trademarks, trademark applications, tradenames, copyrights, trade secrets, domain names, customer lists, and other intellectual property rights as specifically listed in Exhibit B;

(d) All contracts and agreements as specifically listed in Exhibit C; and

(e) All permits, licenses, accreditations, and authorizations issued by any governmental or regulatory entity as specifically listed in Exhibit D.

2.2 Excluded Assets

Notwithstanding anything to the contrary contained herein, the following assets of Seller are not part of the sale and purchase contemplated hereunder and are excluded from the Assets (collectively, the "Excluded Assets"):

(a) All cash and cash equivalents;

(b) All accounts receivable of Seller as of the Closing Date;

(c) All rights to tax refunds, credits, or similar benefits relating to the period prior to the Closing Date;

(d) All corporate minute books, stock records, corporate seals, and other corporate records;

(e) All insurance policies and rights thereunder; and

(f) All other assets specifically listed in Exhibit E.

**3. PURCHASE PRICE AND PAYMENT TERMS**

3.1 Purchase Price

The aggregate purchase price for the Assets shall be Two Million, Five Hundred Thousand US Dollars (USD2,500,000.00) (the "Purchase Price"), subject to adjustments as provided in Section 3.3.

3.2 Payment Schedule

The Purchase Price shall be paid as follows:

(a) A deposit in the amount of One Million US Dollars $1,000,000.00 (the "Deposit") shall be paid by Buyer to Seller upon execution of this Agreement, which Deposit shall be applied toward the Purchase Price at Closing;

(b) The balance of the Purchase Price, subject to adjustments as provided in Section 3.3, shall be paid by Buyer to Seller at the Closing by wire transfer of immediately available funds to an account designated by Seller in writing.

3.3 Adjustments

The Purchase Price shall be subject to the following adjustments:

(a) Increased or decreased by the amount of any change in the value of inventory between the date of this Agreement and the Closing Date, as determined by a physical count and valuation of inventory to be conducted jointly by Seller and Buyer on the day immediately preceding the Closing Date;

(b) Decreased by the aggregate amount of any liabilities of Seller that Buyer agrees to assume at Closing; and

(c) Adjusted for any other items mutually agreed upon by Seller and Buyer in writing prior to the Closing Date.

Page 2 \| 11<br>

**4. CLOSING**

4.1 Closing Date

The closing of the purchase and sale of the Assets (the "Closing") shall take place at 1 Kaki Bukit Ave 3, #09-11 on 15 March, 2023 at 1700hrs or at such other date, time, and place as may be mutually agreed upon by the parties in writing (the "Closing Date").

4.2 Deliverables at Closing

At the Closing:

(a) Seller shall deliver to Buyer:

(i) All necessary documents to transfer title to the Assets, including assignments of all intellectual property rights, duly executed by Seller;

(ii) All necessary consents from third parties, if any, required for the assignment of contracts included in the Assets;

(iii) Possession and control of the Assets; and

(iv) All other instruments and documents reasonably requested by Buyer to effectuate the transactions contemplated hereby.

(b) Buyer shall deliver to Seller:

(i) The Purchase Price, as adjusted pursuant to Section 3.3, by wire transfer of immediately available funds to an account designated by Seller;

(ii) The Assignment and Assumption Agreement, dulyexecuted by Buyer; and

(iii) All other instruments and documents reasonably requested by Seller to effectuate the transactions contemplated hereby.

**5. REPRESENTATIONS AND WARRANTIES**

5.1 Seller's Representations

Seller represents and warrants to Buyer as follows, each of which is true and correct on the date hereof and will be true and correct on the Closing Date:

(a) Seller is a Singapore Business duly organized, validly existing, and in good standing under the laws of the state of Singapore;

(b) Seller has full power and authority to enter into this Agreement and to carry out the transactions contemplated hereby;

(c) This Agreement has been duly executed and delivered by Seller and constitutes a valid and binding obligation of Seller, enforceable against Seller in accordance with its terms;

(d) Seller has good and marketable title to all of the Assets, free and clear of all liens, encumbrances, and security interests;

(e) The Assets include all assets necessary for the conduct of the business as currently conducted by Seller;

(f) All financial information provided by Seller to Buyer is true, complete, and accurate in all material respects;

(g) Seller is not a party to any pending or threatened litigation or governmental proceeding affecting the Assets or the transactions contemplated by this Agreement; and

Page 3 \| 11<br>

(h) Seller has complied with all applicable laws, rules, and regulations in connection with the ownership and operation of the Assets.

5.2 Buyer's Representations

Buyer represents and warrants to Seller as follows, each of which is true and correct on the date hereof and will be true and correct on the Closing Date:

(a) Buyer is a USA Company duly organized, validly existing, and in good standing under the laws of the state of Wyoming;

(b) Buyer has full power and authority to enter into this Agreement and to carry out the transactions contemplated hereby;

(c) This Agreement has been duly executed and delivered by Buyer and constitutes a valid and binding obligation of Buyer, enforceable against Buyer in accordance with its terms;

(d) Buyer has sufficient funds available to pay the Purchase Price and to consummate the transactions contemplated by this Agreement; and

(e) Buyer is not a party to any pending or threatened litigation or governmental proceeding affecting the transactions contemplated by this Agreement.

**6. COVENANTS**

(a) Non-Competition: Seller agrees that for a period of 5 years after the Closing Date, Seller shall not, directly or indirectly, engage in any business that competes with the business conducted by Buyer using the Assets within a 100-mile radius of Singapore.

(b) Non-Solicitation: Seller agrees that for a period of 5 years after the Closing Date, Seller shall not, directly or indirectly, solicit or attempt to solicit any customers, suppliers, or employees of the business conducted by Buyer using the Assets.

(c) Confidentiality: Seller agrees to keep confidential and not to use or disclose any confidential information relating to the Assets or the business conducted by Buyer using the Assets.

(d) Transition Assistance: Seller agrees to provide reasonable assistance to Buyer for a period of 3 years after the Closing Date to ensure a smooth transition of the Assets and business operations to Buyer.

(e) Further Assurances: Each party agrees to execute such additional documents and take such additional actions as may be reasonably necessary to carry out the purposes and intent of this Agreement.

**7. INDEMNIFICATION**

7.1 Indemnification by Seller

Seller shall indemnify, defend, and hold harmless Buyer and its officers, directors, employees, agents, successors, and assigns from and against any and all losses, damages, liabilities, deficiencies, actions, judgments, settlements, interest, awards, penalties, fines, costs, or expenses of whatever kind, including reasonable attorneys' fees, that arise out of or result from:

(a) Any breach or non-fulfilment of any representation, warranty, covenant, or agreement made by Seller in this Agreement;

(b) Any Excluded Asset or any liability of Seller not expressly assumed by Buyer pursuant to this Agreement; or

Page 4 \| 11<br>

(c) Any third-party claim based upon, resulting from, or arising out of the business, operations, properties, assets, or obligations of Seller conducted, existing, or arising prior to the Closing Date.

7.2 Indemnification by Buyer

Buyer shall indemnify, defend, and hold harmless Seller and its officers, directors, employees, agents, successors, and assigns from and against any and all losses, damages, liabilities, deficiencies, actions, judgments, settlements, interest, awards, penalties, fines, costs, or expenses of whatever kind, including reasonable attorneys' fees, that arise out of or result from:

(a) Any breach or non-fulfilment of any representation, warranty, covenant, or agreement made by Buyer in this Agreement; or

(b) Any third-party claim based upon, resulting from, or arising out of the business, operations, properties, assets, or obligations of Buyer conducted, existing, or arising after the Closing Date.

**8. TERMINATION**

This Agreement may be terminated at any time prior to the Closing:

(a) By mutual written consent of Buyer and Seller;

(b) By either Buyer or Seller if the Closing has not occurred by [Termination Date], provided that the party seeking termination is not in material breach of this Agreement;

(c) By Buyer if there has been a material breach of any representation, warranty, covenant, or agreement made by Seller in this Agreement, which breach cannot be or has not been cured within 30 days after written notice of such breach is given to Seller; or

(d) By Seller if there has been a material breach of any representation, warranty, covenant, or agreement made by Buyer in this Agreement, which breach cannot be or has not been cured within 30 days after written notice of such breach is given to Buyer.

**9. MISCELLANEOUS PROVISIONS**

9.1 Governing Law

This Agreement shall be governed by and construed in accordance with the internal laws of the State of Singapore without giving effect to any choice or conflict of law provision or rule.

9.2 Dispute Resolution

Any dispute, controversy, or claim arising out of or relating to this Agreement, or the breach, termination, or validity thereof, shall be settled by arbitration administered by the American Arbitration Association in accordance with its Commercial Arbitration Rules, and judgment on the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof. The place of arbitration shall be Singapore.

9.3 Amendments

This Agreement may only be amended, modified, or supplemented by an agreement in writing signed by each party hereto.

**10. NOTICES**

All notices, requests, consents, claims, demands, waivers, and other communications hereunder shall be in writing and shall be deemed to have been given:

(a) when delivered by hand (with written confirmation of receipt);

Page 5 \| 11<br>

(b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested);

(c) on the date sent by facsimile or e-mail (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient; or

(d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the following addresses:

If to Buyer: 30N Gould St, STE 4000, Sheridan, Wyoming 82801, USA email:<u>contact@pharmaceiticalresource.com</u> ; Phone: +65 6841 0120

If to Seller: 1 Kaki Bukit Ave 3, #09-11, KB-1, Singapore 416087, email:<u>alicia@geteffective.biz</u> ; Phone: +65 9621 0119

**11. CONFIDENTIALITY**

Each party acknowledges that it will have access to certain confidential information of the other party concerning the other party's business, plans, customers, technology, and products, and other information held in confidence by the other party ("Confidential Information"). Each party agrees that it will not use in any way, for its own account or the account of any third party, except as expressly permitted by this Agreement, nor disclose to any third party (except as required by law or to that party's attorneys, accountants and other advisors as reasonably necessary), any of the other party's Confidential Information and will take reasonable precautions to protect the confidentiality of such information. IN WITNESS WHEREOF, the parties hereto have executed this Asset Purchase Agreement as of the date first above written.

SELLER: GET Effective Products Industry

---

| | |
|:---|:---|
| Signature:  | */s/ Hui Eng Ling* |
| Name: | Hui Eng Ling |
| Title: | Director |
| Date: | March 15, 2023 |

---

BUYER: Pharmaceutical Resource Technology, Inc.

---

| | |
|:---|:---|
| Signature: | */s/ Jacksaa Tan* |
| Name: | Jacksaa Tan |
| Title: | CEO |
| Date: | March 15, 2023 |

---

Page 6 \| 11<br>

**Exhibit A**

---

| | | | |
|:---|:---|:---|:---|
| **No.** | &nbsp;&nbsp; **Descriptions** | **Qty** | **Unit** |
| 1. | All Formulation Certificates of Pharmaceutical and Dietary Supplements | 150 | sets |
| 2. | Manufacturing Procedures of Soft Gelatine Capsules Products  | 1 | set |
| 3. | Manufacturing Procedures for Hard Gelatine Capsules Products | 1 | set |
| 4. | Manufacturing Procedures for Tablets and Caplets Products | 2 | sets |
| 5. | Operating Manual for Food Safety Management System | 3 | sets |

---

Page 7 \| 11<br>

**Exhibit B**

Not Applicable

Page 8 \| 11<br>

**Exhibit C**

All Contracts entered after closing date.

Page 9 \| 11<br>

**Exhibit D**

**-** **GETEffective device and Trademark**

**-** **ISO9001: 2015 Certification**

**-** **GMP Certification**

**-** **FSMS Certification**

**-** **SFA Import License for processed food ingredients and receptacles**

Page 10 \| 11<br>

**Exhibit E**

All contracts entered into prior to closing and all projects completed prior to closing.

<br> <u> Page 11 \| 11</u>

## Exhibit 10.2

**EXHIBIT 10.2**

**CONTRACT FOR MANAGEMENT AND CONSULTANCY SERVICES**

*No: SNS/JPI-2019/01*

- Based on the need and capability of the parties concerned. <br> - Based on agreements between the parties.

This contract is made in Singapore on this date of 20<sup>th</sup> June, 2019 by and between:

---

| | |
|:---|:---|
| **PARTY A**: | **SUPERBEE NETWORK SINGAPORE PTE LTD**  |
| Address: | 1 Kaki Bukit Ave 3, #09-11, KB-1 |
|  | Singapore 408726 |
| Tel: | +65 - 6841 0120 |
| Fax: | +65 - 6841 0280 |
| Representative: | Alicia Ling Hui Eng |
| Position: | Executive Director |

---

and

---

| | |
|:---|:---|
| **PARTY B**: | **JAISON PHYTOCHEM, INC.** |
| Address: | 30N Gould St STE R  |
|  | Sheridan, WY82801, Wyoming USA |
| Tel: |  |
| Fax: |  |
| Representative: | Tan Jacksaa Jayson |
| Position: | Director |

---

The two parties have agreed to be bound to the following terms and conditions:

**Article 1. General Provision**

1.1 Party A is in the business of manufacturing healthcare and other products whereas Party B is a new startup company formed in Wyoming USA.

By this Contract, Party B hereby appoints Party A as a sole contractor to manage the business of Party B.

1.2 This agreement does not supersede any prior agreement that is still valid and remains in force.

**Article 2. Role and Performance**

2.1. Party A is obliged to perform the following functions in Party B to meet regulatory requirements in the territory that it operates.

(i) Strategic;

(ii) Tactical;

(iii) Operational;

(iv) Others that are required and deemed necessary by the controlling authority of Party B country provided that they do not infringed the rights, privacy and trade secrecy of Party A.

2.2. Party B shall be solely liable for the cost, fees and charges incurred in the business operation.

**Article 3. Business Functions**

3.1. Party B, shall procure products and materials from organization appointed by Party A only.

3.2. Party B shall only sell products to organization appointed by Party A only.

3.3. Party B shall not have any other dealings with any organization that is not appointed by Party A.

**Article 4. Costs and Payment**

4.1. The Management and Consultancy cost are as follows:-

(i) Fixed USD15,000 per month

(ii) Additional variable bonus to 4.1(i) payable in June and December solely to be determine by Party A.

4.2. Party B shall pay Party A in accordance to the terms and conditions when invoice from Party A is presented.

4.3 All payment to be paid by Party B shall be paid to Party A in cash or to the designated bank account without demand.

*Bank Name: DBS Bank Ltd*

*Bank Address: 12 Marina Boulevard, Marina Bay Financial Centre Tower 3, S(018982)*

*Beneficiary Name: Superbee Network Singapore Pte Ltd*

*Beneficiary Address: 1 Kaki Bukit Ave 3, #09-11, KB-1, Singapore 416087*

*Account number: 0104-000352-01-6-022 USD*

*Swiftcode: DBSSSGSG*

**Article 5. Approved Purpose**

Party A does not accept any responsibility or liability for the success or otherwise of the Approved Purpose and is not liable for any losses which may be suffered by Party B in the appointment of the Approved Purpose.

**Article 6. Dispute Resolution**

6.1. All disputes arising out of, and in relation to, this Contract will be informed by the Parties to each other for mutual resolution.

6.2. In case of failure of resolution, the dispute will be settled in accordance with Singapore laws according to the jurisdiction of the State Court.

SNS Page 2 of 3 JPI

**Article 7. Effect and Duration**

This contract shall take effect immediately upon being signed by the Parties and shall terminate immediately when Party B becomes insolvent or cease to exist.

---

| | |
|:---|:---|
| **FOR AND ON BEHALF OF**<br> **SUPERBEE NETWORK SINGAPORE PTE LTD** | **FOR AND ON BEHALF OF**<br> **JAISON PHYTOCHEM, INC** |
| ![](pharmaceutical_ex102img6.jpg) | ![](pharmaceutical_ex102img5.jpg) |
| By: Alicia Ling Hui Eng<br>Position: Executive Director | By: Tan Jacksaa Jayson<br>Position: Director |

---

SNS Page 3 of 3 JPI

## Exhibit 10.3

**EXHIBIT 10.3** 

**PATENT LICENSE AGREEMENT**

**(HONEY STRAW SEALING MACHINE)**

THIS AGREEMENT, effective this **25<sup>th</sup>** day, of **May** (Month), **2020** (year), is entered into by **Superbee Network Singapore Pte Ltd** (hereinafter "LICENSOR") and **Jaison Phytochem, Inc.** (hereinafter "LICENSEE").

**BACKGROUND**

WHEREAS, LICENSOR has designed and developed a **Honey Straw Sealing Machine** (hereinafter "INVENTION").

WHEREAS, LICENSOR is the owner of all right, title and interest in a Singapore Letter of Patent filed 17<sup>th</sup> March 2020 and is under application process as Singapore Patent Number 10202002434U.

WHEREAS, LICENSOR desires to transfer to LICENSEE and LICENSEE desires to acquire from LICENSOR an exclusive license to manufacture and market the INVENTION covered by the patent rights in all other countries, territories and jurisdictions on the terms and conditions set forth in this Agreement.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, parties agree as follow:

**SECTION 1. <u>DEFINITIONS</u>**

1.1. GROSS SALES. "Gross Sales" shall mean the aggregate compensation the LICENSEE, or its subsidiaries, receives for goods sold under the Patent Rights without a reduction for taxes, transportation, returns, depreciation or other expenses.

1.2. CLOSING. "Closing" shall occur when both LICENSOR and LICENSEE have applied their respective signatures to this Agreement.

1.3. PATENT RIGHTS. "Patent Rights" means the following listed patents and/or patent applications, patents to be issued pursuant thereto, and all divisions, continuations, reissues, substitutes, and extensions thereof:

**Applications**

(a) Singapore Application Serial No. 10202002434U Date Filed: 17th March 2020

Page 1 of 8

**SECTION 2. <u>GRANT OF INVENTION AND PATENT RIGHTS</u>**

In consideration for the up-front monies and royalty to be paid under Sections 3 and 4, LICENSOR grants to LICENSEE:

(a) an exclusive, nontransferable license to manufacture and market the INVENTION in Singapore;

(b) an exclusive, nontransferable license to manufacture and market the INVENTION in all foreign countries;

(c) all rights under the Patent Rights; and

(d) all technology, trade secrets and know-how related to the design and manufacture of the INVENTION, including all design plans, blueprints and any documentation or software related thereto.

**SECTION 3. <u>UP-FRONT MONIES</u>**

LICENSEE shall pay to LICENSOR on the date of Closing $25,000,000 in United States dollars. The up-front monies are not to be considered part of the royalties due under Section 4 of this Agreement.

**SECTION 4. <u>ROYALTY</u>**

Upon Closing, LICENSEE shall pay LICENSOR a royalty payment based upon the Gross Sales of the LICENSEE. Said royalty payment shall be calculated based upon 25% of the Gross Sales of the LICENSEE with regard to the Invention exceeding $2,500,000 per annum in United States dollars.

**SECTION 5. <u>TIMING OF ROYALTY PAYMENTS AND MINIMUM ROYALTY</u>**

5.1. YEARLY PAYMENTS. LICENSEE shall pay LICENSOR a royalty for each year during which this Agreement is in effect. LICENSEE shall pay LICENSOR per year, on or before the 30<sup>th</sup> day after January 1 of each year during which this Agreement is in effect.

5.2. MINIMUM PAYMENT. No minimum royalty payment shall be paid if the Gross Sales of the LICENSEE falls below $2,500,000 at the end of each year.

Page 2 of 8

**SECTION 6. <u>REPORTS AND RECORDS</u>**

6.1. FINANCIAL STATEMENT. LICENSEE shall provide a annual financial statement to LICENSOR showing the number of units manufactured during each year when each yearly royalty payment is made.

6.2. RECORDS. LICENSEE shall keep records of the Gross Sales and number of units manufactured and sold pursuant to this Agreement in sufficient detail to enable the royalty payment to LICENSOR to be determined.

6.3. ANNUAL INSPECTION. LICENSEE shall allow LICENSOR's representative, one annual inspection, during regular business hours or at such other times as may be mutually agreeable, to inspect LICENSEE's books and records to the extent reasonably necessary to determine LICENSEE's compliance with the terms of this Agreement.

6.4. PENALTY. If the LICENSOR determines through an annual inspection that the LICENSOR was undercompensated as required by this Agreement, then the LICENSEE shall pay to the LICENSOR a Penalty Fee. The Penalty Fee shall comprise three times the difference between the actual compensation and the required compensation. The LICENSEE shall still be obligated to pay full compensation as required under the Agreement.

**SECTION 7. <u>OBLIGATIONS OF LICENSOR</u>**

The LICENSOR agrees with the LICENSEE to execute such documents and give such assistance as the LICENSEE may reasonably require:

(a) to defeat any challenge to the validity of, and resolve any questions concerning the Patent Rights;

(b) to apply for and obtain patents or similar protection for the INVENTION in other parts of the world at the LICENSEE's expense;

(c) to do all that is necessary to vest such protection in the LICENSEE;

(d) to inform the LICENSEE of all technical information concerning the INVENTION; and

(e) to supply the LICENSEE with any documents or drawings relevant to the INVENTION.

Page 3 of 8

**SECTION 8. <u>REPRESENTATIONS AND WARRANTIES OF LICENSOR</u>**

8.1. LICENSOR represents and warrants to LICENSEE as follows:

(a) LICENSOR is the sole and exclusive owner of the INVENTION and the Patent Rights. No other parties have any right or interest in or to the INVENTION nor to the Patent Rights;

(b) All rights to the INVENTION and the Patent Rights are free and clear of all liens, claims, security interests and other encumbrances of any kind or nature;

(c) The LICENSOR has not granted any licenses to use the INVENTION to any other parties;

(d) LICENSOR has the right and power to enter into this Agreement, and has made no prior transfer, sale or assignment of any part of the INVENTION, patent rights pertaining to the INVENTION or the Patent Rights;

(e) As of the date hereof and as of the Closing date, LICENSOR is not aware of any parties infringing on the patent rights transferred hereunder;

(f) LICENSOR is not aware that the INVENTION infringes upon any patent, but LICENSOR does not otherwise warrant or guarantee the validity of the Patent Rights or that the INVENTION does not infringe any valid and subsisting patent or other rights not held by the LICENSOR; and

(g) The INVENTION was not procured by the use of confidential information, trade secrets, or in other respects in violation of law, and there is no action, order or proceeding, to the LICENSOR's knowledge, alleging any of the foregoing.

8.2 Each of the warranties and representations set forth above shall be true on and as of the date of Closing, as though such warranty and representation was made as of such time. All warranties and representations shall survive closing.

**SECTION 9. <u>LICENSEE'S OBLIGATIONS</u>**

9.1. INDEMNIFICATION. The LICENSEE agrees to indemnify the LICENSOR and his heirs successors, assigns and legal representatives for liability incurred to persons who are injured as a consequence of the use of any INVENTION manufactured by the LICENSEE or as a consequence of any defects in the INVENTION.

9.2. QUARTERLY ROYALTY. The LICENSEE agrees to pay the above stated quarterly royalty without demand.

9.3. REASONABLE EFFORTS. The LICENSEE agrees to utilize all reasonable efforts to manufacture and market the INVENTION.

9.4. FINANCIAL STATEMENT. The LICENSEE agrees to provide the financial statement at the end of each quarter without demand.

Page 4 of 8

9.5. PROFESSIONALISM. The LICENSEE agrees to the extent reasonably possible, have all manufacturing, shipping, and sales performed in a professional and equitable manner.

9.6. LIABILITY INSURANCE. The LICENSEE agrees to maintain liability insurance to cover the INVENTION in an amount greater than or equal to $25,000,000.

9.7. TRADE SECRETS. The LICENSEE agrees to take all reasonable steps to maintain the confidentiality of all trade secrets provided by the LICENSOR to the LICENSEE during and after this Agreement.

**SECTION 10. <u>CONDITIONS TO CLOSING</u>**

LICENSEE's obligation to pay the up-front monies and the royalty shall be subject to the satisfaction on or before the Closing of the following conditions, any one or more which may be waived by LICENSEE:

(a) The warranties and representations made by the LICENSOR in this Agreement shall be true and correct in all material respects on the Closing date as if such warranties and representations had been given as of the Closing date.

(b) LICENSOR shall have delivered to LICENSEE such instruments of transfer as may be reasonably requested by LICENSEE to consummate the transactions contemplated hereby.

**SECTION 11. <u>MARKING OF INVENTION</u>**

LICENSEE agrees to affix patent pending and patent notices to all INVENTIONs prior to their sale. Each device shall have either the words "PATENT PENDING" or "Patent No." followed by the patent number conspicuously marked on each of the goods sold under the Patent Rights subject to the reasonable approval of the LICENSOR.

**SECTION 12. <u>DURATION AND TERMINATION</u>**

12.1. This Agreement shall remain in full force and effect unless and until termination or cancellation as hereinafter provided.

12.2. If LICENSEE shall at any time default in rendering any of the statements required hereunder, and payment of any monies due hereunder, or in fulfilling any of the other material obligations hereof, and such default is not cured within fifteen days after written notice is given by the LICENSOR to LICENSEE, LICENSOR shall have the right to terminate this Agreement by giving written notice of termination to LICENSEE. LICENSEE shall have the right to cure any such default up to, but not after the written notice of termination.

Page 5 of 8

12.3. LICENSOR shall have the right to terminate this Agreement by giving written notice of termination to LICENSEE in the event of any of the following:

(a) liquidation of LICENSEE;

(b) insolvency or bankruptcy of LICENSEE, whether voluntary or involuntary; or

(c) appointment of a Trustee or Receiver for LICENSEE.

12.4. LICENSOR shall have the right to terminate this Agreement, by giving three months written notice, if after the second year of this agreement the previous years total royalty payment is lower than $625,000.

12.5. LICENSEE shall have the right to terminate this Agreement, by giving three months notice, if all patent applications, continuation, continuation-in-part or divisional applications, related to the INVENTION become abandoned without issuing into a patent.

12.6. LICENSEE shall have the right to terminate this Agreement, by giving three months notice, if a court of law determines all of the issued patents to be invalid.

**SECTION 13. <u>MAINTENANCE FEES AND INFRINGEMENT COSTS</u>**

13.1. MAINTENANCE FEES. LICENSEE shall be responsible for paying all maintenance fees for the Patent Rights until they expire.

13.2. DEFENDING AN INFRINGEMENT LAWSUIT. LICENSEE shall be responsible for all expenses, including but not limited to legal fees, associated with defending an infringement action involving the INVENTION. LICENSEE also agrees to vigorously defend at its own expense any invalidity actions brought against the Patent Rights.

13.3. BRINGING AN INFRINGEMENT LAWSUIT. LICENSEE shall also be responsible for all expenses, including but not limited to legal fees, associated with bringing an infringement action involving the Patent Rights. LICENSEE agrees to initiate and vigorously prosecute proceedings to the termination of any infringements on the Patent Rights.

13.4. NOTIFICATION. LICENSEE and LICENSOR both agree to notify each other of any legal action involving the Patent Rights or the INVENTION.

Page 6 of 8

**SECTION 14. <u>BINDING ARBITRATION</u>**

Any controversy or claim arising out of or relating to this contract, or the breach thereof, between the LICENSOR and the LICENSEE shall be settled by the competent jurisdiction of Singapore or United States of America. The judgment upon the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof.

**SECTION 15. <u>GOVERNING LAW</u>**

This Agreement shall be governed in accordance with the substantive laws of the Singapore or United States of America.

**SECTION 16. <u>SEVERABILITY</u>**

16.1. The parties agree that if any part, term, or provision of this Agreement shall be found illegal or in conflict with any valid controlling law, the validity of the remaining provisions shall not be affected thereby.

16.2. In the event the legality of any provision of this Agreement is brought into question because of a decision by a court of competent jurisdiction, LICENSOR, by written notice to LICENSEE, may revise the provision in question or delete it entirely so as to comply with the decision of said court.

**SECTION 17. <u>NOTICES UNDER THE AGREEMENT</u>**

For the purposes of all written communications and notices between the parties, their addresses shall be:

---

| | |
|:---|:---|
| LICENSOR: Attn: | Ms. LING Huieng Alicia |
|  | Superbee Network Singapore Pte Ltd<br>1 Kaki Bukit Ave 3

#09- 11, KB-1<br>Singapore 416087<br>|
| LICENSEE: Attn:  | TAN Jacksaa Jayson |
|  | <br> 30N Gould St STE R<br>Sheridan, WY 82801<br>USA |

---

Page 7 of 8

**SECTION 18. <u>NONASSIGNABILITY</u>**

The parties agree this Agreement imposes personal obligations on LICENSEE. LICENSEE shall not assign any rights under this Agreement without the written consent of LICENSOR. LICENSOR may assign all rights hereunder.

**SECTION 19. <u>ENTIRE AGREEMENT</u>**

This Agreement sets forth all of the covenants, promises, agreements, conditions and understandings between the parties and there are no covenants, promises, agreements or conditions, either oral or written, between them other than herein set forth. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon either party unless reduced in writing and signed by them.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized officers on the respective dates hereinafter set forth.

**For and on behalf of LICENSOR:**

---

| | | | |
|:---|:---|:---|:---|
| By: | */s/HuiEng Ling* | Date: | 25 May 2020 |
|  | Alicia Ling Hui Eng |  |  |
| **For and on behalf of LICENSEE:**  | **For and on behalf of LICENSEE:**  | **For and on behalf of LICENSEE:**  | **For and on behalf of LICENSEE:**  |
| By: | */s/Jacksaa Tan* | Date: | 25 May 2020 |
|  | Tan Jacksaa Jayson |  |  |

---

Page 8 of 8<br>

**Industrial Design License Agreement**

**Prepared for:**

Jacksaa Jayson Tan

Jaison Phytochem, Inc.

Alicia Ling Hui Eng

Superbee Network Singapore Pte Ltd

**License Agreement**

For use of **Packaging for Honey in Straw Shape**.

This License Agreement (this "Agreement" of this "License Agreement") is made and effective as of 3<sup>rd</sup> January 2020 (the "Commencement Date") by and **between Superbee Network Singapore Pte Ltd**, a company organized and existing in Singapore, with a registered address at 1 kaki Bukit Ave 3, #09-11, KB-1, Singapore 416087 ("Licensor") and **Jaison Phytochem, Inc**, a company organized and existing in USA, with a registered address at 30N Gould St STE R, Sheridan, WY 82801 ("Licensee").

**WHEREAS:**

1. Licensee wishes to obtain a license to use Packaging for Honey in Straw Shape (hereinafter, the "Asset"), and

2. Licensor is willing to grant to the Licensee an exclusive, non-transferable License to use the Asset for the term and specific purpose set forth in this Agreement,

**NOW, THEREFORE,** in consideration of the foregoing, and of the mutual promises and undertakings contained herein, and other good and valuable consideration, the parties agree as follows:

Page 1 of 19

**1. Definitions**

1.1 "Agreement" means this License Agreement including the attached Exhibit and Schedule.

1.2 "Confidential Information" means information that:

a. is by its nature confidential;

b. is designated in writing by Licensor as confidential;

c. the Licensee knows or reasonably ought to know is confidential;

d. Information comprised in or relating to any Intellectual Property Rights of Licensor.

1.3 "Asset" means the Asset provided by Licensor as specified in Item 6 of the Schedule in the form as stated in Item 7 of the Schedule.

1.4 "Intellectual Property Rights" means all rights in and to any copyright, trademark, trading name, design, patent, know how (trade secrets) and all other rights resulting from intellectual activity in the industrial, scientific, literary or artistic field and any application or right to apply for registration of any of these rights and any right to protect or enforce any of these rights, as further specified in clause 5.

1.5 "Party" means a person or business entity who has executed this Agreement; details of the Parties are specified in Item 2 of the Schedule.

1.6 "Term" means the term of this Agreement commencing on the Commencement Date as specified in Item 4 of the Schedule and expiring on the Expiry Date specified in Item 5 of the Schedule.

1.7 CLOSING. "Closing" shall occur when both LICENSOR and LICENSEE have applied their respective signatures to this Agreement.

**2. License Grant**

2.1 Licensor grants to the Licensee an exclusive, non-transferable License for the Term to use the Asset for the specific purpose specified in this Agreement, subject to the terms and conditions set out in this Agreement.

**3. Charges**

3.1 In consideration of the Licensor providing the License under clause 2 of this License Agreement, the Licensee agrees to pay Licensor the amount of the License Charge as specified in Item 9 of the Schedule

**4. Licensee's Obligations**

4.1 The Licensee cannot use the Asset, for purposes other than as specified in this Agreement and in Item 8 of the Schedule.

4.2 The Licensee may permit its employees to use the Asset for the purposes described in Item 8, provided that the Licensee takes all necessary steps and imposes the necessary conditions to ensure that all employees using the Asset do not commercialise or disclose the contents of it to any third person, or use it other than in accordance with the terms of this Agreement.

Page 2 of 19

4.3 The Licensee will not distribute, sell, License or sub-License, let, trade or expose for sale the Asset to a third party.

4.4 No copies of the Asset are to be made other than as expressly approved by Licensor.

4.5 No changes to the Asset or its content may be made by Licensee.

4.6 The Licensee will provide technological and security measures to ensure that the Asset which the Licensee is responsible for is physically and electronically secure from unauthorised use or access.

4.7 Licensee shall ensure that the Asset retains all Licensor copyright notices and other proprietary legends and all trademarks or service marks of Licensor.

**5. Intellectual Property Rights**

5.1 All Intellectual Property Rights over and in respect of the Asset are owned by Licensor. The Licensee does not acquire any rights of ownership in the Asset.

**6. Limitation of Liability**

6.1 The Licensee acknowledges and agrees that neither Licensor nor its board members, officers, employees or agents, will be liable for any loss or damage arising out of or resulting from Licensor's provision of the Asset under this Agreement, or any use of the Asset by the Licensee or its employees; and Licensee hereby releases Licensor to the fullest extent from any such liability, loss, damage or claim.

**7. Confidentiality**

7.1 Neither Party may use, disclose or make available to any third party the other Party's Confidential Information, unless such use or disclosure is done in accordance with the terms of this Agreement.

7.2 Each Party must hold the other Party's Confidential Information secure and in confidence, except to the extent that such Confidential Information:

a. is required to be disclosed according to the requirements of any law, judicial or legislative body or government agency; or

b. was approved for release in writing by the other Party, but only to the extent of and subject to such conditions as may be imposed in such written authorisation.

7.3 This clause 7 will survive termination of this Agreement.

Page 3 of 19

**8. Disclaimers & Release**

8.1 To the extent permitted by law, Licensor will in no way be liable to the Licensee or any third party for any loss or damage, however caused (including through negligence) which may be directly or indirectly suffered in connection with any use of the Asset.

8.2 The Asset is provided by Licensor on an "as is" basis.

8.3 Licensor will not be held liable by the Licensee in any way, for any loss, damage or injury suffered by the Licensee or by any other person related to any use of the Asset or any part thereof.

8.4 Notwithstanding anything contained in this Agreement, in no event shall Licensor be liable for any claims, damages or loss which may arise from the modification, combination, operation or use of the Asset with Licensee computer programs.

8.5 Licensor does not warrant that the Asset will function in any environment.

8.6 The Licensee acknowledges that: a. The Asset has not been prepared to meet any specific requirements of any party, including any requirements of Licensee; and b. it is therefore the responsibility of the Licensee to ensure that the Asset meets its own individual requirements.

8.7 To the extent permitted by law, no express or implied warranty, term, condition or undertaking is given or assumed by Licensor, including any implied warranty of merchantability or fitness for a particular purpose.

**9. Indemnification**

9.1 The Licensee must indemnify, defend and hold harmless Licensor, its board members, officers, employees and agents from and against any and all claims (including third party claims), demands, actions, suits, expenses (including attorney's fees) and damages (including indirect or consequential loss) resulting in any way from:

a. Licensee's and Licensee's employee's use or reliance on the Asset,

b. any breach of the terms of this License Agreement by the Licensee or any Licensee employee, and

c. any other act of Licensee.

9.2 This clause 9 will survive termination of this Agreement.

**10. Waiver**

10.1 Any failure or delay by either Party to exercise any right, power or privilege hereunder or to insist upon observance or performance by the other of the provisions of this License Agreement shall not operate or be construed as a waiver thereof.

Page 4 of 19

**11. Governing Law**

11.1 This Agreement will be construed by and governed in accordance with the laws of Singapore. The Parties submit to exclusive jurisdiction of the courts of Singapore.

**12. Termination**

12.1 This Agreement and the License granted herein commences upon the Commencement Date and is granted for the Term, unless otherwise terminated by Licensor in the event of any of the following:

a. if the Licensee is in breach of any term of this License Agreement and has not corrected such breach to Licensor's reasonable satisfaction within 7 days of Licensor's notice of the same;

b. if the Licensee becomes insolvent, or institutes (or there is instituted against it) proceedings in bankruptcy, insolvency, reorganization or dissolution, or makes an assignment for the benefit of creditors; or

c. the Licensee is in breach of clause 5 or 7 of this Agreement.

12.2 Termination under this clause shall not affect any other rights or remedies Licensor may have.

**13. License Fee**

13.1 In consideration for the License grant described in this License Agreement, Licensee shall pay the yearly License fee as stated in Item 9 of the Schedule immediately upon execution of this Agreement and upon each anniversary date of this Agreement.

13.2 The License fee and any other amounts payable by the Licensee to the Licensor, under this Agreement, are exclusive of any and all foreign and domestic taxes, which if found to be applicable, will be invoiced to Licensee and paid by Licensee within 30 days of such invoice.

**14. Assignment**

14.1 Licensee shall not assign any rights of this License Agreement, without the prior written consent of Licensor.

**15. Notices**

15.1 All notices required under this Agreement shall be in writing and shall be deemed given (i) when delivered personally; (ii) five (5) days after mailing, when sent certified mail, return receipt requested and postage prepaid; or (iii) one (1) business day after dispatch, when sent via a commercial overnight carrier, fees prepaid. All notices given by either Party must be sent to the address of the other as first written above (unless otherwise changed by written notice).

Page 5 of 19

**16. Counterparts**

16.1 This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which taken together shall constitute one instrument.

**17. Severability**

17.1 The Parties recognize the uncertainty of the law with respect to certain provisions of this Agreement and expressly stipulate that this Agreement will be construed in a manner that renders its provisions valid and enforceable to the maximum extent possible under applicable law. To the extent that any provisions of this Agreement are determined by a court of competent jurisdiction to be invalid or unenforceable, such provisions will be deleted from this Agreement or modified so as to make them enforceable and the validity and enforceability of the remainder of such provisions and of this Agreement will be unaffected.

**18. Entire Agreement**

18.1 This Agreement contains the entire agreement between the Parties and supersedes any previous understanding, commitments or agreements, oral or written. Further, this Agreement may not be modified, changed, or otherwise altered in any respect except by a written agreement signed by both Parties.

**IN WITNESS WHEREOF**, this Agreement, including the attached Schedule, was signed by the Parties under the hands of their duly authorized representatives and made effective as of the 3<sup>rd</sup> January 2020.

**For and on Behalf of Superbee Network Singapore Pte Ltd**

*/s/HuiEng Ling*

Alicia Ling Hui Eng

03/01/2020

**For and on Behalf of Jaison Phytochem, Inc**.

*/s/Jacksaa Tan*<br>

Jacksaa Jayson Tan

03/01/2020

Page 6 of 19

**Exhibit A**

![](pharmaceutical_ex103img23.jpg)

Page 7 of 19

**Exhibit B**

![](pharmaceutical_ex103img24.jpg)

Page 8 of 19

![](pharmaceutical_ex103img25.jpg)

Page 9 of 19

**Exhibit C**

![](pharmaceutical_ex103img26.jpg)

Page 10 of 19

**Schedule**

Item 1 – License Agreement

THE LICENSE AGREEMENT OF WHICH THIS SCHEDULE FORMS A PART IS DATED AS OF 3<sup>RD</sup> JANUARY 2020 AND IS BY AND BETWEEN THE PARTIES REFERENCED IN ITEM 2 BELOW.

Item 2 – Name and Address of Licensor and Licensee

Licensor: Superbee Network Singapore Pte Ltd, a company organized and existing in Singapore, with a registered address at 1 Kaki Bukit Ave 3, #09-11, KB-1, Singapore 416087.

Licensee: Jaison Phytochem, Inc., a company organized and existing in USA with a registered address at 30N Gould St STE R, Sheridan, Wyoming WY82801.

Item 3 – Other License Terms

As delineated

Item 4 – Commencement Date

Strictly on the 3<sup>rd</sup> day of January in the Year 2020

Item 5 – Expiry Date

- Industrial Design – EU by 2033

- Industrial Design – HK by 2032

- Industrial Design – MY by 2021

Item 6 – Description of Asset

Industrial Design for the Packaging of Honey in Straw Shape. The novelty of the design resides in the features of the shape and configuration in the articles of representation in the format in item 7.

Page 11 of 19

Item 7 – Format of Asset

European Union (EU)

![](pharmaceutical_ex103img27.jpg)

Page 12 of 19

Hong Kong (HK)

![](pharmaceutical_ex103img28.jpg)

Page 13 of 19

![](pharmaceutical_ex103img29.jpg)

Page 14 of 19

Malaysia (MY)

![](pharmaceutical_ex103img30.jpg)

Page 15 of 19

![](pharmaceutical_ex103img31.jpg)

Page 16 of 19

![](pharmaceutical_ex103img32.jpg)

Page 17 of 19

![](pharmaceutical_ex103img33.jpg)

Page 18 of 19

Item 8 – Approved Purpose

The Licensor does not accept any responsibility or liability for the success or otherwise of the Approved Purpose and is not liable for any losses which may be suffered by the Licensee in undertaking the Approved Purpose.

Item 9 – License Fee

LICENSEE shall pay to LICENSOR up-front monies on the date of Closing in United States dollars as follows:-

- Industrial Design EU = $500,000

- Industrial Design HK = $500,000

- Industrial Design MY = $80,000

The up-front monies are not to be considered as part of the royalties.

Upon Closing, LICENSEE shall pay LICENSOR a royalty payment based upon the Gross Sales of the LICENSEE. Said royalty payment shall be calculated based upon 20% of the Gross Sales of the LICENSEE with regard to the Industrial Design exceeding $6,000,000 per annum in United States dollars.

<br> <u>Page 19 of 19</u>

## Exhibit 23.1

**EXHIBIT 23.1**

![](pharmaceutical_ex231img5.jpg)

January 8, 2026

**To Whom It May Concern**

**RE: AUDITOR'S CONSENT FOR PUBLICATION OF AUDITED FINANCIAL STATEMENTS**

We refer to the audited financial statements of **PHARMACEUTICAL RESOURCE TECHNOLOGY, INC** for the financial year ended **2024 and 2025**, together with our independent auditor's report thereon.

We hereby give our consent to the publication, filing, and use of the audited financial statements and our auditor's report for their intended purpose. This consent is provided in accordance with applicable professional standards and is limited strictly to the audited financial statements and auditor's report as issued by us.

We do not accept responsibility for any other information, representations, or documents with which the audited financial statements may be presented or associated. Furthermore, this consent does not extend to any subsequent events, amended financial statements, or other financial information not audited or reviewed by us.

Yours faithfully,

![](pharmaceutical_ex231img6.jpg)

FORTUNE CPA, INC., 8831

Orange, California 92868

## Exhibit 99.1

**EXHIBIT 99.1**

**SUBSCRIPTION AGREEMENT**

The undersigned (the "Subscriber"), desires to become a holder of common shares (the "Shares") of **PHARMACEUTICAL RESOURCE TECHNOLOGY, INC** a corporation organized under the laws of the state of Wyoming (the "Company"); one share of Common Stock has a par value $0.01 per share. Accordingly, the Subscriber hereby agrees as follows:

1. <u>Subscription</u>.

1.1 The Subscriber hereby subscribes for and agrees to accept from the Company that number of Shares set forth on the Signature Page attached to this Subscription Agreement (the "Agreement"), in consideration of  **<u>$0.50</u>** per share. This offer to purchase is submitted in accordance with and subject to the terms and conditions described in this Subscription Agreement (the "Agreement"). The Subscriber acknowledges that the Company reserves the right, in its sole and absolute discretion, to accept or reject this subscription and the subscription will not be binding until accepted by the Company in writing.

1.2 The closing of the Subscription of Shares hereunder (the "Closing") shall occur immediately upon: (i) receipt and acceptance by the Company of a properly executed Signature Page to this Agreement; and (ii) receipt of all funds for the subscription of shares hereunder.

2. <u>Purchase Procedure</u>. The Subscriber acknowledges that, in order to subscribe for Shares, he must, and he does hereby, deliver to the Company:

2.1 One (1) executed counterpart of the Signature Page attached to this Agreement together with the passport copy or government ID copy; and

2.2 A check, trade draft or media due bill in the amount set forth on the Signature Page attached to this Agreement, representing payment in full for the Shares desired to be purchased hereunder, either made payable to the order of  **<u>PHARMACEUTICAL RESOURCE TECHNOLOGY, INC</u>** ; or an escrow agent as agreed upon by the Company, for the benefit of  **<u>PHARMACEUTICAL RESOURCE TECHNOLOGY, INC</u>** . Wire transfer and telegraphic transfer are also accepted.

3. <u>Representations of Subscriber</u>. By executing this Agreement, the Subscriber makes the following representations, declarations and warranties to the Company, with the intent and understanding that the Company will rely thereon:

3.1 Such Subscriber acknowledges the public availability of the Company's current prospectus which can be viewed on the SEC Edgar Database, under the CIK number  **<u>_____________</u>** . This prospectus is made available in the Company's most recent S-1 Registration Statement deemed effective on  **<u> </u>** . In this prospectus it makes clear the terms and conditions of the offering of Common Stock and the risks associated therewith are described.

3.2 All information herein concerning the Subscriber is correct and complete as of the date hereof and as of the date of Closing.

3.3 If the Subscriber is purchasing the Shares in a fiduciary capacity for another person or entity, including without limitation a corporation, partnership, trust or any other entity, the Subscriber has been duly authorized and empowered to execute this Subscription Agreement and all other subscription documents. Upon request of the Company, the Subscriber will provide true, complete and current copies of all relevant documents creating the Subscriber, authorizing its investment in the Company and/or evidencing the satisfaction of the foregoing.

4. <u>Applicable Law</u>. This Agreement shall be construed in accordance with and governed by the laws applicable to contracts made and wholly performed in the State of Nevada.

5. <u>Execution in Counterparts</u>. This Subscription Agreement may be executed in one or more counterparts.

6. <u>Persons Bound</u>. This Subscription Agreement shall, except as otherwise provided herein, inure to the benefit of and be binding on the Company and its successors and assigns and on each Subscriber and his respective heirs, executors, administrators, successors and assigns.

7. <u>Notices</u>. Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally, telegraphed, telexed, sent by facsimile transmission or sent by certified, registered or express mail, postage prepaid, to the address of each party set forth herein. Any such notice shall be deemed given when delivered personally, telegraphed, telexed or sent by facsimile transmission or, if mailed, three days after the date of deposit in the United States mails.

8. <u>CERTIFICATION</u>. **THE SUBSCRIBER CERTIFIES THAT HE HAS READ THIS ENTIRE SUBSCRIPTION AGREEMENT AND THAT EVERY STATEMENT MADE BY THE SUBSCRIBER HEREIN IS TRUE AND COMPLETE.**

***[SIGNATURE PAGE FOLLOWS]***

**<u>SUBSCRIBER SIGNATURE</u>**

1<br>

The undersigned, desiring to subscribe for the number of Shares of **<u>PHARMACEUTICAL RESOURCE TECHNOLOGY, INC</u>**, (the "Company") as is set forth below, acknowledges that he/she has received and understands the terms and conditions of the Subscription Agreement attached hereto and that he/she does hereby agree to all the terms and conditions contained therein.

**IN WITNESS WHEREOF**, the undersigned has hereby executed this Subscription Agreement as of the date set forth below.

**(PLEASE PRINT OR TYPE)**

---

| |
|:---|
| Number of Shares |
| x **$0.50** Per Share |
| Total Amount of Subscription: USD |
| Exact name(s) of Subscriber(s):  |
| Signature of Subscriber(s):  |
| (Signature) |
| Date: |
| Name of Director of the Company: |
| Signature of Director of the Company: |
| (Signature) |
| Date: |

---

Residence or Physical Mailing Address (cannot be a P.O. Box):

__________________________________

__________________________________

Telephone Numbers (include Area Code):

Business: (___)_____________

Home: (___)________________

Social Security, Taxpayer, or other type Identification Number(s): _____________

2<br>

## Exhibit 99.2

**EXHIBIT 99.2**

![](pharmaceutical_ex992img2.jpg)

## Ex-Filing

?xml version='1.0' encoding='ASCII'? pharmaceutical_ex107.htm

**EXHIBIT 107**

**Calculation of Filing Fee Tables**

**Form S-1** 

(Form Type)

**PHARMACEUTICAL RESOURCE TECHNOLOGY, INC.** 

(Exact Name of Registrant as Specified in its Charter)

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type** | **Security** <br>**Class Title** | **Fee** <br>**Calculation**<br>**or Carry**<br>**Forward Rule** | **Amount** <br>**Registered** | **Proposed** <br>**Maximum**<br>**Offering Price**<br>**Per Share** | **Proposed** <br>**Maximum** <br>**Aggregate**<br>**Offering Price (1)** | <br>**Fee Rate** | **Amount of** <br>**Registration** <br>**Fee (3)(4)** |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
| Fees to be Paid | Equity | Common Stock $0.01 par value. | 457(o) | 270175496 | $0.50 | $135087748 | $0.00013810 | $18655.62 |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |  |  |
|  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $135087748 |  | $18655.62 |
|  | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  |  | $3088.78 |
|  | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  | $3088.78 |
|  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $15566.84 |

---

**Table 1: Newly Registered and Carry Forward Securities**

(1) Pursuant to Rule 457(p) under the Securities Act, the registration fee for this registration statement is being offset by $3088.78, representing the unused portion of the registration fee ($3,088.78) previously paid by the Registrant in connection with the registration statement on Form S-1 (File No. 333-259689) filed with the SEC on September 21, 2021 (the "Prior Registration Statement"), which was withdrawn on June 16, 2022.